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Summary  
 
The bacteria located within the human gastrointestinal tract (the gut microbiota) perform 
numerous protective, immunological and metabolic functions for the host. They are 
increasingly implicated in the pathogenesis of acquired inflammatory diseases of the gut in 
childhood, namely: necrotising enterocolitis (NEC) and inflammatory bowel disease 
(Crohn’s disease (CD) and ulcerative colitis (UC)). Study of the role that the microbiota 
may play in the development of such diseases may lead to new therapies to modulate or 
even cure them. However many current techniques depend on the ability to study such 
bacteria outwith their natural ecosystem. Although molecular techniques can identify 
species independent of standard cultures they can enlighten little on the metabolic activity 
of identified bacterial species, which may be important in the propagation of inflammatory 
responses. Little is known about the potential of novel therapeutic strategies, such as 
probiotics, to modulate diseases such as NEC. In addition inadequate scientific rigour has 
been applied to the science of probiotics. The aims of the study described in this 
dissertation were to test the following hypotheses.  
Hypotheses: 
1. Probiotics prevent NEC in at risk infants of very low birth weight (VLBW). 
2. The human gut microbiota can be labelled by stable isotope probing (SIP) to 
measure metabolic activity. 
3. Quantitative measurement of the metabolic activity of the unculturable gut 
microbiota is a useful way of studying changes in the microbiota, compared 
with measures of bacterial diversity, and may enlighten our understanding 
of bacterially mediated inflammatory stimuli in inflammatory gut diseases of 
childhood. 
Aims: 
1. To evaluate the evidence for the use of prophylactic oral probiotics for the 
prevention of NEC by systematic review of the published literature. 
2. To develop stable isotope probing as a novel tool to study the metabolic activity of 
the gut microbiota in children. 
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Methods: 
1. Systematic review of randomised controlled trials (RCT) and quasi-RCTs of the 
administration of oral probiotic preparations to preterm infants, looking for 
outcome measures including; incidence, severity, need for surgery and mortality in 
NEC. Electronic searches were performed on MEDLINE and CINAHL using 
keyword and subject heading (MeSH) using combinations of the terms infant, 
preterm; infant, VLBW; enterocolitis, necrotising; probiotic. In addition, all 
potential studies had citation searches performed. 
2. Stable isotope probing methodology was developed to examine bacterial RNA 
extracted from human faecal samples. The potential to enrich bacterial RNA with 
13C from candidate tracers 16s rRNA was then to be isolated by adapting 
oligonucleotide probe capture technology to measure eubacterial and group specific 
16s rRNA 13C enrichment as a proxy for bacterial metabolic activity.  
Results: 
1. Systematic review of more than 45000 citations identified five randomised 
controlled trials of sufficient quality. 640 infants were in the treatment group in 
comparison to 627 controls. Statistical analyses demonstrated a cumulative 
reduction of NEC in the treatment group. However major heterogeneity in terms of 
type, dosage and administration of probiotics, precluded further interpretation of 
meta-analysis. No studies reported on long-term safety or observations of 
unintended outcomes.  
2. Using a non-radioactive isotope of carbon (13C), enrichment of faecal bacterial 
RNA was reliably achieved and detected by liquid chromatograph isotope ratio 
mass spectrometry (IRMS) and enrichments were related to stimuli for bacterial 
activity and correlated with faecal short chain fatty acid profiles. A protocol for the 
isolation of 13C enriched bacterial 16s rRNA was developed and 13C urea was 
identified as a reliable tracer to produce enrichment in 16s rRNA. 16s rRNA 
enrichments were shown to correlate with total RNA enrichment across varying 
stimuli for bacterial activity. Phylogenetic group specific probes also suggested 
some specificity when probing the faecal bacterial consortia. However sufficient 
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specificity of 13C labelled sequence specific RNA was not reliably demonstrated, 
despite examination of many steps in the protocol using a highly 13C enriched E. 
coli model. 
Conclusions: 
1. The data appear to support the use of oral probiotics for the prevention of NEC in 
preterm VLBW infants. However the data are insufficient to comment on their 
short and long-term safety. Type of probiotics as well as timing and dosage are still 
to be optimised. The gut microbiota undoubtedly play a pivotal but, as yet, not 
clearly defined, role in the pathogeneses of inflammatory gut diseases of childhood. 
However before the development of targeted therapies to modulate these diseases 
can be successfully implemented expansion of the evidence base is required. Future 
work should aim to improve definitions and understanding of mechanisms of action 
and safety of probiotic preparations and to enhance the methods to determine the 
effects of unculturable bacteria on the ecology of the gastrointestinal tract.  
2. RNA SIP-IRMS methodology can be applied to study changes in the metabolic 
activity of the unculturable bacterial in human faecal samples. The use of 
oligonucleotide probe capture techniques potentially allows the study of the 
metabolic activity of individual bacterial species within such complex consortia. 
Studies of unculturable bacteria should focus on both metabolic activity and 
diversity because of functional redundancy within the microbiota. Optimisation of 
the existing SIP methodology could lead to a powerful new way of investigating 
the metabolic activity and diversity of the gut microbiota.  
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the 13C incorporations were performed at the Scottish Universities Environmental Research 
Centre (SUERC) with the aid of Dr Douglas Morrison.  
 
Collation and analysis of data was performed by myself on Excel for Windows, or in 
conjunction with Dr Douglas Morrison when using SPSS. 
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1 Introduction 
1.1 The Human Gut Microbiota 
The mucosal surface of the gastrointestinal tract represents the largest and most active 
interface between the host and its external environment (1).  A single monolayer of 
cuboidal cells separates the sub-epithelium from the luminal contents. Many species of 
bacteria have evolved and adapted to live in the human intestinal tract. In the adult human, 
microbial cells contained in the gut out-number the total eukaryotic cells of the body by a 
factor of 10. These several hundred grams of bacteria play many important roles in 
physiological homeostasis and metabolism for health. However most cannot be easily 
studied outwith the environmental niches they inhabit.  
The ‘gut microbiota’ can be defined as all the species within the ecosystem 
(gastrointestinal tract) which are involved in symbiotic relationships with the host (2). 
Many bacteria are potential pathogens, causing infections and sepsis in the susceptible host 
when barrier function or immunity is compromised. The gut microbiota have been long 
known to have this duality and recently they are being increasingly linked to the 
pathogenesis of complex acquired diseases (3). The nature of the gut microbiota is 
complex and many factors influence it. As the intraluminal environment of the gut changes 
along its course, so does the microbial composition. Many bacteria cannot be directly 
studied outwith the gut because of the specific nutrient requirements and conditions that 
they are provided with in vivo. All this makes the study of the gut microbiota’s effects on 
preventing or propagating acquired diseases difficult. 
The aim of this chapter is to review current knowledge of the gut microbiota, the factors 
influencing its formation and composition, its role in the maintenance of health, methods 
of analysis of its composition and how it is implicated in acquired diseases of childhood, 
highlighting in particular necrotising enterocolitis (NEC) and inflammatory bowel disease 
(IBD).  
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1.1.1 Development of gut microbiota from birth 
The human gut is sterile at birth but rapidly colonised thereafter (4). Although protozoa 
and fungi come to inhabit the gut, by far the most numerous micro-organisms are bacteria. 
Many environmental factors, including maternal colonisation, mode of delivery, length of 
gestation, composition of first enteral feed and antibiotic exposure, affect the rate of 
bacterial colonisation and species diversity of the newborn (1;5;6).  This process continues 
until adult type diversity and numbers are established by around two years, by which time 
around 1014 bacteria are resident in the gut, outnumbering human eukaryotic cells by an 
order of magnitude (7). 
The composition and number of bacteria increase cranio-caudally along the gastrointestinal 
tract and also vary in number radially from lumen to mucosa.  In the upper gut only 
relatively small numbers, of few species, are found, which have adapted to survive the 
acidic pH of the stomach.  Many bacteria in this part of the digestive system are commonly 
carried by food particles in the diet and generally do not establish themselves permanently 
on the mucosa or in the lumen and are thereby considered ‘transient’.  The relative number 
of bacteria rises in the small bowel until in the colon 1011-1012 bacteria per g of faecal 
material are present (8).  Bacteria in the colon are relatively stable and colonies will 
establish themselves permanently there, both in the lumen and on the mucosal surface, 
where they exist within biofilms on the mucous layer overlying the epithelium. 
In the lower gastrointestinal tract of healthy individuals the majority of bacteria are strict 
anaerobes, outnumbering the facultative anaerobes 10-100 fold (8).  The biofilm 
microbiota differ in composition from the luminal bacteria (9).  Within individuals species 
numbers and diversity are stable over time (10) and these bacteria are therefore considered 
‘resident’.  Luminal bacteria in health include a mixture of resident and transient bacteria.  
Mucosal biofilms tend to be more static in healthy individuals and comprise mainly 
resident bacteria.  Inter-individual variations in the microbiota, however, are marked (10), 
giving rise to difficulty in characterising a ‘normal’ healthy microbiota.  Nevertheless, in 
spite of such variability the gut microbiota undoubtedly perform important protective, 
immunological and metabolic functions for the host in health. 
1.1.2  Influences on gut microbiota composition in infants and 
young children 
Colonisation of the gut begins with organisms derived form the maternal vaginal, intestinal 
and skin microbiota. Aerobic and facultative anaerobes such as Staphylococci and 
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Enterococci colonise within the first week. Oxygen consumption by such bacteria  results 
in a drop in the redox potential within the gut allowing strict anaerobes such as 
Bifidobacteria, Bacteroides and Clostridia to colonise (11). However many exogenous 
factors have been shown to affect colonisation patterns. Infants born by caesarean section 
are less likely to acquire Bifidobacteria by ten days of age in comparison to vaginally 
delivered infants (4). The effect of early diet on colonization patterns has been studied 
extensively. Breast-fed infants have less bacterial diversity than formula-fed infants with a 
predominance of Bifidobacteria species. Such differences disappear when mixed diets are 
introduced (12).  
Length of gestation at time of delivery also appears to be of importance. Infants born 
prematurely are likely to have slower rates of colonisation with fewer overall numbers of 
bacteria present, with less species diversity and a relative lower incidence of Bifidobacteria 
in comparison to healthy term controls. It is difficult, however, to separate the relative 
roles of immature gut immune function, neonatal care (nursing in incubators, strict 
hygiene, and antibiotic usage) and feeding (tube feeding and formula feeds) in the genesis 
of this pattern (4-6). Infants delivered in Westernised countries have more delayed 
colonization of bacteria and fewer Bifidobacteria than those delivered in developing 
countries, suggesting that environmental factors such as hygiene are of importance to the 
term infant also (6). The effects of such differences have not been studied but the 
hypothesis relating environmental changes to the development of acquired disease 
(hygiene hypothesis) discussed in section 1.3 may be relevant. 
1.2 Functions of the Gut Microbiota in Health  
1.2.1 Protective functions 
Resident bacteria within the gut provide resistance against enteropathogens (colonisation 
resistance). Mucosal bacteria compete for binding sites on the epithelial surfaces of the gut, 
thus preventing attachment and subsequent invasion of cells by pathogenic bacteria (13).  
Luminal bacteria can inhibit the growth of enteropathogens by competing for common 
substrates (14), by reducing intraluminal pH and by producing specific bacterocidins 
against such species (15). 
1.2.2 Immunological functions 
Microbiota affect the development of the gut associated lymphoid system (GALT).  The 
intestine contains 70% of the body’s circulating lymphocytes, many of which are found 
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within the epithelium (16).  In the lamina propria there are several lines of immune cells, 
key to the host response to microflora, such as macrophages, dendritic cells and 
myofibroblasts (17-19).  Animals bred in sterile conditions have low densities of gut 
lymphoid cells and are particularly susceptible to infection (20;21).  Lymphoid tissue, and 
surface and circulating immunoglobulin concentrations rise substantially with the 
introduction of bacteria to the gut of such animals (20;22).  In early human life, pioneering 
species in the gut interact through surface cell receptors on gut immune cells, such as 
CARD15 and toll-like receptors (TLRs), to promote the expression of host genes that 
generate an intraluminal and mucosal environment that further favours their colonisation 
(23). 
Host bacteria and the immune system are constantly engaged in a process of sensing and 
feedback with one another (24). Pioneer bacteria within the human gut can regulate host 
responses to maintain an intraluminal environment which favours their continued 
establishment, meaning that early colonisation contributes to life-long gut microbial 
patterns and host immune responses (23). Immune stimulation by the microbiota in early 
life can also affect differentiation of immune memory and response to antigens.  This 
interactive modelling of gut microbial composition and host immune response is referred 
to as ‘crosstalk’ (23).  The exposure of the host to a numerous and diverse microbiome 
programmes the primed immune system to react appropriately to perceived gut 
commensals and eneteropathogens (oral tolerance) (1;25).  Such mucosal immune 
responses are lessened with exposure to heat treated bacteria, as opposed to live organisms, 
suggesting that such mechanisms involve the metabolic products of bacterial activity as 
well as bacterial cell-receptor mediated sensing (26). 
1.2.3 Metabolic functions 
Colonic bacterial diversity equips the host with a range of enzymes and biochemical 
pathways not present in the human repertoire (27).  This allows the metabolism of 
otherwise indigestible food products, such as carbohydrates, peptides and proteins to 
generate substrates for colonocyte function and energy salvage for use by the body (28;29).  
Of high functional importance is the fermentation of non-digestible carbohydrates (NDC) 
to short chain fatty acids (SCFA) which can regulate colonocyte metabolism and other host 
metabolic functions (figure 1).  
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Figure 1: SCFA producing species of bacteria within the human gut (probiotic species underlined) 
 NDC= non digestible carbohydrates 
 
SCFA produced within the gut lumen can have trophic effects on colonocyte 
differentiation and cell turnover (8;30).  Such products of bacterial activity may also play 
an important role in bacteria-gut crosstalk in health (16;26) and therefore may be involved 
in regulation of the inflammatory response in disease.  
1.3  Gut Microbiota in Disease - The Hygiene Hypothesis 
The recent progressive decline in morbidity and mortality from infectious diseases in 
developed countries has been mirrored by a concurrent rise in allergic and immune 
mediated illness (21). Asthma, hay fever and allergic dermatitis have increased in 
incidence in the last 20 years (31). Migrant families moving to Westernised countries 
appear to develop such diseases after a generation (3). Gastroenterologists have also noted 
dramatic rises in the incidence of inflammatory bowel disease (IBD) (32;33), particularly 
in children (see 1.6.2). Epidemiological studies initially related increases in allergic disease 
to decreasing household size and increasing levels of hygiene (34). An immunological 
hypothesis for this phenomenon is that increasing hygiene alters the programming of the 
developing acquired immune system (hygiene hypothesis).  
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T helper (TH) lymphocytes can develop into two distinct categories: TH1 and TH2. When 
activated these cells secrete different profiles of immunomediators (35;36). Allergic 
diseases are noted for their predominance of TH2 response (37). The hygiene hypothesis 
suggests that Westernized lifestyles lead to a skewing of the TH axis to TH2 resulting in 
increased allergic disease. An extension of this hypothesis is that the TH2 predominance 
results in a decline in illnesses characterized by a TH1 response. However TH1 
characterised illnesses, including Crohn’s disease (CD), coeliac disease, multiple sclerosis 
and autoimmune diabetes, have also shown dramatic increases in incidence (38-42) over 
the last few decades. Observations on the effects of improved hygiene on populations are 
flawed because poor hygiene is associated with other confounding environmental variables 
such as poor dietary intake, lifestyle and limited access to medical care (42). The 
pathogeneses of such illnesses are now thought to be subtler and more complex than 
accounted for by this simple hygiene hypothesis alone, and are not fully understood 
(8;21;43). A prevailing theory for acquired illnesses is that they are the product of 
interactions between human and environmental factors in genetically susceptible 
individuals, resulting in immune dysregulation and clinical disease (44-46). The rising 
prevalence of IBD may be explained this way. Moreover Crohn's disease, because of its 
growing incidence, and NEC, because of its increasing burden on the ex-preterm infant, are 
of great interest to the paediatric gastroenterologist (47).   
1.4 Probiotics  
Probiotic are defined as live microbial organisms that, when consumed in adequate 
quantities confer health benefits to the host (48). The possibility of bacteria having positive 
as well deleterious effects to the host was first postulated by Ilya Metchnikoff in 1913 after  
he observed the longevity of Bulgarian peasants who consumed fermented milk products 
(49). However it was Lilly and Stillwell who coined the phrase ‘probiotic’ (defining them 
as ingested bacteria with benefits to the host) in 1965 (50) leading to a revival of interest in 
this area of science. Commercial manufacture of probiotics products, in particular yogurt 
based products, has increased dramatically over recent years. The scientific evidence to 
support the health claims of such products remains limited and in the 1990s attempts were 
made to standardise criteria and definitions for probiotic bacteria (51). 
The Lactic Acid Bacteria Industrial Platform (LABIP) workshop of 1998 summarised 
criteria for probiotic bacteria to include: human origin, non-pathogenic, resistant to gastric 
acid and bile, adherent to gut epithelial tissue, persistent within the gut epithelial tract, 
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production of antimicrobial substances, modulation of immune responses and metabolic 
activities (52). Other authors have argued that these bacteria should be studied in isolation 
and that data from closely related strains cannot be extrapolated to other strains of bacteria. 
Where possible evidence of beneficial effects should be demonstrated in well-designed 
placebo randomised double blind controlled trials in humans (53;54). Species commonly 
identified under these criteria as ‘probiotic’ belong to the genus: Lactobacillus, 
Bifidobacterium, Bacillus, Streptococcus, Enterococcus and the yeast Saccharomyces. 
However the FAO/WHO have reported that the Enterococcus species should not be 
considered probiotic (55). The species Lactobacillus, Bifidobacterium and Streptococcus 
have been most commonly studied to date because they are common and ‘natural’ 
members of the intestinal microflora (53;56). However authors have noted that differences 
between the behaviour of such bacteria in vitro and in vivo limit our ability to study their 
mechanisms of action (51). In addition these bacteria do not necessarily need to be alive, as 
products of the bacteria, such as cell wall and bacterial DNA, can modulate the profile of 
the gut microbiota and immune responses (55;57). 
1.4.1 Prebiotics and synbiotics 
‘Prebiotics’ are defined as non-digestible food components that confer a health benefit to 
the host by the selective stimulation of one or more species of probiotics (58). The majority 
of prebiotics are non–digestible carbohydrates (NDC) which require colonic bacteria for 
their degradation.  NDCs such as galacto-oligo saccharides (GOS) and fructo-oligo 
saccharides (FOS) have been included within artificial milk formula for infants (59). GOS 
and FOS have been shown to increase faecal Bifidobacteria counts and soften stools in 
term and preterm infants (60). Some observations of decreased numbers of 
enteropathogens have also been made (61). Some NDCs may also directly affect gut 
barrier function in addition to modulating the gut microbiota. A ‘synbiotic’, as the name 
implies, is an ingestible combination of prebiotics with probiotic species with the purpose 
of assisting the establishment of probiotic bacteria in the host gut (58).  
1.4.2 Evidence of probiotic mechanisms of action 
Production of antimicrobial compounds by lactic bacteria has been well demonstrated. 
These compounds can include fatty acids, hydrogen peroxide and diacetyl (51). Peptides 
with direct bacterial inhibitory properties have been termed ‘bacteriocidins’, of which there 
are now purified products available for human consumption (62).  The gut epithelium is a 
selective barrier to epitopes and increased intestinal permeability has been implicated in 
the aberrant immune response. Lactobacillus has been demonstrated to enhance intestinal 
   23 
barrier function in IBD animal models and in patients with IBD (63;64). Localised immune 
responses have been demonstrated with up-regulation of non specific mucosal IgA and IgE 
production (65;66). Increased antibody response has also been demonstrated in patients 
receiving vaccinations and concomitant probiotics (67). Enhanced activity of natural killer 
cells and phagocytosis by peripheral monocytes has been reported (68). Monocyte activity 
and cytokine profiles can be altered by exposure to Lactobacillus GG and VSL#3 (69;70). 
Probiotic induced increased cytokine (IFN-γ INF-α IL-2) production has also been 
demonstrated (71). Inhibitory immunomediators can also be induced by exposure to 
VSL#3 (72). T-cell function and redistribution of T-cells within the gastrointestinal tract 
has been demonstrated with Saccaromyces boullardii (73). 
Table 1: Mechanisms of action of probiotics 
Mechanism Biological effect 
Microbial compounds Bacterial inhibition 
Intestinal barrier function Enhanced barrier function 
Immunoglobulin Increased surface and circulating immunoglobulin 
levels 
Antigen presentation Enhanced natural killer cell activity, increased 
phagocytosis 
Cytokine production Both inhibition and up-regulation of cytokines 
T-cells Redistribution of T-cells within gastrointestinal tract 
 
1.4.3 Evidence of clinical effects of probiotics in adults 
The first studies of the prevention and treatment of acute infectious diarrhoea with 
probiotics were conducted on children (74). A Cochrane review of probiotics to treat 
infectious diarrhoea, collating  data from 1917 patients, demonstrated that probiotics were 
associated with less diarrhoea at three days and a shorter duration of diarrhoea (75). It was 
unable to conclude what was the most effective type of probiotic or probiotic effects on 
reducing mortality. Meta-analysis of the use of oral probiotics for the prevention of 
antibiotic associated diarrhoea in adults (AAD) suggests that they can reduce the frequency 
of AAD when administered concomitantly with oral antibiotics for nosocomial infections 
(76).  Probiotics have been demonstrated to moderately reduce Helicobacter pylori 
infection rates in adults patients with gastritis and increase eradication rates and reduce 
side effects when used as adjunct therapy (77).  
Probiotics have also been used to modulate complex acquired disease. In a Finnish study 
132 expectant mothers, who either had atopic dermatitis (AD) or first degree relatives with 
AD, were randomised to receive either Lactobacillus GG or placebo for two months 
antenatal and four months post-nasally (78). The frequency of allergy of the offspring in 
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the probiotic group was found to be half that of the placebo group at two years of age. Four 
year follow-up of this study replicated this finding (79). Several small studies have been 
performed to investigate the use of probiotics in alleviating the symptoms of irritable 
bowel syndromes, some with positive results (77). In contrast to this, a recent study of 
acute pancreatitis suggested an adverse effect of probiotic administration (80).  
1.4.4 Evidence of clinical effects of probiotics in children 
Many clinical studies using Lactobacilli, Bifidobacterial and the yeast Saccaromyces 
bouldaardi have been performed, both for prevention and treatment of infectious diarrhoea 
in children. A Cochrane review in 2003 pooled results from 1449 children (75). 
Conclusions for children alone were that probiotics reduced diarrhoea rates at three days 
and overall diarrhoeal duration. Meta-analysis for the use of probiotics for prevention of 
diarrhoea are not as conclusive (81). Studies in Finland suggested that probiotics could 
reduce the likelihood of AAD in children receiving antibiotics for respiratory or urinary 
tract infection (82;83). Meta-analysis from ten paediatric studies demonstrated a pooled 
reduction in the per protocol incidence of AAD by probiotics. However the intention-to-
treat analysis did not reach statistical significance (84). More recent studies have supported 
this indication. Of note, is a French study administering fermented milk products with 
inactivated bacteria or control formula to 971 infants which demonstrated a significant 
reduction in rates of consultation with a physician and for prescription of oral rehydration 
solution (57). A Finnish study in which Lactobaccillus GG was supplemented to 971 
nursery day-care children found a significant reduction in number of days of non-
attendance for respiratory or gastrointestinal infection when compared to the treatment 
group (85).  
Following publication of the data from Finnish mothers, probiotics have been trialled for 
the treatment of AD.  Weston et al (86) used as an adjunct to conventional therapy, 16 
weeks of treatment with a Lactobacillus in children with moderate and severe 
exacerbations of AD. They demonstrated a modest reduction in patient’s subjective 
symptoms of AD in the treatment group. In contrast to this Taylor et al (87) found that the 
administration of Lactobacillus GG to newborns at risk of allergy was associated with an 
increased risk of having AD and positive skin prick tests at 12 months of age. Several 
trials, with conflicting results for the treatment of allergy, have been published and the 
evidence remains inconclusive (88). Other conditions where limited evidence for positive 
effects exists for children include irritable bowel syndrome, constipation and the treatment 
of Helicobacter pylori (77). 
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1.4.5 Conclusions: probiotics 
The data supporting the clinical use of probiotics for both adults and children is growing. 
However promising therapeutic results in the areas of diarrhoea treatment and prevention 
of infection have not been consistently replicated. In particular the lack of standardisation 
of probiotic preparations in terms of bacterial species, dose and timing, limits the 
generalisability of many studies. As the pathogenesis of different diseases is diverse, the 
mechanisms by which bacteria impact on diseases processes are unique. Therefore the 
application of species beneficial in one illness will not necessarily hold for another. The 
use of such preparations for the treatment of childhood inflammatory diseases therefore 
requires further study of both disease pathogenesis and mechanisms of action of probiotics.  
1.5 Necrotising Enterocolitis (NEC) 
Necrotising enterocolitis (NEC) is the commonest acquired abdominal emergency of the 
newborn (89). It is characterised by mural intestinal ischaemia which can result in necrosis, 
perforation and death (90-92). Perforation of the bowel may occur in up to one third of 
affected infants (93). Clinical manifestations include abdominal distension, bloody stools, 
acute shock and systemic collapse (92). Changes on abdominal x-ray of pneumatises 
intestinalis (intramural air) are pathognomic (94). Perforations can be managed either with 
placement of peritoneal drains or laparotomy and resection of non-viable gut (95;96). 
Resected intestinal tissue demonstrates oedema, necrosis, intramural air and mucosal 
ulceration (97).  
1.5.1 Epidemiology 
The overall incidence of NEC has been estimated to vary between 1 and 3 per thousand 
live births (98). The principal risk factor is prematurity with 90% of cases of <33wks and 
of very low birth weight (VLBW) <1500g (90;93). NEC rates in this population have been 
calculated to be between 3 and 7% (99-101). This figure rises to 10% in the extremely low 
birthweight (ELBW) (<1000gm) (102). There is wide variability in rates between 
individual centres and sporadic incidence with clustering of cases has been reported (103).  
Minor risk factors have been noted with a slight male predominance and ethnicity, and a 
greater risk for Black and Hispanic populations noted in North America (104;105). The 
association of increased risk with lower socio-economic status is most likely a reflection of  
poorer infant nutritional status and lower birthweight (106). NEC is an acquired disease; it 
is not observed in stillbirths and very rarely occurs before the commencement of milk 
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feeds (91). There is a lower incidence of NEC in infants fed maternal breast milk as 
opposed the formula milk (107;108). The use of donor expressed breast milk may also 
reduce risk (109). The antenatal administration of corticosteroids to mothers in preterm 
labour has also been shown to consistently decrease NEC incidence (105). 
1.5.2 Diagnosis 
Suspicion of NEC is aroused by clinical signs, symptoms, biochemical and inflammatory 
indicators. Abdominal distension, bloody aspirates and stools are often accompanied by 
non-specific signs such as apnoea, poor skin capillary perfusion and sudden circulatory 
collapse (92). Abdominal tenderness is often difficult to detect clinically. Bell’s criteria 
classify NEC into three stages (94): Stage 1 suspected, Stage 2 confirmed by x-ray and 
Stage 3 perforated or ‘surgical’. Stage 1 and 2 are usually managed conservatively 
(intravenous antibiotics and nil by mouth) while stage 3 requires surgical intervention. 
Meta-analysis of biochemical indicators prior to development of NEC has demonstrated 
acidosis, hypoglycaemia and thrombocytopenia to be potent predictors (110). Prolonged 
and severe thrombocytopenia also correlates with mortality. However, none of these 
indicators is specific to NEC and are present in other causes of neonatal morbidity. This 
has led investigators to seek specific non-invasive markers of NEC.  
Calprotectin, a calcium-binding protein found in neutrophils, has been shown to be a 
reliable indirect marker of gut inflammation in adults and children with IBD (111). A study 
of over a hundred preterm infants demonstrated that elevated faecal calprotectin can be 
detected in cases with NEC. However identification of elevated calprotectin in the stool 
was detected before NEC was clinically suspected only in the minority of cases (112). 
Salivary epidermal growth factor (S-EGF) is detectable from the second trimester onwards 
and contributes to gut maturation. Attempts to correlate low serial levels of S-EGF infants 
with the onset of NEC have generated some promising preliminary results (113). Fatty acid 
binding proteins (FABs) are a class of organ specific cytoplasmic small mass proteins. 
Elevations of intestinal and hepatic FABs have been demonstrated in the serum of preterm 
infants with NEC suggesting their potential as early biomarkers (114). Paradoxically rises 
in faecal butyrate levels have also been correlated with intestinal injury in preterm injury 
(115) whereas a sizeable body of evidence supports its protective role post weaning and 
into adulthood (116;117). Whether butyrate itself is pathogenic or simply a biomarker for 
colonising pathogenic bacteria which may elevate the risk of developing NEC remains to 
be elucidated.  
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1.5.3 Management and current outcomes in NEC  
Clinical management of NEC is usually informed by a sliding scale according to Bell’s 
classification (94). Stage 1 NEC is managed with broad spectrum antibiotics and a period 
of observation with gut rest (118). Confirmed NEC requires patients to receive nothing by 
mouth for a prescribed period of time (89). Supportive management, including blood 
volume expansion, inotropic drugs, ventilation and blood transfusion may be necessary to 
maintain perfusion and oxygenation to vital tissues. Reintroduction of feeds should be 
cautious, as stricture formation and reoccurrence complicate recovery from stage 2 NEC 
(95). Stage 3 NEC is managed in conjunction with surgeons. Options include laparotomy 
and resection of tissue or the placement of a drain and deferral of surgery unless or until 
complications such as stricture formation require it. Although many clinicians suspect that 
the removal of an inflammatory mass by resection will be of benefit to patients, careful 
analysis of treatment options has failed to demonstrate significantly better results (95;96).  
Overall mortality for infants with stage 2 and 3 NEC remains high with little significant 
reduction in peri-operative mortality over the last decade (98). However other major 
contributors to morbidity and mortality in VLBW infants, such as bronchopulmonary 
dysplasia and intraventricular haemorrhage, have declined (98;104). This means that the 
relative contribution that NEC has made to infant mortality and survival with morbidity 
has increased.  Survivors of NEC have an overall uncertain prognosis with higher risk of 
neurodevelopmental delay and cerebral palsy in comparison to other preterm populations 
(119;120). Infants surviving massive intestinal resection face inadequate gut function and 
intestinal failure (121). Although long-term management with parenteral nutrition (PN) can 
permit intestinal adaptation, this treatment carries significant morbidity and mortality 
through recurrent line sepsis and intestinal failure associated liver disease (IFALD) 
(121;122). Although long term survival for intestinal failure is improving, data from 
centres with high NEC rates suggest that mortality is still significant even after extended 
PN (123). This significant long term morbidity and mortality continues to focus attention 
on efforts to better understand the pathogenesis of NEC and strategies for its primary 
prevention. 
1.5.4  Pathogenesis of NEC 
The ‘Santulli hypothesis’ is now over 30 years old (92). Santulli argued that NEC required 
the presence of excessive luminal substrate, abnormal bacterial colonisation and intestinal 
ischaemia (92) (figure 2). The exact pathogenesis of NEC remains unclear. However the 
combination of several factors resulting from, or affecting, the immature gut appear to be 
responsible (118). The intestinal migrating motor complex does not fully develop until 
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33wks of post-conceptual age resulting in inadequate digestion of food substrates which 
can exert direct antigenic stress on the gut (124). Immature circulatory function has been 
postulated as a mechanism for enterocyte damage and inflammation, as suggested by 
animal models in which hypoxic ischaemic injury can induce NEC (125). However more 
recently this has been called into question as hypoxia and ischaemia have been found to be 
less potent predictors of NEC than inflammatory cytokine levels (126;127). 
 
 
Figure 2 :The inflammatory cycle of NEC 
 
Microcirculatory abnormalities may lead to local nitric oxide deficiencies. Nitric oxide 
synthase deficiency is implicated in other diseases of the preterm infant, including 
bronchopulmonary dysplasia and retinopathy of prematurity (128). Inadequate intestinal 
barrier functions has also been demonstrated in preterm infants with reduced levels of 
mucin, alpha-defensins and prostaglandins, which may all regulate intestinal barrier 
function (129). Intestinal permeability can also be compromised (130).  
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1.5.5 Gut microbiota in NEC 
Several lines of evidence point to the involvement of the gut microbiota in the 
pathogenesis of NEC. NEC does not occur in the sterile environment in utero (92). As 
discussed earlier, the bacterial colonisation of preterm infants is often delayed and less 
diverse than that of the healthy term infant (see 1.1). Faecal samples from infants’ exhibit 
colonisation with Clostridia spp, Enterobacteria and coagulase negative Staphlycocci prior 
to the development of NEC (129;131). Abnormal colonisation with Salmonella sp. and E. 
coli can lead to inflammatory responses in immature intestinal tissue (132).  Alterations in 
the metabolic profile of the gut microbiota also have been observed prior to NEC 
development (115). Epidemiological studies of NEC demonstrate temporal and 
geographical clustering that can be reduced by preventative measures (118) (see 1.5.7). 
Gas taken from intestinal pneumatosis is derived from the metabolic activity of pathogenic 
bacteria. Perceived enteropathogens have been cultured from the blood of patients with 
NEC (118). NEC most commonly affects the terminal ileum and colon, the region of the 
gut most densely colonized with bacteria (90).  
However several different organisms are associated with NEC rather than a single 
identifiable agent (133). In addition, many preterm infants develop NEC despite being on 
intravenous antibiotics (105;106). In animal models, NEC rates induced by cold stress are 
reduced but not eradicated by the absence of bacteria (134). This suggests that rather than 
inducing infection directly, bacteria are an important co-factor in propagating the 
inflammatory response seen in NEC. Whether the inflammatory response in NEC is an 
appropriate response to clinical infection by pathogenic micro-organisms or it represents 
an inappropriate inflammatory response to bacterial colonisation is a topic of debate (118). 
The introduction of substrates into the lumen of the gut (most often milk feeds) appears to 
predispose to abnormal patterns of gut microbiota that are a factor in the development of 
inflammation and ischaemia. However it may be that these substrates merely provide for 
abnormal bacterial colonisation rather than being pro-inflammatory themselves. 
1.5.6 Inappropriate immune response  
Jillings et al (134) elegantly demonstrated the interaction of the innate immune system and 
gut microbiota in the pathogenesis of NEC in an animal model. They induced NEC by cold 
and hypoxic stress in neonatal rats. Pups were randomised to feeding with formula 
delivered via a sterilised feeding catheter, or one that was freely colonised by 
environmental bacteria. The sterile fed pups had significantly lower NEC rates than the 
standard feeding pups (20% vs.53%) demonstrating the proinflammatory role of bacteria. 
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However in a second experiment toll-like receptor 4 (TLR-4) knockout mice were bred. 
TLR-4 is a key component for bacterial sensing of the innate immune system. These mice 
were compared to wild type mice under cold hypoxic stress and the TLR-4 knockout mice 
had significantly less NEC in comparison to the wild type mice (12% vs. 62%). This 
demonstrated that the innate immune response to bacteria is important in propagating 
inflammatory responses in NEC. The inflammatory response is now well characterised in 
NEC with demonstration of the key roles of cytokines including platelet aggregating factor 
1, TNFα, IL-6 and IL-8 (90;135).  
1.5.7 Novel preventative strategies for NEC  
Other than reducing prematurity, the single best modifiable factor for reducing NEC to 
date is the administration of human milk, as opposed to preterm formulae (136;137). 
Components of human breast milk, such as amino-acids, nucleotides and long chain fatty 
acids, have been found to have direct positive effects on the immune response. Infants fed 
on formula milk have a different profile of bacterial colonisation from breast fed infants, 
the latter with greater numbers of Bifidobacteria, Lactocbacilli and fewer perceived 
enteropathogens such as Clostridia, Bacteroides and Pseudomonas (138-141). Preterm 
infants display a delay in bacterial colonisation with less species diversity and greater 
numbers of perceived eneteropathogens (4). Recent attempts to identify potential 
protective strategies for NEC have focused on mimicking or augmenting the effects of 
human breast milk, in terms of immune response or manipulation of the gut microbiota 
(142).  
1.5.7.1 Altering the immune response 
A simply conceived method to alter the preterm immune response is to supplement 
formula fed infants with immunoglobulin, because human-milk may exert some of its 
protective effects through the presence of IgA in colostrum and by human milk’s ability to 
stimulate IgA production in the preterm neonate (143). However trials of the 
administration of both intravenous IgA and IgG have demonstrated only a non-significant 
trend towards NEC reduction (144;145). 
Initial research into the therapeutic use of the amino-acids glutamine and arginine showed 
promise. Glutamine is the most abundant amino-acid in muscle and plasma and is a 
preferential substrate for rapidly dividing cells such as enterocytes (146). It has been 
suggested that glutamine becomes ‘essential’ during periods of stress and therefore 
deficiency in the newborn exposes enterocytes to the risk of oxidative damage. A study of 
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enteral supplementation of glutamine in 436 preterm infants demonstrated a reduction in 
NEC-related morbidity (147), but a larger study examining parenteral administration of 
glutamine did not show any significant reduction (148). The recently updated Cochrane 
review on the use of enteral glutamine demonstrates no clear effects on NEC rates in the 
preterm infant (149). Arginine is an essential precursor of nitric oxide synthesis via nitric 
oxide synthase, deficiency of which is implicated in several diseases of the newborn (127). 
Again arginine appears to be conditionally essential for the newborn. A single controlled 
study of arginine supplementation to preterm formula fed infants demonstrated a 
significant reduction in the incidence of NEC in the treatment group (6.7 vs. 23% p<0.01) 
(150). However this small study (154 infants) has not been replicated. Down-regulating the 
immature inflammatory response by enhancing gut maturation is another measure and 
correlations of gut maturation with growth factors such as EGF have been demonstrated 
(113). However, to date, only one study using insulin-like growth factor 1 (IGF-1) (151) in 
which preterm VLBW infants were randomised to receive either IGF-1 supplement or 
placebo in their milk, has been conducted. No effect on NEC rates was observed in this 
small study, although the treatment group did establish full feeds over a significantly 
shorter duration than controls.  Reduction in NEC rates has been demonstrated with other 
feed components in NEC models. Lu et al  (152) demonstrated significant reductions in 
NEC rates in a rat model by supplementing formulae with differing long chain fatty acids, 
However, as yet, no uses of this type of ‘immunonutrition’ have advanced to clinical trial.  
1.5.7.2 Manipulating the gut microbiota 
Direct manipulation of the gut microbiota can be achieved by the administration of enteral 
antibiotics. This practice has found little favour amongst neonatalogists, due to concerns 
about the development of antibiotic resistance. However it was first trialled thirty years ago 
(153). Cochrane meta-analysis has identified five studies which used either enteral 
gentamicin or vancomycin for the prevention of NEC (154). Cumulative results suggest a 
reduction in the incidence of NEC and NEC-related mortality. It also demonstrated an 
increased incidence in colonisation with resistant bacteria in the treatment group. Despite 
these promising results concerns remain about a therapy that may make such drastic and 
potentially long-term changes to the gut microbiota in these vulnerable infants 
(103;118;154). Clinicians are inclined to seek safer methods to change the composition of 
the microbiota. 
Prebiotic-supplemented infant milk formulations now exist containing either GOS, FOS or 
a combination thereof. Several studies have demonstrated that these prebiotics are well 
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tolerated and can enhance faecal Bifidobacterial populations in term and preterm infants 
(59;61) and reduce faecal enteropathogen numbers (61;155). They have been shown to 
result in softer stool consistency (60;156) and increased levels of secretory IgA (157). 
However, no large clinical trials of their effects on NEC rates have been performed. In the 
light of data on the benefits of mother’s breast milk, and now the effects of donor human 
milk (109) on NEC rates, it is more likely that the formula fed preterm infant will become 
increasingly rare. Therefore to most effectively reduce NEC rates in the VLBW 
population, strategies which will confer benefits over and above those of human milk 
feeding must be adopted. The most pertinent strategy therefore might be the administration 
of prophylactic oral probiotics.  
1.5.8 Probiotics for NEC? 
Interest in the use of oral probiotics for the prevention of NEC began to develop in the late 
1980s as the understanding of NEC pathogenesis evolved. Enthusiasm for the perceived 
benefits were tempered by a lack of knowledge as to whether oral probiotics could 
establish themselves in the immature preterm gut, safety concerns over probiotic sepsis in 
the immunocompromised infant and their long-term effects on nutrition and immune 
function (132). Nevertheless by the early 1990s a neonatal rat model had demonstrated a 
reduction in NEC rates with the supplementation with Bifidobacteria (158) and a pioneer 
infant trial demonstrated changes in microflora composition in infants receiving oral 
Bifidobacteria (159). In a large retrospective case control study Hoyos (160) studied the 
administration of Lactobacillus acidophilus and Bifiodbacteria infantis to 1237 infants and 
compared it to 1282 infants from the previous year. The study results showed a significant 
reduction in the NEC rates and NEC-related mortality in the treatment group. These 
developments led to attempts to examine the evidence for the benefits of oral probiotics for 
the prevention of NEC in VLBW infant. This question forms the basis of experimental 
work in chapter 2. 
1.6  Inflammatory Bowel Disease (IBD) 
Inflammatory bowel disease (IBD) is a chronic, relapsing inflammatory disease of the 
bowel, which can affect the whole gut (Crohn’s disease CD), be localised to the large 
bowel (ulcerative colitis - UC) or exhibit features of both (indeterminate colitis) (161). IBD 
is characterised by bloody diarrhoea, abdominal pain and weight loss (161). Extraintestinal 
manifestations of IBD include specific rash (eythema nodosum, pyostomatitis vegetans), 
arthropathy, posterior uvietis and primary sclerosing cholangitis. Diagnosis is made by 
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macroscopic examination of the bowel mucosa either directly (endoscopically) or 
indirectly (capsule biopsy) and with histological tissue examination (162).  
Crohn’s disease is characterised by discontinuous disease that can affect any region of the 
gastrointestinal tract from mouth to anus (163). In children the most commonly affected 
regions are the distal small bowel, colon, peri-anal region and mouth. Rectal sparing is 
common in CD. Affected areas demonstrate transmural thickening, oedema, chronic 
inflammation causing lumen narrowing which can lead to intestinal obstruction (164). The 
mucosal surface may show apthous ulceraction which can coalesce into extensive linear 
serpiginous ulceration (cobblestoning). Microscopic appearances are dependant on the 
duration and severity of inflammation, ranging from superficial apthoid ulcerations to 
confluent depressed ulcer beds, sub-mucosal obliteration, crypt abscesses and epitheloid 
granuloma formation (164).  
Ulcerative colitis most often affects a continuous segment of large bowel ranging from a 
limited short segment (proctitis) to affecting the entire large bowel (pancolitis) (165). 
Inflammation is characteristically confined to the mucosal surface. It varies from 
generalized eythema with loss of normal mucosal vascularity, to surface ulceration with 
exudative flecks and deep ulcers and pseudo-polyps. Neutrophillic infiltrate of crypts with 
crypt abscesses and chronic inflammation in the lamina propria are typically seen on 
histological examination (165).  
In around 10% of cases of IBD in which the inflammation is limited to the large bowel it 
may be impossible, at least at presentation, to differentiate between CD and UC. These 
cases are referred to as indeterminate colitis (166). 
1.6.1 IBD in children 
Inflammatory bowel disease is often characterised by bloody diarrhoea, abdominal pain 
and weight loss (163), but only around 25% of children present with this classic triad 
(167). Younger age of onset is associated with delay in diagnosis which can lead to 
malnutrition, growth failure (168-171), inadequate bone mineralisation (172-174) and 
pubertal delay (175). There is a higher prevalence of abdominal pain in children with CD 
(33). Children with UC have a greater incidence of pancolitis (33;176). Children with IBD 
are more likely to have a positive family history for IBD, suggesting that genetic factors 
are more important in these patients than in adults (177). The Scottish Childhood IBD 
population is characterised by extensive intestinal involvement with rapid progression of 
disease, in particular an early requirement for surgery in UC (178). 
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1.6.2 IBD epidemiology 
The incidence and prevalence of all age on-set IBD has risen dramatically world-wide in 
the last four decades. Both CD and UC have risen in Europe (179;180), the UK (33;181-
183) and North America (184) where their incidences have always been relatively high. 
Childhood onset IBD has also seen a dramatic increase over the same time period although 
the proportion of patients diagnosed with IBD in childhood and adulthood has remained 
relatively equal (184). There is a slight female predominance of CD and a male 
predominance of UC (185). Within North America, African Americans and Hispanics are 
less likely to develop IBD than the Caucasian population (186). However in the UK ethnic 
minorities appear to have a similar risk of IBD to Caucasian populations (33;187).  The 
single greatest risk factor for IBD is a family history of IBD, with 5-35% of newly 
diagnosed IBD patients having a first degree relative with established IBD (188). Disease 
concordance rises to 66% in monozygotic twins (188). Appendicectomy and cigarette 
smoking are the only firmly established environmental factors: smoking protects against 
the development of UC, as does appendicectomy for proven appendicitis, whereas, in 
contrast, smoking is a risk factor for the development of CD (189;190). Other potential 
environmental modifiers include childhood immunisations, unrefined dietary sugars and 
breast-feeding (191;192). Within the UK cases of CD in children appears to have increased 
three-fold between 1960-1990 whilst UC rates remained relatively static (193). A 
prospective study of the UK population for 1998-1999 calculated  that the incidence of 
childhood onset IBD has risen again to 5.2/100 000 child years (CD 3.1 and UC 1.4/100 
000 child years) (33). The Scottish population has a yet higher incidence, with 6.5/100 000 
child years of IBD (CD 4.2 and UC 1.8/100 000). Better disease recognition may in part 
account for this rapid rise, although elsewhere in Europe and North America similar rises 
have been recorded (180;184). 
1.6.3  IBD genetics 
Epidemiological studies have long supported a genetic basis for IBD (183;194;195). There 
is a greater risk of IBD amongst first degree relatives, with higher concordance between 
monozygotic twins than dizygotic twins (188).  Early onset disease may confer a higher 
risk of IBD, especially CD, to first-degree relatives. There are also marked differences in 
incidence with ethnicity (196).  There is a north to south cline across Europe, with the 
highest prevalence of childhood onset IBD found in Scandinavia and Scotland (33;180). 
Several gene loci have been associated with an increased susceptibility to IBD, and the 
strongest evidence for genetic linkage in IBD susceptibility is located on chromosome 16 
and is designated IBD1 (197).  Within the IBD1 locus the causal gene has been identified 
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as the caspase activating recruitment domain gene (CARD15), otherwise known as the 
nucleotide oligomerisation domain (NOD2) with allelic variations in the CARD15 protein 
conferring an increased risk for the development of CD (198;199). The CARD15 protein is 
an intracellular receptor that identifies pathogen associated molecular pathways from 
bacterial muramyl dipeptide (MDP) (200). MDP is a common component of most Gram-
positive and Gram-negative bacteria. CARD 15 protein mutations also appear to interplay 
with a family of equivalent cell surface receptors known as toll-like receptors (TLRs) 
(196), numerously present on the enterocytes of the gut mucosa (45). Specific allelic 
variations have been characterised in the Scottish childhood onset IBD population (201-
203) and these other IBD candidate genes also appear to encode for components involved 
in immuno-surveillance (196). These recent observations have focused interest on the 
interface between the immune system of the gut and its microbiota (figure 3). 
 
Figure 3: Interrelationship of factors associated with the pathogenesis of IBD 
 
1.6.4 Immunology in IBD 
The involvement of the immune system in the pathogenesis of IBD, via inflammatory 
cytokines, has been demonstrated in animal experimental models (204). A self-
perpetuating inflammatory cascade occurs due to an imbalance between pro- and anti-
inflammatory mediators (44). Cytokines implicated in the initiation and perpetuation of 
inflammation includes; interleukin-1 (IL-1), IL-6, IL-8 IL-12, interferon gamma (IFN-γ) 
and tumour necrosis factor alpha (TNFα) (23;44;204-206). 
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The pro-inflammatory effects of TNFα in both local inflammation and peripheral organ 
involvement in IBD is elegantly demonstrated by the effectiveness of specific TNFα 
antibodies to reduce intestinal inflammation (207;208) and extra-intestinal manifestations 
of IBD such as pyoderma gangrenosum (209).  TNFα may exert its effect upstream 
through regulation of transcription factors (210). Nuclear factor κB (NFκB) appears to be 
one such important factor in the propagation of intestinal inflammation. Activated NFκB 
up-regulates the expression of pro-inflammatory molecules in IBD (211). The precise 
regulation of NFκB in the inflammatory response is unclear, but is known to involve the 
CARD15 protein, TLRs, TNFα and bacterial lipopolysaccharide directly (212;212-215).  
This implicates the bacterial microbiota in triggering and propagating immune dysfunction, 
and thus inflammation, in IBD.  
1.6.5 Gut microbiota in IBD 
The intestinal T-cells of patients with CD are hyper-reactive to bacterial antigens.  CD can 
be characterized by a Th1 skewing of T-cell response (216;217), whereas UC exhibits a 
Th2 response (44). The initiating and perpetuating stimuli for such immune dysregulation 
are not fully explained by genetic predisposition, as the number of known IBD promoting 
gene mutations, such as CARD15, greatly exceeds the clinical prevalence of disease (196).  
Mouse models also demonstrate that clinically identical mucosal inflammation can be 
initiated by different genetic immune defects (44). This indicates that other modifying 
factors must be present and suggests that it is changes in the luminal environment that are 
crucial to the pathogenesis of IBD. The fact that experimental colitis does not develop in 
germ-free animals (205), that the introduction of single bacterial species can induce 
mucosal inflammation in animal models (218) and that diversion of the faecal stream is an 
effective treatment of active CD (219), further implicates gut bacteria in the pathogenesis 
of IBD. 
1.6.5.1 Exaggerated or altered immune response? 
There are two prevailing hypotheses which might explain these findings:   
• IBD is the result of a normal (if prolonged and aggressive) immune response to a 
single pathological agent. 
• IBD is the result of an altered immune response to a ‘normal’ microbiota (loss of 
tolerance). 
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Certain mycobacteria have been detected in the gut wall of patients with CD (220;221). 
However the lower incidence of CD in rural areas, the protective effects of poor sanitation 
in the development of CD and the effectiveness of immunosuppressive agents in the 
treatment of intestinal inflammation argue against a single infective agent as the cause of 
CD (222). Moreover anti-tuberculosis therapy does not cure IBD. Such observations may 
also be a consequence of loss of intestinal mucosal integrity due to the inflammatory 
process of IBD, rather than to an aetiological factor. Other agents implicated have been 
various bacteria, Coxsackie, Reovirus, Norwalk virus, Influenze B, Herpes, Paramyxovirus 
and measles. However more stringent analysis of such observations suggest these are no 
more than co-factors (223). 
Another working model for the pathogenesis of IBD is that changes in the gut flora disturb 
the balance of pro- and anti-inflammatory responses (44;224). Rather than implicating a 
single species, it is hypothesised that such disturbance of immunoregulation involves 
changes across many of the bacteria present. This concept of an imbalance between 
‘harmful’ and ‘protective’ bacteria has been termed dysbiosis (225;226). Probiotics, have 
been shown to suppress local inflammation in experimental colitis, supporting the 
hypothesis that bacteria are involved in both promoting and down-regulating the 
inflammatory responses in IBD (227;228). 
Changes in the luminal bowel flora, including loss of population diversity leading to a 
dominance of pathogenic species such as Clostridia difficle, Bacteriodes vulgates and E. 
coli, have been observed before relapse in IBD (229;230). Reduced bacterial diversity has 
been demonstrated in mucosal biopsies of patients with active IBD, with loss of 
commensals such as Clostridium leptum, Eubacteria and Bifidobacteria (231;232). Such 
changes in bacterial diversity have been shown to be independent of CARD15 mutations 
(233). In addition, modifications of the composition of the bowel flora have been observed 
in patients with CD between relapse and remission (234;235). 
Although bacterial sensing has been implicated in the pathogenesis of IBD, recent research 
has demonstrated that the products of bacterial activity have a regulatory effect on 
inflammation in IBD (116;117). The SCFA, butyric acid, is a product of the bacterial 
fermentation of non-digestible carbohydrate and in the acidic pH of the colon exists 
predominantly in its anionic form; butyrate. Butyrate is the preferential energy substrate 
for human colonocytes (236). It has a regulatory effect on colonocyte metabolism, cell 
division and apoptosis (237). Butyrate down-regulates mucosal inflammatory responses in 
vitro by inhibiting the activation of NFκB (117;216;238). Butyrate has been used as a 
   38 
proxy measure of bacterial metabolic activity when comparing stool samples of healthy 
controls and patients with IBD (239). Loss of butyrate-producing species has been 
demonstrated in faecal samples of patients with CD (230;239). Moreover butyrate has been 
shown to be an effective local topical treatment of UC (240-242) and oral therapy has been 
shown to positively affect mild to moderate CD (240;241;243). This suggests that changes 
in the metabolic activity, as well as diversity of bacteria, play a part in the pathogenesis of 
IBD.  
Luminal and mucosal bacteria may play differing roles in the pathogenesis of IBD as 
luminal bacteria only interact indirectly with the gut epithelium through production of 
metabolites and bacteriocidins, whereas mucosal bacteria lying on the epithelium are more 
likely to interact with cell surface receptors. In the healthy gut, direct bacteria-mucosa 
interaction is inhibited by the mucin layer which keeps the biofilm bacteria away from 
direct contact with the mucosal surface. However in active IBD the mucin layer thickness 
can be decreased or absent resulting in disturbances in the mucosal biofilm (244). This loss 
of barrier function leads to increased numbers of bacteria adhering to cell surfaces and 
increased permeability allowing more of these bacteria to injure or invade the epithelium. 
This suggests that in active IBD bacteria normally present in the lumen, as opposed to the 
mucosa can also play a role in direct host-bacteria crosstalk. 
These findings pose two key questions concerning the role of the microbiota in the 
pathogenesis of IBD:  
• How are changes in bacterial diversity involved in the pathogenesis of IBD? 
 
• Are there changes in metabolic activity that instigate or propagate IBD?  
 
Whilst these two questions are inextricably linked, the tools with which each can be 
investigated are not equally well developed. The colonic microbiota, whilst diverse, is also 
complex and the activity of groups of bacteria within it varies temporally and spatially 
within the gut lumen, regulated by nutrient supply, host immunological response and inter-
microbe interaction and competition for survival and growth (see 1.1). 
1.6.5.2 Bacterial diversity versus activity? 
The bacterial genomic reservoir of the collective human gut is very diverse (>100 000 
species) but within each human individual the number of species may be much smaller 
(around 1000 species) (245). This has lead to the concept of a ‘personalised microbiome’.  
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Different bacterial strains may be performing the same protective, immunological and 
metabolic activities in different individuals, which could be either preventing or 
stimulating the inflammatory response in IBD. This is termed ‘functional redundancy’.  
However, molecular bacterial species diversity assays alone may be poor indicators of 
functional activity because they rely on the amplification of short sequences of DNA/RNA, 
which can be derived from active, inactive or dead bacteria. Around 80% of the gut 
microbiota can be characterised only by culture-independent methods and these do not 
assess the complete genome of bacteria, far less which genes are being expressed, nor 
information about their metabolic activity (246). Assumptions cannot be made about the 
functions of even highly phylogenetically similar species as other factors in the microbial 
genome can affect the expression of genes encoding for metabolic function. 
To understand the complex changes in the gut microbiota that may predispose to the 
genesis and/or relapse in IBD, techniques are needed which can assay and link metabolic 
activity and diversity of the unculturable bacteria (figure 4). Bacterial activity in vivo has 
been assessed, by proxy, through analysis of metabolites such as SCFAs, ammonia, 
hydrogen-sulphide, phenols and bile acids (247;248).  SCFA analysis has been used to 
study gut bacterial metabolic activity in culture models and human faecal samples 
(12;249;250). However such measures are affected by confounding factors within the 
colonic environment including intestinal motility and transit time, absorption and 
colonocyte metabolism. A more direct measure linking the microbiota’s functional activity 
with diversity is required (see 1.9-1.12).
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LPS= lipopollysaccharide, MDP= muramyl dipeptide, NfκB= nuclear factor kappa B, SCFA= short chain fatty acids, IFγ= intereferon gamma, IL-1= interleukin 1, TNFα= 
tumour necrosis factor alpha, TLRs= toll like receptors
 
Figure 4: Hypothesised interrelationship between bacterial diversity and activity in relapsing IBD 
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1.7  Medical Therapies in IBD 
Effective medical therapies for the treatment of IBD began with the use of 5-
aminosalicylates (5-ASA) and oral corticosteroids in the 1940s and 1950s respectively 
(251). These therapies work primarily by targeting the inflammatory cascade at various 
levels to reduce mucosal and peripheral inflammation. Modern medical therapies are now 
categorised into corticosteroids, 5-ASA, immunomodulators and biological therapies 
(164). 
1.7.1 Corticosteroids 
Corticosteroids bind to specific intracellular receptors to effect the transcription of steroid 
responsive genes (252). It is also recognised that activated steroids receptors interact with 
NF-κβ in regulating the inflammatory response (252). Pro-inflammatory proteins 
suppressed by corticosteroids include IL-1, IL-2, IL-8, IL-6, γ-interferon, and TNF-α. 
These in turn result in impaired inflammatory signalling in terms of antigen presentation, 
and inflammatory cells activation (253). 
Oral corticosteroids (primarily prednisolone) have long been used to induce remission in 
CD (254) and they have been proven effective in the treatment of adults and children for 
more than four decades. A Cochrane systematic review has demonstrated that they are 
effective in achieving clinical remission in CD in comparison to placebo (255). 
Corticosteroids are also effective in inducing remission in patients with active UC (256). 
However the adverse effects of oral corticosteroids are high with Cushingoid appearance, 
hypertension and increased infections being commonly encountered in the short-term and 
osteoporosis, adrenal suppression and growth retardation as long-term concerns (253). Oral 
budesonide is a topically-active glucocorticoid that has a much lower systemic 
bioavailability due to first pass metabolism and evidence suggests that it can be effective in 
treating active CD with fewer systemic adverse effect (257;258). 20% of patients 
encounter recurrence of symptoms on tapering of oral corticosteroids (259) and a Cochrane 
review suggests that there are no benefits in using steroids to maintain long-term remission 
in patients with quiescent CD (260). There is also little evidence to support their use in the 
maintenance of remission in UC (256).  
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1.7.2 5-Aminosalicylates (5-ASA) 
Sulphalasazine was the first 5-ASA used in clinical practice for the treatment of IBD (261). 
Sulphasalazine consists of a sulphapyridine linked to a 5-aminosalicylate, which is the 
active moiety, released as a result of bacterial cleavage in the colon (262). Further 5-ASAs 
have been developed, including mesalazine and olsalazine. Aminosalicylates down-
regulate inflammatory responses through inhibition of IL-1, IL-2 and IL-6, lymphocyte 
proliferation and epithelial HLA-DR expression and enhancement of barrier function 
(263). High level evidence supports the use of 5-ASAs for induction of remission in UC 
(264) and for a moderate benefit in maintenance of remission in UC (264). Modest benefits 
have been demonstrated with 5-ASAs in inducing remission in patients with mild to 
moderate colonic CD, but, the evidence does not support their use in maintaining remission 
in CD (265). 5-ASA’s also have a well documented adverse effect profile, including rash, 
headache and pruritus and, more rarely, toxic hepatitis, leucopenia, pancreatitis and 
neurotoxicity (265). Because of the limitations of both steroids and 5-ASA in maintaining 
remission in many IBD patients often require additional therapy with immunomodulating 
agents is required. 
1.7.3 Immunomodulators 
The imidazole derivative 6-mercaptopurine (6-MP) and its precursor, azathioprine, have 
been used in clinical practice for the treatment of IBD for over four decades. The majority 
of clinical experience, in the UK, is with azathioprine, which was developed in 1957 as a 
slower release formulation of 6-mercaptopurine (266). Azathioprine is rapidly metabolised 
to 6-MP in the body which exerts its effect by inhibiting purine synthesis in DNA and 
RNA and thus reducing cell proliferation and thereby causing immunosuppression (266). 
Azathioprine has been shown to be effective in both inducing remission and for 
maintenance therapy for CD, with significant steroid-sparing effects. (267). Azathioprine 
may reduce the requirements for steroids in inducing remission in UC (268) and appears to 
reduce maintenance relapse rates long term (269). The related compound, cyclosporine, 
has been used as a rescue therapy in patients with severe UC before establishment on 
azathioprine (270). 
Methotrexate also causes immunosuppression by inhibiting purine synthesis in DNA and 
reducing T-cell proliferation. Methotrexate at higher dose (25mg weekly) appears to 
induce remission in CD (271). Methotrexate has also been shown to be superior to placebo 
for the maintenance of remission in CD and is now commonly used as an adjunct to 
therapy in patients who relapse on or are intolerant to purine metabolites (272).  
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Adverse events with immunosuppressants are significant with nausea and vomiting both 
common. Over-immunosuppression leading to leucopenia is a potential risk with both 
azathioprine and methotrexate, which requires frequent white cell level monitoring (268). 
In addition methotrexate is also associated with the development of hepatitis and 
hypersensitivity pneumonitis (272). Fatal sepsis and malignancy risk are low (273). A 
significant proportion of patients are intolerant of, or do not achieve long-term remission of 
symptoms, with immunosuppressive agents.  
1.7.4 Biological therapies 
Because of the limited success of immunosuppressive agents to treat moderate and severe 
IBD, and because of their adverse effect profile, newer drug therapies have been developed 
to target more specific aspects of the inflammatory cascade. Infliximab, a chimeric 
monoclonal antibody to TNF-α, was the first such ‘biologic’ agent employed for the 
treatment of IBD (207). Infliximab binds to both trans-membrane and circulating TNFα 
preventing it binding to receptors on target cells, thus down regulating the inflammatory 
cascade (274). Infliximab appears effective in inducing remission in active CD (275) and 
has been used extensively in adults and children for this purpose (208). Clinical trials 
suggest that repeated infusion can help maintain remission in infliximab-sensitive patients 
(276;277). Infliximab, as adjunct therapy, also appears to promote mucosal healing and 
reduce short-term need for surgery in UC (278). Limited evidence also suggests a role for 
infliximab as maintenance therapy for UC (279).  ‘Human’ anti-TNF (adulibumab, 
certolizumab) therapies are now in use and appear to have similar effects (280). 
Enthusiasm for the biological agents, particularly in North America, has led authors to 
promote their early use in CD (280). Other specific biological agents of promise include Il-
1 antibodies, TNF-α converting enzyme inhibitor, CD cell antibodies and B-cell directed 
therapies (281;282).  
Adverse events reported with biological agents include acute infusion reactions, delayed 
hypersensitivity reaction and auto-immune phenomena (258;283). Immunosuppression 
related infections have been reported, with concerns over fatal sepsis and the development 
of tuberculosis. Case reports of malignancy have been described as infusion numbers have 
increased, with most recently reports of invariably fatal hepato-splenic T-cell lymphoma 
(284;285).  
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1.7.5 Conclusions: medical therapies 
Medical therapies have evolved over the last fifty years to meet the increasing complexity 
of the natural history of IBD. Although mortality remains consistently low in IBD, despite 
maximal medical therapies, a significant minority of patients do not achieve long-term 
remission or experience significant complications of primary disease or treatment (need for 
surgery, malnutrition, poor bone mineral density). In children and adolescents growth 
failure and pubertal delay remain significant clinical problems despite the availability and 
use of more complex therapies (174). Medical therapies target the inflammatory cascade 
rather than the stimuli for inflammation, such as the gut environment. They also do not 
address malnutrition as a factor contributing to the inflammatory process nor its effect on 
the individual patient. The adverse events of medical therapies contribute to the long-term 
morbidity of patients with IBD, and now appear to pose a significant mortality risk. With 
these issues in mind, a separate approach of ‘nutritional therapies’ for IBD has been 
developed over the last two decades.  
1.8  Nutritional Therapies in IBD 
Theories linking the aetiology of IBD to dietary factors have existed for some time. These 
have implicated Westernised diet, in particular refined sugars (286), ‘fast food’ (287), 
margarine (288) and dairy produce (289). However critical examination of these 
hypotheses are inconclusive and specific dietary recommendations cannot go beyond 
general advice about healthy eating (290). 
Disease related malnutrition (undernutrition) is common in both CD and UC, with 
decreased adipose tissue, lean body mass, and muscle bulk, linear growth and bone mineral 
density all described (290). Gut rest and PN were previously used as a primary therapy for 
active CD, but they have now been shown to have little impact on clinical remission rates 
and they are limited to patients with severe active disease and undernutrition (290).  
The possibility that enteral nutrition had a direct positive effect on the natural history of 
IBD was speculated in the 1970s when it was noted that patients with IBD receiving 
exclusive elemental feeds for preoperative supplementation appeared to have an 
improvement in their clinical condition (291). A broad experience in the use of nutritional 
therapy now exists for IBD. In adults, nutritional therapy has been shown to be effective in 
achieving clinical remission in CD and to a limited extent in UC. However meta-analysis 
has consistently shown that corticosteroids are more effective than enteral nutrition in 
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achieving remission in adults and their role in adult practice remains controversial 
(292;293). However, in children with IBD, enteral nutrition appears to be at least 
equipotent at achieving remission in CD (294) and has additional benefits on nutritional 
status and linear growth (295). Adult data suggesting that disease location is important in 
predicting clinical responsiveness to nutritional therapy in CD have not been replicated in 
paediatric studies, where response has been good even in patients with disease limited to 
the large bowel. Nutritional therapy is regarded as the first line treatment of choice for 
paediatric CD in the UK and Europe (296). Some data also suggest that long term 
supplementation with enteral nutrition reduces relapse rates and improves linear growth 
(297;298).  
1.8.1 Mechanisms of action of enteral nutrition? 
The first clinical trials of enteral nutrition focused on elemental formulae (in which 
nitrogen is delivered in the form of amino acids). It was postulated from in vitro and in 
vivo observations that the mechanism by which gut rest and enteral nutrition stimulated 
mucosal healing was through a reduction of antigenic stimuli (299;300). However recent 
analysis has shown no difference between elemental, semi-elemental (oligopeptides) or 
polymeric (whole protein) feeds in terms of efficacy (292;301). Micronutrient deficiency 
has been shown to be commonly present in IBD and nutritional therapies (302;303) have 
been shown to increase enterocyte levels of micronutrients prior to mucosal healing. The 
anti-inflammatory properties of enteral nutrition have been demonstrated by the reduction 
in inflammatory markers, including serum I-6 preceding nutritional restoration in 
polymeric liquid fed CD patients (304;305). This has in particular led to interest in the lipid 
content of feeds, especially the relative composition of long chain fats and ω-3 fatty acids. 
Changes in dietary lipids can alter cell membrane phospholipid profiles, which in turn can 
modulate cellular inflammatory responses. In addition ω-3 fatty acids may also directly 
interact with surface receptors of the GALT (306). Preliminary data support the hypothesis 
that the lipid profile of enteral nutrition may play a role in its therapeutic effects in IBD 
(307).  
1.8.2 Mechanism of action of enteral nutrition: modulation of the 
gut microbiota? 
As previously discussed in section 1.5.6, evidence exists implicating the gut microbiota in 
the pathogenesis of IBD. Modulation of the gut microbiota to ameliorate the inflammatory 
process has been demonstrated with diversion of the faecal stream in colitis and the use of 
antibiotics in perianal CD (205;219). It has been speculated that the primary anti-
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inflammatory mechanisms of nutritional therapy may lie in its restoration of a ‘healthy’ gut 
microbiota. This prebiotic effect may result in the restoration of metabolic functions and 
products (such as butyrate) to promote mucosal healing. However the effects of enteral 
nutrition on the metabolic function of the flora in the small bowel are not well 
characterised (308). One study has demonstrated changes in the faecal flora during 
treatment with enteral nutrition for active IBD. Lionetti et al (234) studied the faecal flora 
of nine children with active CD who were all treated for eight weeks with an excusive 
polymeric feed. Faecal samples were obtained every 2-3 weeks and the bacterial consortia 
typed by TGGE of 16s rRNA PCR products. All children showed changes in bacterial 
banding patterns during treatment and although species stabilisation was maintained after 
treatment the band diversity was not as marked as during the treatment period. The direct 
effects of nutritional therapy on the gut microbiota require more study, and very little is 
known about their effects on the small intestine. 
1.8.3 Probiotics for IBD? 
With our evolving knowledge of the role that the gut microbiota play in the pathogenesis 
of IBD there has been increasing interest in the possibility of using probiotics to modify 
the natural history of the disease. Post-operative pouchitis, a common complication of ileal 
pouch anal anastamosis in UC, has been studied by Giochetti et al (309) who demonstrated 
a benefit in the maintenance of antibiotic induced remission in twenty patients treated with 
a cocktail of Bifidobacteria, Lactobacilli and a non-pathogenic Streptococci (VSL#3) in 
comparison to placebo. The findings that VSL#3 extends time to pouchitis relapse has been 
confirmed by other independent researchers and demonstrated with Lactobacillus GG 
(310-312). The successes with pouchitis led to great enthusiasm for the possibility of a new 
class of treatment for IBD. However the treatment of IBD in general has been met with 
more conflicting results.  
Initial small studies into inducing remission and for maintenance for CD reported two 
positive outcomes (313;314) and three negative outcomes (315-317). Larger trials have 
since been conducted. Marteau et al (318) recruited 98 patients with CD in clinical 
remission and randomised them to six months of Lactobacillus johnsoni or placebo. They 
demonstrated no significant difference in the relapse rate between the groups at the end of 
the study. These findings were replicated by another group (319). The only paediatric 
study of probiotic usage in IBD to date was performed by Bousvarous et al (320), who 
randomised children with CD in remission to receive either Lactobacillus GG or placebo 
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over two years. There were no significant differences in time to relapse between the groups 
by the end of the study.  
Early studies of probiotic use for the treatment of UC were more positive. Four small 
studies demonstrated the benefits of Bifidobacteria, Sarccharomyces boulardii, E. coli 
Nissle 1917 and VSL#3 over placebo in inducing remission (321-324).  Rembacken et al 
(325) demonstrated, in a larger study, that oral E. coli Nissle 1917 was as effective as 
standard therapy (mesalazine) in inducing remission. One study has shown E. coli Nissle to 
be effective in maintaining remission (326) whereas two studies have shown no significant 
treatment effect (325;327). Two studies have also failed to demonstrate any beneficial 
effects in the use of Lactobacillus salivarus, Bifidobacterium infantis and Lactobacillus 
GG (328) respectively.  
Non digestible carbohydrates have been used for their ‘prebiotic’ effects in small trials in 
IBD. A double-blind cross over study examined the effect of inulin in patients with chronic 
pouchitis (329) and demonstrated a significant reduction in clinical and endoscopic 
markers of ileal inflammation.  A small randomised study of oligofructose and inulin and 
Bifidobacteria significantly reduced mucosal TNFα levels in 18 patients with UC; however 
clinical parameters were not statistically significantly altered possibly due to small study 
numbers (330).  Oligofructose has also been given to adults with CD in an open label non-
controlled study with reduction in disease activity as an adjunct to conventional therapies 
(331). The current limited data need to be extended with larger well designed placebo 
controlled studies.  
1.8.4 Conclusions: nutritional therapies 
The recent developments in enteral nutritional therapies have provided benefits to many 
patients with IBD, particularly children, in terms of reduction of symptoms, and adverse 
events. However much is still poorly understood about nutritional therapies. The exact 
mechanisms for the mode of action of exclusive enteral diets remains obscure and a 
significant proportion of patients remains recalcitrant to nutritional therapy (both 
predictably and unpredictably).  Potential benefits of probiotics have been seen in the 
maintenance of remission of pouchitis and in the treatment of active UC, but in other forms 
of IBD results have been disappointing. This has led authors to speculate that the effects of 
enteral nutrition and probiotics may be site-specific (location in the GI tract) and patient-
specific (differing genetic susceptibilities) (226;332;333). To understand the potential 
benefits of such nutritional therapies, and therefore to design new tailored treatments, it is 
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firstly necessary to understand the activity of the full microbial population of the 
gastrointestinal tract and secondly to understand the impact of nutritional therapies on their 
metabolic activities in vivo. The development of innovative culture-independent techniques 
will be necessary produce objective measurements which can be used to determine the 
effects of therapies on the metabolic activity of the gut microbiota. The evolution of the 
techniques used to determine the nature and function of bacteria will therefore be discussed 
next. 
1.9 Studying the Gut Microbiota 
1.9.1  Traditional methods: microbiological culture techniques 
There is a variety of methods available to characterise the microbiota of the large bowel 
including those that may be involved in the aetiology of IBD and NEC. Traditional 
bacterial culture techniques allow the activity of species to be studied under varying 
conditions, albeit in isolation from their natural ecosystem. However they have limitations 
because the vast majority of species found in the colon are anaerobic and difficult to 
culture. It has been suggested that less than 20% of the gut microbiota have been cultivated 
and identified in this manner (246). 
1.9.2 Molecular techniques 
The development of culture-independent methods of identifying micro-organisms has 
rapidly expanded since their first description in the mid 1980s (334;335). These utilised the 
key discovery of the polymerase chain reaction (PCR) to facilitate dot-blot analysis and 
fluorescene in situ hybridization (FISH) (336). Isolation of bacterial DNA and gene 
sequencing has led to a rapid expansion of gene libraries of bacterial species. The most 
commonly used DNA sequences now encode 16S rRNA due to its combination of hyper-
conserved and variable regions, allowing phylogenetic typing. Over 120 000 sequences 
have been identified (334;337;338). A specific library of the microbiota of the human 
intestine identified using molecular techniques has been established through a unique 
European collaboration (245). This has demonstrated that the human bacterial genome is 
vast (>100 000 species). However within each individual the number of species is far 
lower (around 1000 species). 
The use of phylogenetically-specific RNA probes and temporal temperature gradient gel 
electrophoresis (TTGE) can resolve complex flora into the dominant phylogenic groups 
(10). This produces a picture loosely related to the dominance of each group, known as a 
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‘community profile’. TTGE has been used to characterise the microbiota of healthy 
individuals and of patients with IBD. Seksik et al (235) used such methods to demonstrate 
that 30% of bacteria identified in stool samples from patients with CD were not usually 
found as dominant phylotypes in the microbiota of healthy individuals. These differences 
were seen in patients whether in remission or with active CD. In addition two major groups 
of bacteria were identified in patients in disease remission but were lost when these 
patients relapsed. Other groups identified during relapse were not present when patients 
achieved remission. These floral changes are confusing and appear paradoxical. It is worth 
noting that PCR techniques ‘identify’ bacteria through a single copy of DNA which may 
be derived from active, inactive or dead bacteria. Quantitative and real time PCR 
experiments have been performed for single organism studies (339), but as yet this 
technique is unable to detect quantitative changes in diversity in complex consortia with 
sufficient sensitivity (340). 
PCR and DNA phylotyping has expanded our knowledge of bacterial diversity. Of the 52 
characterised major bacterial phyla, 26 have been identified by culture-independent 
methods alone (334). In the human gut microbiota, molecular techniques have revealed 
that 80% of the species identified had never been cultured and thus no information on their 
metabolic activity is known (246). Assumptions cannot be made about the functions of 
even phylogenetically similar bacteria as many factors influence the microbial genome and 
the expression of genes encoding for metabolism. The interactions of these bacterial 
species may be better understood by assessing their relative activities between relapse and 
remission rather than by simple species identification. This dilemma has led to the 
development, over the last ten years, of techniques that combine culture-independent 
identification with assays of metabolic function. 
1.10 Techniques to Assay Bacterial Metabolic Activity 
1.10.1 Metabolite assays 
Bacterial activity in vivo has been assessed, by proxy, through analysis of metabolites such 
as SCFAs, ammonia, hydrogen-sulphide, phenols and bile acids (247;248).  SCFA analysis 
has been used to study gut bacterial metabolic activity in culture models and human faecal 
samples (12;249;250). Faecal SCFA measurements have also been measured in VLBW 
infant and correlated with gut inflammation (115). However addition these markers cannot 
be used to construct phylogenetic relationships since bacteria that are phylogenitcally 
distant may possess similar genes which encode for saccharolytic enzymes which produce 
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similar SCFA profiles; the concept of ‘functional redundancy’. A more direct measure 
linking the microbiota’s functional activity with diversity is required. 
1.10.2 Fluorescence in situ hybridisation-
microautoradiography 
The combination of fluorescence in situ hybridisation and microautoradiagraphy (FISH-
MAR) was the first such technique to measure metabolic activity, described in 1999 
(341;342). Bacterial communities are incubated in environments enriched with a 
radioactively labelled substrate. Fluorescene probe labelled bacteria were identified 
microscopically, and assessed as to whether they have sequestrated the labelled substrate, 
using a microradiograph (343). FISH-MAR has been used to extend our knowledge of the 
activity of single species within microbial consortia in the environment and to give 
quantitative functional data on microbial activity (344). FISH-MARs application in 
studying bowel flora is however limited by the number fluorescent probes that can be used 
(usually a maximum of seven) meaning that not all functionally active phyla of bacteria 
can be studied together. 
1.10.3 Isotope array 
The isotope array allows identification of all bacteria involved in the degradation of a 
radio-labelled substrate by using rRNA oligonucleotide probes which are covalently linked 
to fluorescent dye (345). The multiple RNA probe technique allows the identification of 
many bacteria with a specific metabolic activity (such as 14C-glucose consumption). 
Combining analysis of radioactivity and fluorescence of a bacterial population can also 
give quantitative data on relative substrate degradation. However the use of radioactive 
substances in metabolic studies may not be readily applicable to the study of patients in 
vivo. An alternative to this is the use of non-radioactive (stable) isotopes.  
1.10.4 Stable isotopes 
Stable isotopes (SIs) are non-radioactive isotopes of elements (such as 15N, 18O, 2H, 13C). 
They differ in their atomic mass from the most commonly occurring forms of that element 
in the environment, by an additional neutron in their nucleus. There are three natural 
isotopes of carbon: 12C 13C and 14C. Due to the natural abundance of these isotopes the 
relative atomic mass of carbon is 12.011 (figure 5).  
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Figure 5: Atomic structure of carbon (reproduced with permission of Tom Preston) 
 
Compounds containing stable isotopes are distinguishable by any methods that can resolve 
mass, such as mass spectrometry. This principle allows SIs to be used as tracers of 
metabolic and gastrointestinal function in vivo (29;346-348). SIs have been used to 
indirectly measure intestinal bacterial function in vivo by studying their effects on substrate 
metabolism. This has included investigation of SCFA production and SCFA 
interconversion using SIs (349;350). 13C containing urea (lactose ureide) has shown 
excellent potential as a marker of intestinal function as ingested, it remains intact until 
hydrolysed by bacteria in the large bowel (351). Carbon flow from13C urea can be 
followed into the large intestine and systemically by breath testing and urinary monitoring 
of the isotope (348). Urea can potentially be used as a precursor of bacterial de novo RNA 
and DNA synthesis since it is readily hydrolysable by bacteria, produces inorganic C 
(HCO3-/CO2) and therefore can potentially label the building blocks of RNA. Urea and 
lactose ureide, as colon specific urea delivery systems, therefore have potential as in vivo 
tracers of bacterial activity.  
1.11 Stable Isotope Probing (SIP) 
Stable isotope probing (SIP) is a term used to describe a technique of exposing 
environmental samples containing bacteria to stable isotope enriched substrates and 
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subsequently analysing labelled biomarkers such as RNA or DNA(338;352). Current SIP 
experiments have used mainly 13C and 15N labelled substrates (353;354). SIP works on the 
principle of being able to separate ‘heavy’ labelled DNA from ‘light’ unlabelled DNA. SIP 
experiments conducted in environmental and human ecology studies to date have isolated 
labelled DNA via density gradient centrifugation. DNA obtained containing 13C represents 
that of the collective genomes of the metabolically active micro-organisms that have 
incorporated the labelled substrate into their nucleic acids. The greater the incorporation of 
SIs, the more metabolically active the bacteria. SIP is being used increasingly to link the 
identity of micro-organisms with their function within their natural environment (338;352). 
The central premise of SIP studies has been to determine which bacterial groups are 
involved in substrate specific metabolism. Clearly in human studies, even the use of simple 
primary substrates for bacteria would introduce bias since not all bacteria, for example, 
would be primary glucose utilisers. An alternative approach is to use generic tracers of de 
novo purine and pyrimidine synthesis which, at least theoretically, are less prone to 
substrate specific bias. The technique of using SIs of commonly occurring molecules to 
study bacterial turnover was used long before the term SIP was coined. 13C labelling 
through de novo nucleic acid synthesis was the basis of the first demonstration of the semi-
conservative replication of DNA in E. coli in 1958 (355). 
1.11.1 DNA SIP  
SIP experiments on DNA have been used to isolate methane-degrading bacteria in soil and 
biodegradation of multi-carbon pollutants (356;357). Isolated DNA can be amplified via 
PCR and species identified using primers targeting the 16S rRNA gene. 13C labelled DNA 
SIP also provides a potentially novel method of bacterial identification and classification 
via their genetic sequence (metagenomics). A potential advantage of DNA SIP taxonomy 
over 16S rRNA is that it can be used to classify bacterial phyla according to common 
metabolic function (338). Such techniques offer a new way of studying the activity of the 
colonic microbiota. However there are potential limitations in these approaches, 
particularly when trying to measure bacterial activity in the stool samples of patients with 
IBD. To achieve adequate incorporation of stable isotopes into bacterial DNA requires 
relatively lengthy incubation periods, owing to the time taken for DNA replication. 
Moreover faecal samples do not fully resemble the colonic environment and laboratory 
analysis of the former will not necessarily reflect the latter.  
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1.11.2 RNA SIP 
RNA synthesis occurs more rapidly than DNA turnover. This makes RNA SIP a 
potentially more attractive technique for analysing bacterial activity in humans over short 
time-frames which may retain a more representative picture of in vivo activity (358;359).  
RNA based SIP experiments have now been carried out successfully to examine bacterial 
degradation of phenol in an industrial bioreactor (358;359).  Such techniques can 
potentially be scaled down to study bacterial metabolism in the smaller bioreactor of the 
human colon. It has been proposed that time-based SIP, using a combination of both RNA 
and DNA methods over time, could track the flow of 13C through micro-organisms in the 
environment (360). 
1.12 Application of SIP to Assay Gut Microbiota in IBD 
SIP experiments on DNA and RNA have been used within bioreactors and in their natural 
ecosystem to identify unculturable bacteria which carry out specific degradative functions 
(356). Isolated DNA can be amplified via PCR and species identified using primers 
targeting the 16S rRNA gene. 13C labelled DNA SIP also provides a potentially novel 
method of bacterial identification and classification according to their genetic sequence 
(metagenomics). Combining DNA and RNA SIP experiments over time has enabled 
temporal tracking of labelled substrates through ecosystems. This can include the flow of a 
labelled substrate into secondary degradators (cross-feeding) (361).  Such methods lend 
themselves to the measurement of the metabolic activity of the gut microbiota in vitro 
(340) and in vivo. However there are a number of obstacles that must be overcome before 
SIP will elucidate our understanding the possible central role of the gut microbiota in the 
pathogenesis of IBD. Obtaining stool samples from patients with IBD, both in remission 
and relapse, and performing SIP experiments on them is a logical starting point to gain an 
insight into changes in bacterial metabolic activities that precede (or lead to) changes in 
microbial diversity. However the application of SIP in vivo demands adequate appropriate 
bacterial genetic material and sufficient enrichment of target nucleic acids. This involves;  
• Enrichment and isolation of RNA/DNA 
• High sensitivity of analytic techniques of isotopic enrichment, and  
• Validation of an appropriate substrate for bacterial metabolic activity. 
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1.12.1 Isolation and enrichment of nucleic acids 
There are potential limitations to centrifugal methods of isolation of RNA/DNA that rely 
on the separation of light and heavy bacterial nucleic bands, particularly when working 
with faecal samples.  To achieve sufficient incorporation of SIs into bacterial DNA for 
adequate band separation by centrifugation requires relatively lengthy incubation periods, 
owing to the time taken for DNA replication and cell turnover.  Moreover faecal samples 
do not fully resemble the colonic environment and laboratory analysis of the former does 
not reflect the latter.  This can result in changes in the metabolic activity of the flora over 
time that could lead to a misrepresentation of bacterial activity.  RNA, with its more rapid 
turnover, would therefore seem to be a better candidate nucleic acid for such studies (359) 
and coupling isotopic enrichment with taxonomic profiling afforded by 16s rRNA could 
overcome some of the limitations of DNA SIP. 
SIP has proved useful in environmental microbiology through the exploitation of density 
ultra-centrifugation to separate isotopically heavy nucleic acids from unlabelled light 
nucleic acids. This has the potential advantage of limiting bias and removing the 
requirement for a priori knowledge of species diversity. However, there are some 
disadvantages of applying this methodology, particularly to SIP studies of the human 
microbiota. Effectively separating heavy nucleic acid bands from light bands requires 
significant enrichment in the heavy nucleic acid fraction (362;363). Achieving this 
enrichment in the nucleic acid fraction often requires extended incubation times. 
Maximising time for nucleic acid enrichment must be balanced against the changes in the 
faecal bacterial community which occurs once a stool is voided. Exposure to oxygen, type 
of culture media, loss of immunological stimuli and secondary degradation of substrates 
(cross-feeding), whether in batch or continuous culture, can effect bacterial diversity and 
metabolic activity (350;364;365). 
The current achievable resolution afforded by centrifugal separation (i.e. band separation 
of heavy and light nucleic acids) can only be improved by increasing isotopic 
incorporation into studied bacterial nucleic acids. Bands of uniform enrichment will travel 
together, but bands of lower enrichment will migrate a shorter distance within the gradient 
owing to their buoyant density, resulting in a band profile reflecting isotopic enrichment.  
Across a spectrum of bacteria this may result in overlapping bands from bacteria with low 
isotopic enrichment and bacteria with a high guanine and cytosine content of their nucleic 
acids, due to their similar buoyant densities within the gradient. This effect becomes more 
problematic when trying to study RNA at lower enrichments, such as after short incubation 
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times (i.e. those most closely reflecting the colonic environment). 16s RNA SIP 
experiments performed in vitro on bacteria in conditions simulating the human intestine 
have shown that high concentrations of labelled tracer are needed to separate labelled and 
unlabelled RNA (366). Investigators have suggested that lower limits of enrichment 
required would be 20atom% for 13C and 40atom% for 15N (362;367). Trying to establish 
this level of enrichment in an in vivo ecosystem, such the human colon, is problematical 
due the systemic dilution of tracer within the whole host.  
1.12.2 High resolution, high precision SIP 
Whilst the advantages of not requiring a priori knowledge of bacterial diversity and the 
potential sensitivity of using centrifugal methods and PCR amplification of isolated heavy 
nucleic acids are acknowledged, alternative approaches are possible when studying the 
activity of the human gut microbiota. As discussed in section 1.1 the gut microbiota, 
particularly in the large intestine, are part of a densely populated ecosystem containing in 
excess of 200g of faecal material and 1010-1012 viable organisms per g (8;28). This 
represents a significant pool of microbial nucleic acids, of which RNA may account for 
20% of dry weight (68). This is many orders of magnitude greater in cell density than is 
often observed in extra-intestinal microbial ecology and alternative low-sensitivity but 
high-resolution approaches become possible. 
Gene capture technology has used biotin labelled oligonucleotide probes to capture DNA 
targets (Helicobacter pylori) and streptavidin coated magnetic bead capture technology to 
extract and isolate the target DNA (368). This method can be modified to target 16s rRNA. 
Magnetic bead capture of 16s rRNA coupled with isotopic analysis has been pioneered in 
single species and environmental samples (369). An extension of this technique to capture 
16s rRNA from complex consortia by using oligo-dt coated paramagnetic beads has been 
described (370). 
1.12.3 Universal substrates for gut microbiota activity 
SIP experiments have previously focussed on bacteria according to their metabolic 
functions by exploiting their preferential metabolism and sequestration of isotope from 
specific 13C labelled substrates. Probing all metabolically active bacteria in the faecal flora 
requires the adoption and validation of a ‘universal’ substrate to obtain results which are 
not subject to substrate bias. The requirement for an isotope labelled substrate that avoids 
phylogenic selection bias upon incubation is paramount if the functional activity of the 
whole microbiota is to be assessed. The highly complex and diverse nature of the colonic 
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microbiota means that the metabolism of many substrates, particularly carbohydrates, will 
vary within and between different bacterial phyla, resulting in selection bias for bacteria 
that can utilise the substrate. The addition of even relatively simple labelled substrates such 
as 13C-glucose will result in selective changes in metabolic activity. 13C-glucose has been 
shown to inhibit lactic acid producing bacterial activity in an in vitro model of the human 
gut as measured by RNA-SIP and nuclear magnetic resonance spectroscopy (371). The 
ideal substrate therefore should lead to efficient enrichment of all active bacterial RNA 
over the shortest timescale without bias toward any phylogenetic group. Such candidate 
substrates are isotope-labelled precursors of de novo bacterial RNA synthesis (figures 6, 7). 
Simple substrates that are inherent to these pathways (rapidly producing HCO3-/CO2 in 
bacterial systems), such as urea, aspartate, glycine and uracil, have optimal potential for 
SIP experiments.  
 
Figure 6: Purine synthesis 
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Figure 7: Pyrimidine synthesis 
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1.13 Mass Spectrometry  
Mass spectrometry is a method of measuring the molecular and sometimes elemental 
composition of substances and is considered the gold standard method for the identification 
and quantitification of complex organic compounds. Mass spectrometry is the tool of 
choice with which to determine isotopic natural abundance and enrichment at low levels.  
1.13.1 Isotope ratio mass spectrometry  
For measurements of the isotopic ratios of light elements such as C, N, and S, very high 
precision is required (372). The concept of isotope ratio mass spectrometry (IRMS) was 
first demonstrated in 1947 by the seminal work of Neir and colleagues (373). A critical 
advance in modern IRMS experiments on solid material was that analytes are combusted 
prior to passing through the ionisation field. C, N, O, S and H, are combusted to CO2, N2, 
CO, SO2 and H2. After passing through the electron beam which results in a positive 
charge of particles they are deflected by magnetic field and collected by Faraday cups 
(372). It is the static nature of this mass spectrometer design that leads to the high precision 
analysis necessary for isotope ratio measurements. For the measurement of 13C three 
collectors are used to measure the ion beams at m/z 44, 45 and 46 to collect isotopes of 
carbon in the form of carbon dioxide; 12C16O2, 13C16O2, 12C 18O16O (46 is measured to 
correct for the contribution of the isotopomer 12C17O16O at m/z 45 based on the 18O/17O 
ratio; the Craig correction (374)).
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Figure 8: IRMS methodology 
 
1.13.2 Elemental analysis IRMS 
The analysis of 12C:13C ratios can be performed on relatively small samples by coupling 
IRMS with an elemental analyser (EA). A compound is loaded into a combustion chamber 
and all organic compounds are transformed to simple gases by hot-oxidation followed by 
reduction. These simple gases are easily directed into the ionisation field (figure 8). The 
use of EA-IRMS allows the examination of compounds with much smaller enrichments 
(down to natural isotopic abundances) of SIs than standard molecular mass spectrometry (1 
atom% to 0.00001atom%) (375).  
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Figure 9: Elemental analyser method 
 
However the need to maintain high carrier gas flow of material through the EA system 
before entry into the ionisation chamber (100ml/min) can limit the sensitivity of the system 
when analysing very small amounts of compounds (<1mg C). Even this level of sensitivity 
may be inappropriate for small amounts of 16s rRNA in SIP analysis. The analyses of  low 
13C enrichment in very small quantities by combining IRMS liquid chromatography (LC) 
has been described; so called LC-IRMS (375). 
1.13.3 Liquid chromatography (LC) IRMS 
In LC-IRMS the transportation of soluble organic compounds in a liquid phase prior to 
oxidation enables reduction in He carrier flow rate into the ionisation field, thus increasing 
sensitivity of analysis (375). Carbonaceous compounds are oxidised to CO2 and thereafter 
the dissolved gases are stripped from the liquid flow into a helium (He) counter flow by 
means of a microporous PTFE membrane (figure 10). The use of low-flow He prior to 
introduction to the ionisation chamber (1mL/min) enables the analysis of very small 
amounts of organic compounds (<1µg).  
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Figure 10: LC-IRMS schematic 
 
1.13.4 Delta notation 
As such small variances in 13C/12C ratios occur between stable isotopes at natural 
abundance a unit of expression is required. The δ notation termed in units of parts per mil 
has been adopted to express deviations from an internationally accepted standard 
(arbitrarily set at 0): 
δ13C (0/00) = [(Rsample/Rstandard)-1] x103    
Where R=13C/12C ratio of the sample or the standard 
∆13C= δ13C sample- δ13C baseline 
A change in δ13C of 10/00 is equivalent to a change of 0.001099 atom%. This nomenclature 
for expressing isotope ratios have been standardised and accepted by the isotope 
community (375).  
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1.14 16s rRNA-IRMS-SIP 
As discussed in section 1.10 the development of culture-independent methods to determine 
the metabolic activity of unculturable gut microbiota may afford the opportunity to gain 
new insights into human intestinal microbial ecology and disease pathogenesis. The 
investigation of faecal microbiota with SIP can be conceptualised (figure 11). This can be 
conceived as either utilising ultracentrifugation methods or, as preferred and discussed 
above, 16s rRNA probe technology with IRMS.  
The exposure of a faecal sample to a 13C labelled precursor of de novo nucleic acid 
synthesis would result in the metabolically active bacteria utilising 13C and incorporating it 
into its cell structure and nucleic acids. After isolation of nucleic acids, analysis can be 
performed by either buoyant density ultracentrifugation or by oligonucleotide probe 
extraction and IRMS. This latter approach was identified as the most suitable due to its 
applicability to short incubation times and RNA/DNA with low levels of enrichment not 
amenable to centrifugal separation. 
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a) Faecal material exposed to a 13C rich substrate the metabolically active bacteria incorporate 13C into cell structures during cells replication. b) nucleic acids can then be 
attained by centrifugal methods c) light and heavy labelled DNA  can separated by buoyant densities and then phylotyped by d) PCR and phylotyping or alternatively e) 16s 
rRNA of previously identified bacteria can be captured by biotin labelled probes. Relative incorporation of 13C can then be analysed by f) isotope ratio mass spectrometry
 
Figure 11: Conceptualisation of SIP experiments using human faecal material 
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1.15 Hypotheses and Aims of Research 
Chapter one outlined the background to the subject of this thesis: an investigation into the 
role of the gut microbiota in inflammatory gut diseases of childhood; NEC and IBD. The 
gut microbiota plays a critical but, as yet, poorly defined role in the aetiology of these 
diseases. This suggests that manipulation of the gut microbiota might have positive 
therapeutic effects in such diseases. As the science of intestinal ecology is evolving there 
are many hypotheses that might be tested to expand knowledge in this field. The aim of 
this thesis was to test the three hypotheses: 
1. Probiotics prevent NEC in at risk infants of very low birth weight (VLBW). 
2. The human gut microbiota can be labelled by stable isotope probing (SIP) to 
measure metabolic activity. 
3. Quantitative measurement of the metabolic activity of the unculturable gut 
microbiota is a useful way of studying changes in the microbiota, compared 
with measures of bacterial diversity, and may enlighten our understanding 
of bacterially mediated inflammatory stimuli in inflammatory gut diseases of 
childhood. 
To test the first hypotheses a systematic review of the published literature was undertaken, 
designed to evaluate the current data concerning the routine administration of oral 
probiotics to VLBW and <33wk infants with particular interest in their safety and efficacy.  
To test the second two hypotheses a series of experiments was undertaken to develop a 
new methodology, stable isotope probing (SIP) for use in the field of human gut 
microecology. These experiments were designed to develop a working protocol for 16s 
rRNA SIP using human faecal samples.  
 
   65 
2 Prospective Study of the Evidence for Use of 
Oral Probiotics for the Prevention of NEC 
As discussed in 1.5, NEC results in significant morbidity and mortality of the preterm and 
VLBW infant. The introduction of feeds or other nutritional substrates to the lumen of the 
gut appears to be factor in initiating and propagating inflammation and such substrates can 
modify this response as evidenced by the effects of human milk feeds as apposed to milk 
formulae. Modulation of the gut microbiota is hypothesised as a contributor to this effect. 
Rather than manipulating the composition of feeds, a more direct method of modifying the 
colonising microbiota might be the administration of enteral probiotics to ‘at risk’ infants. 
A large number of studies have been undertaken in which probiotics have been given to 
newborn infants in an attempt to modulate the gastrointestinal environment and thereby 
change biochemical, physiological and clinical outcomes. However the current level of 
evidence of the efficacy and particularly the safety of such preparations are not well 
documented.  
2.1.1 Background: Why a systematic review? 
When institutions or individuals are formulating policy decisions on whether to implement 
new treatments for patient populations, much emphasis is now placed on the use of 
evidence based medicine (EBM) (376). This has informed many of the recent changes in 
the structure and nature of health services in the UK. In brief, EBM is the conscientious 
use of the current best available data in combination with individual clinical experience to 
make valid treatment decisions for patients. Reviews of rapidly advancing areas of 
medicine are of vital importance to clinical decision-makers as they can synthesize the 
available data and interpret the results of many studies, which often takes far more time 
than is expected or available. Moreover narrative reviews, commissioned from experts in 
the field, have been shown to exhibit the cultural and professional biases of individual 
reviewers. In a landmark article in 1987 (377) Mulrow reviewed 50 review articles in four 
leading medical journals and demonstrated that, according to published guidelines on 
narrative syntheses, only one article defined methods of selecting articles and only three 
articles used a quantitative method of synthesis. Mulrow stated that the review article fell 
below the scientific standards in appraising available evidence. Since Muldrow’s article the 
focus of many reviews has been to ascertain and evaluate all the available evidence on a 
topic before drawing conclusions on that subject. These ‘systematic reviews’ require the 
same level of methodology as that of original research and should be considered as of 
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equal potential value. Systematic review is now considered to be an integral part of the 
practice of EBM (378).  
The systematic review’s power to influence policy has been shown to be greater than that 
of the narrative review. In 1993 the Cochrane Collaboration (http://www.cochrane.org/), an 
international not-for profit organisation, was formed to create an international library of 
systematic reviews and meta-analyses, in order to help individuals and institutions practice 
EBM. Cochrane methodology is highly structured to minimise bias in a review. Expert 
committees on subject areas have been assembled to reach consensus for search strategies 
for specific questions. National health policies on therapeutic interventions are now often 
determined by the examination of current evidence under such methodology. The National 
Institute of Clinical Excellence (NICE; www.nice.org.uk) in England and Wales bases its 
decisions as to which specific medications will be funded by the national health service on 
from the results of commissioned systematic reviews of the evidence. Within Scotland a 
specific commission has been assembled to create guidelines for clinical management 
based on systematic review the Scottish Intercollegiate Guideline Network (SIGN; 
www.SIGN.ac.uk). As a result of these and other initiatives the science of systematic 
review has grown with rapid expansion of the number of guidelines on appraisal and meta-
analysis, as well as an exponential increase in the number of published systematic reviews 
in the last two decades. However the methodology of committee-based reviews such as 
SIGN or Cochrane has been replicated so that individuals can answer their own clinical 
questions using systematic review. The methodologies of systematic reviews are now the 
subject of consensus from experts in this field (379-381).
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Table 2: The QUORUM reporting of meta-analysis (Adapted from Moher et al (382)) 
 
Heading Subheading Descriptor 
Title  Identify the report as systematic review or meta-analysis 
Abstract  Uses structured format 
 Objectives Explicit clinical question 
 Review 
Methods 
Selection criteria, methods for validity assessments, data 
abstraction, study characteristics and quantitative data synthesis 
in sufficient detail to permit replication 
 Results Characteristics of the RCTs included and excluded; qualitative 
and quantitative findings and subgroup analysis 
 Conclusions The main results 
  Describe 
Introduction  The explicit clinical problem, biological rationale for the 
intervention, and rationale for review 
Methods Searching The information sources, in detail (e.g. databases, registers, 
personal files, expert informants, agencies, hand-searching) and 
any restrictions (years considered, publication, status, language 
of publication) 
 Selection Inclusion and exclusion criteria (defining population, 
intervention, principal outcomes and study design) 
 Validity 
assessment 
The criteria process or processes 
 Review 
Methods 
Selection criteria, methods for validity assessments, data 
abstraction, study characteristics and quantitative data synthesis 
in sufficient detail to permit replication 
 Data 
abstraction 
The process or processes used 
 Study 
Characteristics 
The type, study design, participants, characteristics, details of 
intervention, outcome, definitions and how clinical 
heterogeneity were assessed 
 Quantitative 
data synthesis 
Principle measures of effect, method of combining results, 
handling of missing data, how heterogeneity was assessed, a 
rationale for any a-priori sensitivity, subgroup analysis and 
publication bias 
Results Trial flow Provide a meta-analysis profile summarising trial flow 
 Study 
characteristics 
Present descriptive data for each trial 
 Quantitative 
data synthesis 
Report agreement on selection and validity; present simple 
summary results; present data required to calculate effect size 
and confidence intervals in intention to treat analysis 
Discussion  Summarise key findings; discuss clinical inferences based in 
internal and external validity; interpret the results in light of the 
available evidence; describe biases in review process and future 
research agenda 
68 
When combining the results of studies using variable methods and treatments but studying 
the same outcomes, inadequate attention has often been given to reporting individual study 
quality which should include: study design, combinability, control of bias, statistical 
analyses, sensitivity analyses and problems of applicability (383). In particular not only 
should authors report the methods of their own review, but the methods used in each 
individual study included in their review. In 1999 a consensus based guideline for the 
reporting of studies in meta-analysis was devised at the Quality of Reporting of Meta-
Analysis Conference (QUORUM) (382). A QUORUM checklist and flowchart (figure 12) 
was devised which summarised the key points of meta-analysis methodology (table 2). The 
QUORUM methodology increases clarity for the reviewer permitting him or her to assess 
the quality and appropriateness of meta-analysis in any systematic review. The use of the 
QUORUM methodology has been incorporated into the requirements for systematic of 
several high quality peer review publications. The success of these guidelines has also led 
to the development of methodology guides for the reporting of non-randomised (TREND) 
(379) and observational studies (STROBE and MOOSE) (380;381).  
 
Figure 12: Progress through the stages of meta-analysis for RCTs QUORUM flow chart (adapted from 
Moher et al (382)) 
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2.2 Aims of Study 
In light of the large body of literature that exists concerning the use of probiotics in the 
newborn a systematic review requires to be undertaken to evaluate their quality. The 
objectives of this systematic review were: 1. to assess published documentary evidence 
concerning the safety and the effectiveness of the oral administration of probiotics to 
VLBW in the prevention of NEC and 2. To suggest how deficiencies in the existing data 
may be redressed in order to develop evidence to justify the rational use of probiotics for 
VLBW infants.  This was formulated into the clinical question ‘Should VLBW infants be 
routinely administered oral probiotics to prevent necrotising enterocolitis’. 
2.3 Methods: Systematic review 
2.3.1 Setting the clinical question 
A clear focused question is required to set the clinical context for the systematic review 
and will influence the search terms and areas searched. A framework for clinical question 
setting is PICOS (384). The question should include the problem or population (P), the 
intervention (I) the comparator (C) and the dependant variable of interest or outcome (O), 
study limitations (S) can also be applied such as only using higher level evidence (RCTs). 
The clinical question ‘Should VLBW infants (P) be routinely administered (C) oral 
probiotics (I) to prevent necrotising enterocolitis (O)’ was selected. 
2.3.2 Assembling a systematic review team 
Although this study was primarily designed as an independent piece of work the systematic 
review requires a minimum number of individuals to independently validate steps of the 
review process in to order reduce bias in terms of selection and interpretation of studies. To 
maintain a broad range of clinical and research experience the invited team consisted of 
Paediatric Gastroenterologists and Neonatologists from two tertiary paediatric units.  
• David Wilson, Reader in Paediatric Gastroenterology, University of Edinburgh 
• Judith Simpson, Consultant Neonatologist, Queen Mother Maternity Hospital, 
Glasgow 
• Ben Stenson, Consultant Neonatologist, Simpson Centre for Reproductive health 
Edinburgh 
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• Lawrence Weaver, Professor of Child Health, University of Glasgow 
These colleagues agreed the framework for systematic review and assisted in  
independently validating i) the search strategy ii) the inclusion and exclusion of studies and 
iii) the means of synthesis (if any) of appropriate studies.  
2.3.3 Search framework and search strategy 
Once the decision to appraise the clinical question ‘Should VLBW infants be routinely 
administered oral probiotics to prevent necrotising enterocolitis’ was made an appraisal of 
the current available literature was undertaken in order to formulate the methods for 
systematic review. Due to perceived lack of scientific rigour involved in much of the 
published data in the area of probiotics there were specific concerns over the combinability 
of data from probiotic trials in VLBW infants. In view of this the decision was made to 
observe the QUORUM statement on methodology and reporting of systematic reviews as 
this method was most applicable. 
A search was made for publications reporting randomised placebo controlled and quasi-
randomised controlled trials of infants at high risk of NEC (born <33wk or with birth 
weight <1500g) that involved the oral administration of probiotics, defined as bacteria that 
will modify gut microflora to give a predominance of non-pathogenic organisms. Within 
these studies outcome measures were sought that included incidence of NEC diagnosed by 
Bell’s Classification or a modified Bell’s Classification (385;386) (table 3), severity of 
NEC defined by Bell’s stage 2 and 3 of NEC, requirement for surgery, mortality attributed 
to NEC, overall mortality, and adverse reactions attributed to probiotic; defined as episodes 
of sepsis with positive blood culture containing probiotic strain or delay in tolerance of 
enteral feeds. 
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Table 3: The Bell’s Classification of NEC (Adapted from Bell et al (385)) 
 
Stage I (Suspected) 
a) Any one or more historical factors producing perinatal stress 
b) Systemic manifestations- temperature instability, lethargy, apnoea, bradycardia 
c) Gastrointestinal manifestations- poor feeding, increasing pre-gavage residuals, 
emesis (may be bilious or test positive for occult blood)mild abdominal distension, 
occult blood may be present in stool (no fissure) 
d) Abdominal radiographs show distension with mild ileus 
 
Stage II (Definite) 
a) Any one or more historical factors 
b) Above signs and symptoms plus persistent occult or gross gastrointestinal bleeding: 
marked abdominal distension. 
c) Abdominal radiographs show significant distension with ileus; small bowel 
separation (oedema in bowel wall or peritoneal fluid), unchanging or persistent 
“rigid” bowel loops, pneumatosis intestinalis, portal vein gas. 
 
Stage III (Advanced) 
a) Any one or more historical factors 
b) Above signs and symptoms plus deterioration of vital signs evidence of septic 
shock or marked gastrointestinal haemorrhage.  
c) Abdominal radiographs may show pneumoperitoneum in addition to those listed in 
IIc 
 
Electronic searches of MEDLINE (January 1966 – December 2006) and CINAHL 
(January 1982-December 2006) databases were performed using all combinations of the 
following subject heading and keyword searches: infant, preterm; infant very low birth 
weight; enterocolitis necrotising and probiotic. Adaptations for UK and US English were 
made to the word necrotising (necrotizing) for all searches and no language filters were 
applied. The abbreviation probiot$ was also used to obtain all word stems. All abstracts 
from the combination searches were reviewed. For publications which involved trials of 
probiotics administered to preterm or VLBW infants, the full paper was reviewed to 
determine whether NEC was a primary or secondary outcome measure. To identify any 
relevant further papers, citation searches were performed on potential studies using 
MEDLINE, CINAHL and Web of Science databases, and the references of all reviewed 
papers were also checked for further studies. Additional hand searches were performed 
from the proceedings of the Society for Pediatric Research (SPR) and European Society for 
Paediatric Research (ESPR) from the last ten years to identify any unpublished trials. Two 
colleagues (ARB and DW) constructed the search strategy and identified trials for 
consideration.  Two colleagues (BS and JS) were masked to outcome of trials and 
independently assessed the methodological quality of potential studies using a previously 
validated three-point methodology rating scale (387) (appendix 1). A score of three or 
greater defined inclusion in our review.  
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2.4 Results 
The aforementioned subject headings and keywords generated 45860 hits (citations). 
Limiting citations to those that had two or more of all combinations of subject headings 
and keywords in their title or keyword list reduced the potential citations to 745 hits. The 
abstracts of all 745 hits were reviewed to identify all potential clinical trials and review 
articles of importance. Eighteen studies involving administration of probiotics to preterm 
and VLBW infants were identified (table 4). Two of the studies were in foreign languages, 
with the abstract only available in English (388;389). Both studies were read by a native 
speaker with a science degree to ascertain whether NEC outcomes were described. This 
was not the case for either study. Only six randomised controlled trials described the 
incidence of NEC as a primary or secondary outcome (figure 13). Of these, one study 
(160) was identified as ineligible as it was assessed as <3 on the rating score (387). This 
left five eligible studies (390-394) which are discussed in section 2.4.1 and summarised in 
table 5.  
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Table 4: 18 identified studies that administer probiotics to infants 
 
Name Preparation Dose Numbers  Outcomes  
reported 
Reumann et al 
1986 (395) 
Lactobacillus 
acidophilus 
9x106/ml 
formula 
15 infants 
15 controls 
L. acidophilus in 
rectal swab 
Bennett et al 
1992 (396) 
Bifidobacterium 
breve 
Bifidobacteium 
longum  
Lactobacillus 
acidophillus 
3x109 tds 
Breast, 1 
formula 
11 infants Bifidobacteria and 
Lactobacillus in 
stool 
Akiyama et al 
1993 (388) 
Bifidobacterium 
longum biovar 
Bifidobacterium 
longum 
5x108 daily 5 infants 
5 controls 
Bifidobacteria in 
flora at 2wk 
Stansbridge 
1993 (397) 
Lactobacillus GG 108 cfu bd 25 infants Changes in urinary 
SCFA profiles 
Millar et al 
1993 (398) 
Lactobacillus GG 
EBM /DEBM 
formula 
108 cfu bd 20 Colonisation with 
LactobacillusGG, 
reduction in 
pathogens in stool 
Kitajima et al 
1997 (159) 
Bifidobacterium 
breve 
0.5x109 46infants  
46 controls 
Changes 
colonization, better 
feed tolerance 
Gronlunnd et 
al 1997 (399) 
Lactobacillus 
casei Rhamonosus 
(GG) 
2.5x108 bd 30 infants GM neg bacteria in 
stool after 
supplementation 
Uhlemann et al 
1999 (389) 
Bifidobacterium 
tophfer bifidus 
1.25x108 tds 50 infants 
50 controls 
Bifidobacteria 
dominance in stool, 
reduction in sepsis 
Hoyos 1999 
(160) 
Bifidobacterium 
infantis, 
Lactobacillus 
acidophilus 
2.5x108 od 1237 infants NEC reduction  
Dani et al 2002 
(392) 
Lactobacillus GG 6x109 od 295 infants 
290 controls 
NEC and sepsis 
rates 
Marini et al 
2003 (400) 
Sarcaromyces 
Boullardii, 
Bifidobacterium 
subtilis, 
Lactobacillus GG 
Not specified 30 infants 
10 controls 
Faecal colonisation 
with probiotic 
species 
Costalos et al 
2003 (391) 
Sarrcaromyces 
Boullardii 
109 bd 51 infants 
36 controls 
 Faecal bacterial 
diversity 
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Table 4b: 18 identified studies that administer probiotics to infants continued 
 
Name Preparation Dose Numbers  Outcome 
Mihatsz 2004 
(60) 
Bifidobacterium 
lactis 
6x109 
Mixed feed 
65 infant 
63 controls 
Sepsis rates 
Lin 2005 
(393) 
Lactobaccillus 
acidophilus 
Bifidobacterium 
infantis 
1x107 od 180 infants 
187 controls 
NEC 
Bin-Nun 2005 
(390) 
Bifidobacterium 
infantis 
Strep thermophilus 
Bifidobacterial 
bifid us 
109 do 72 infants 
73 controls 
NEC 
Manzoni et al 
2006 (394) 
Lactobacillus GG 6x109/day  
breast 
80 infants Candida in 
gastric asp, stool, 
rectal swab 
Mohan 2006 
(401) 
Bifidobacterium 
lactis 
4.8x109 day 37 infants 
32 controls 
Molecular stool 
stechnique to 
measure 
enterobacters. 
Argarwal et al 
2003 (402) 
Lactobacillus GG 109od 
 
24 infants 
15 control 
Lactobacillus in 
stool flora 
  
Figure 13: QUORUM flowchart for search strategy for included studies 
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Table 5: Characteristics of five studies reviewed in detail 
 
Study Methods Participants Intervention Outcomes Limitations
Dani et al (392) Randomisation by sealed 
envelope. 
Blinding of care giver: yes. 
Blinding of assessors: yes. 
All or almost all subjects 
analysed: yes. 
All infants of gestational age 
<33wk or birth weight <1500g 
admitted to 12 NICU’s. 
Exclusion included, congenital 
malformation, death within 
2wk of life and lack of parental 
consent. 
Daily administration of 
Lactobacillus GG 6x 109 cfu until 
discharge (295) 
or given placebo (290). 
Reported outcomes: 
incidence of UTI, 
incidence of NEC and 
incidence of bacterial 
sepsis.  
No initial power 
calculation. Low 
background incidence of 
NEC which fell during 
study. 
Costalos et al 
(391) 
Randomisation by sealed 
envelope. Blinding of 
caregivers: yes. All or almost 
all subjects analysed: yes. 
All infants between 28-32wk 
some >1500g admitted in two 
NICU’s. Exclusion criteria 
included, breast feeding, 
antibiotic administration, 
congenital malformation. 
12 hourly administration of 109 
cfu/kg of sarccharomyces 
boulardii until discharge (51) or 
placebo (36). 
Reported outcomes: 
weight gain, enteral 
tolerance, sepsis and 
incidence of NEC ≥2.  
Not powered to detect 
changes in NEC rates. Non 
significant trend toward 
less NEC in treatment 
group. Any NEC rather 
than ≥2 reported. 
Lin et al (393) Randomisation by sealed 
envelope. 
Blinding of caregiver:  yes. 
Blinding of assessors: yes. 
All or almost all subjects 
analysed: yes. 
All VLBW infants admitted to 
NICU.  
Exclusion criteria, 
Death <7d and NEC <7d. All 
received maternal or banked 
breast milk.  
After day 7 all enterally fed 
infants received  
L acidophilus 1 million units and 
Bifidobacter infantis (180) or 
placebo (187).  
Reported outcomes: 
incidence of NEC, 
severe NEC, sepsis and 
death. 
Any NEC primary 
outcome, although NEC≥2 
also reported. NEC or 
death reported as 
secondary outcome 
although overall mortality 
reported. 
 
Bin-Nun et al 
(390) 
 
Randomisation by computer. 
Blinding of caregiver: yes 
Blinding of assessors: yes. 
Almost all subjects analysed: 
yes. 
Infants <1500g admitted to 
single neonatal unit (143). 
 
Daily administration of 109 cfu 
Bifidobacteria bifidus, 
Streptococcus thermoplhillus and 
Bifidobacter infantis (71) or 
placebo (72). 
 
Reported outcomes: 
incidence of NEC, 
severity of NEC and 
mortality in relation to 
NEC.  
 
Combined outcome of 
NEC or death or sepsis 
measured rather than 
overall mortality. 
Manzoni et al 
(394) 
Randomisation by computer 
generated table. Blinding of 
care givers: yes. All or 
almost all subjects analysed: 
yes. 
 
Infants <1500g admitted to 
single neonatal unit. 
Daily administration of 6x109 
colony forming units/day of 
Lactobacillus GG  (39) or 
placebo (41) until 6wks age or 
discharge. 
Reported outcomes.  
Bacterial colonization 
rates, NEC 2 and 3, 
overall mortality. 
Not powered to detect 
changes in NEC rates. 
Non-significant trend 
towards less NEC and 
mortality in the treatment 
group.  
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2.4.1  Description of selected studies 
The five selected studies summarised in table 5 were carried out in a variety of locations 
(three European, one Asian and one from the Middle-East). All of the studies were set in 
what would be described in the UK as level three neonatal care units (those managing 
extremely preterm infants). Two of the studies were multi-centred whereas three were on 
single sites. The details of neonatal practice including antenatal steroid policy, 
administration of surfactant to VLBW infants, antibiotic policy and postnatal feeding 
strategies are not described. However the individual feeding practice and probiotic 
administrations are described for each individual study.  
The study by Dani et al (392) was carried out in twelve Italian NICUs. The authors 
enrolled 585 infants with birth weight <1500g or gestation <33 wk. They were randomly 
assigned to receive milk supplemented with Lactobacillus GG or a placebo 
(maltodextrins), from first feed until time of discharge. Infants received mother’s milk, 
donor expressed breast milk or preterm formula. Lactobacillus GG was stopped after NEC 
but not after UTI or sepsis. Incidence of NEC ≥2 was a primary outcome (defined by 
Bell’s staging (385)). UTI, sepsis and adverse events also measured.  Continuous data were 
expressed as mean +/-SD. Mean birth weight was <1300g in both groups with some of the 
population >1500g (but <33 weeks gestation). 
The study by Costalos et al (391) was performed in two NICUs in Athens, Greece. The 
authors enrolled 87 infants between 28-32wk. Patients were randomised to receive either 
preterm formula with additional polyamines and Saccaromyces boulardii, or standard 
preterm formulae to which placebo (maltodextrins) were added. Patients discontinued 
supplementation if they developed NEC, sepsis or vomiting. Clinical data gathered 
included weight changes, enteral tolerance of feeds and sepsis. Incidence of NEC (defined 
by a modified Bell’s criteria (386)) was a secondary outcome measure. Continuous data 
were expressed as median with interquartile ranges. 
The study by Lin et al (393) involved 367 infants of <1500g birth weight admitted to a 
single NICU in China.  Infants were randomised to receive either human milk (mother’s or 
donor) supplemented with Lactobacillus acidophilus and Bifidobacterium infantis twice 
daily, or unsupplemented human milk, from seven days of life to discharge. Demographic 
data included risk factors for NEC. Primary measures were incidence of NEC ≥1 (defined 
by a modified Bell’s criteria (386)), severe NEC (≥2), sepsis, death attributable to NEC 
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and adverse effects attributable to probiotics. Continuous data were expressed as mean +/-
SD.  
The study by Bin-Nun et al (390) from Israel included 143 preterm infants weighing 
<1500g who were randomised to receive milk supplemented with Bifidobacterium infantis, 
Streptococcus thermophilus and Bifidobacterium bifidus or unsupplemented milk. Infants 
received mother’s milk or preterm formula. Clinical parameters relating to NEC were 
collected. Continuous data were expressed as mean +/-SD.  Primary outcomes included 
incidence of NEC (defined by Bell’s criteria (385)), severe NEC and death.  No adverse 
events attributable to probiotics were noted.  
The study by Manzoni et al (394) was carried out in a single Italian NICU. The authors 
enrolled 80 infants with BW<1500g. Patients were randomly assigned to receive human 
milk (mothers or donor) supplemented with Lactobacillus GG or unsupplemented human 
milk. Clinical data gathered included bacterial colonisation rates, invasive fungal 
infections, enteral milk tolerance. Stage 2 and stage 3 NEC (defined by Bell’s criteria 
(385)) were secondary measures. Continuous data were expressed as a mean +/- SD.  
2.4.2 Methodological quality 
Randomisation of patient groups by sealed envelope was reported by Dani et al (26), 
Costalos et al (27) and Lin et al (29), and caregivers and assessors were blinded. Manzoni 
et al (32) described randomisation by computer generated table. Bin Nun et al (31) patients 
were randomised by computer assignment (personal communication, Hammerman C, Jan 
2007). Demographic data in all studies on the two groups showed them to be well-
matched. 
2.4.3 Incidence and severity of NEC 
Dani et al (392) found a lower incidence of NEC≥2 in the probiotic group (1.4% vs. 2.8%) 
but this did not reach statistical significance. Patients were not stratified by severity. 
Costalos et al (391) reported a non-significant trend towards less NEC of any severity in 
the treatment group (9.8% vs. 16% p= 0.5). Lin et al (393) found a lower incidence of all 
NEC in the probiotic group (1.1% vs. 5.3%, p=0.04). There were six cases of severe NEC 
(≥2) in the control group versus none in the probiotic group (p=0.03). Bin-Nun et al (390) 
found a significantly lower incidence of all cases of NEC in the probiotic group (4% vs. 
16.6%, p=0.031) and severe NEC (≥2) (1% vs. 14% p=0.013). Manzoni et al (394) 
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reported a non-significant trend towards less severe NEC in the treatment group (2.6% vs. 
4.9% p=0.51).  
2.4.4 Requirement for surgical intervention 
In the study of Dani et al (392) two patients from the control group underwent surgery as 
opposed to none in the probiotic group (no statistics included). Manzoni et al (394) 
reported one surgical case of NEC in the control group versus none in the treatment arm. 
Costalos et al (391), Lin et al (393) and Bin-Nun et al (390) did not record need for 
surgery. 
2.4.5 Mortality attributable to NEC and overall mortality 
Dani et al (392) recorded two deaths attributable to NEC, both in the control group; all 
deaths before two weeks of life were excluded from analysis. Costalos et al (391) gave no 
figures on mortality. Lin et al (393) reported a significantly lower mortality rate in the 
probiotic group (3.9% vs. 10.7%, p=0.009) but did not differentiate between death 
attributed to NEC or other causes. Infants that died before seven days of life were not 
enrolled in the study. Bin-Nun et al (390) described a non-significant trend to less NEC 
related mortality in the probiotic group (0/3 vs. 3/12). Overall mortality was significantly 
lower in the probiotic group (6/73 vs. 17/72, p=0.025). Manzoni et al (394) described a 
non-significant trend towards lower mortality in the treatment group (12.8% vs. 14.3%) but 
did not differentiate between those attributed to NEC or other causes (table 6). All of the 
systematic review team concluded that the heterogeneity of probiotic preparations and the 
timing and methods of interventions made further synthesis and meta-analysis of data 
inappropriate.  
Table 6: Cumulative results of five included studies 
 
Study  Study 
group 
 
Control Any NEC NEC 
 ≥ 2 
NEC 3 NEC 
Mortality 
Overall  
Mortality 
Dani et al (26) 298 290 4 vs. 8 4 vs. 8 - 0 vs. 2 - 
Costalos et al (27) 51 36 5 vs. 6 - - - - 
Lin et al (29) 180 187 2 vs. 10 2 vs. 10 0 vs. 6 - 7 vs. 20 
Bin Nun et al (31) 72 73 3 vs. 12 1 vs. 10 0 vs. 3 0 vs. 3 3 vs. 8 
Manzoni et al (32) 39 41 1 vs. 2 1 vs. 2 0 vs. 1 - 5 vs. 6 
 
Cumulative 640 627 15 vs. 45 8 vs. 30 0 vs. 10 0 vs. 5  15 vs. 34 
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2.4.6 Adverse reactions attributed to probiotic 
Dani et al (392) recorded no episodes of Lactobacillus sepsis. Time to full enteral feeds 
was also not significantly different between groups. Costalos et al (391) recorded no 
episodes of Sarccaromyces boulardii sepsis and time to full enteral milk feeds and weight 
gain were similar in the two groups. Lin et al (393) also recorded no episodes of 
Lactobacillus or Bifidobacteria sepsis. Time to full enteral milk tolerance was also noted to 
be similar in the two study groups.  Bin-Nun et al (390) reported similar enteral tolerance 
between study groups and reported no adverse events. Manzoni et al (394) reported no 
episodes of Lactobacillus GG sepsis and did not comment on time to full enteral feeds.  
2.5 Discussion 
Five eligible randomized controlled studies of the use of probiotics to prevent NEC in 
preterm and VLBW infants were identified which, between them, enrolled 1267 infants. 
Heterogeneities of study design, in the opinion of the reviewers preclude meta-analysis, but 
the studies broadly suggest that probiotics are likely to be useful in preventing and 
reducing the severity of NEC. However there are limitations to the existing data and the 
degree to which interpretation can lead to firm conclusions that probiotics prevent NEC. 
Mortality rates are related to local attitudes to NEC and the management of VLBW infants, 
but it is of note that overall mortality also appeared to fall in all of the probiotic groups 
(table 6). In the identified studies the authors used a wide variety of dosages and types of 
probiotics. These dosages in terms of cfu/kg often bore little relation to those used in other 
clinical trials of probiotics in children and adults (74;310). This massive variability in 
dosage may reflect a lack of targeted specificity in the desired effects of probiotics in 
preventing NEC. 
Despite strict definitions of NEC and staging, individual management and indications for 
surgical intervention, and thus mortality, may vary from neonatal unit to unit. The 
outcomes measured in individual studies also varied, with some authors reporting 
suspected NEC (Bell’s grade 1) and others confirmed cases (Bell’s grade ≥2). Mortality 
directly arising from NEC and overall mortality are the most important outcome measures, 
but these were not consistently reported by all authors. Studies demonstrating positive 
outcomes for the administration of probiotics to prevent NEC to date have reported high 
background rates of NEC. It is hypothesised that such rates can be attributed to local 
environmental factors, such as antenatal antibiotic policy, surgical delivery rates and breast 
feeding rates, which affect rates of infant bacterial colonisation (see section 1.5). The only 
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study performed in neonatal units with low background rates of NEC (392) generated 
results that failed to reach statistical significance, this may have been due to an inadequate 
number of infants. The existing studies also have variable entry criteria, feeding practices 
and insufficient statistical power.  Breast milk feeding, which may affect NEC rates 
(107;108), was universal in two studies (393;394), not in two (390;392) and preterm 
formula was exclusively used in one study (391). The practice of human milk donation is 
not universal in neonatal intensive care units (NICUs) and donor rates within Europe are 
low. This effects the generalisability of these data to units within the UK No adverse 
events attributable to probiotics were recorded in any of the studies. However insufficient 
information was given on observation for perceived adverse outcomes or for other 
morbidities suffered by the VLBW infants at follow-up. In addition none of the studies had 
sufficient power to attribute safety of administration of oral probiotics to this 
immunocompromised population of VLBW and preterm infants. Insufficient numbers of 
infants were included in these trials to reach statistical significance for overall mortality. 
The exact pathogenesis of NEC remains unclear. However the triad (figure 2) of intestinal 
ischaemia, substrate (often feeds) and microbial colonisation with pathogenic bacteria all 
play a part in the inflammatory cycle (92;118). Colonisation of the gut is significantly 
delayed in preterm neonates and differs from healthy term infants with a greater proportion 
of perceived enteropathogens (4-6;403) (see section 1.1.2). However host-bacterial 
interactions (cross-talk) through the products of bacterial metabolic activity, or by sensing 
of bacterial components, may be important in both stimulating and inhibiting the 
inflammatory response in NEC (23;134;404). Genetic variations in components of the gut 
immune system involved in bacterial sensing, such as toll-like receptors, result in reduction 
in NEC rates in experimental models (as discussed in 1.5.6.)(134). This suggests that 
predisposed immune responses to enteropathogens may also affect the development of 
NEC. 
The mechanisms by which probiotics may ameliorate NEC are not fully understood. 
Probiotics compete for intraluminal substrates and binding sites on the mucosal surface of 
the gut, and produce an array of antimicrobial compounds, thus reducing enteropathogen 
numbers and ability to attach and invade the gut epithelium (13-15;405). Pioneer bacteria 
in the gut have been shown to up-regulate the expression of host genes which favour the 
continuance of an intraluminal environment that will promote their own proliferation and 
dominance. This again encourages commensal bacteria rather than pathogenic species (23). 
Bacteria are required for the development of a normal healthy mucosal and systemic 
immunity (20), and probiotics have been shown to up-regulate markers of immune system 
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function in human studies (58). Commensal bacteria can also down-regulate programmed 
inflammatory responses to bacterial sensing (oral tolerance) (25). 
The reduction of NEC rates from probiotics may be accounted for by any of the above 
mechanisms rather than simply through reduction of numbers of, or invasion by, 
enteropathogens.  The reduction in overall mortality rates identified, independent of NEC 
mortality, suggests that probiotics may have other beneficial effects on the preterm 
neonate, such as immune stimulation or reduction of bacterial sepsis rates. A greater 
understanding of probiotic functions including the development of methods to better 
analyse bacterial metabolic activity may help to refine probiotic administration through 
better definition of type, dose and timing of interventions for future studies. The 
development of such methods to measure the pathophysiological and clinical effects of the 
gastrointestinal microbiota is the subject of sections 1.9-1.12. 
2.6 Conclusions 
The conclusions arising out of this systematic review illustrate the difficulties involved in 
designing intervention studies to evaluate dietary products for infants and children. 
Apparently ‘similar’ therapeutic strategies can reveal major heterogeneity in terms of 
species, viability, dose and timing of interventions when pharmaceutical standards are 
applied. Quite apart from those alluded to in section 2.5, infant feeds affect not simply 
growth and nutritional status, but also the development of gastrointestinal, respiratory and 
allergic disease in childhood and metabolism and health in later life (406-409). None of the 
studies reviewed involved long-term follow-up of infants. The ESPGHAN committee on 
nutrition has been critical of previous research into the use of probiotics in infants and 
children (55). It found limited high quality data on the safety and efficacy of probiotics 
added to infant formulae, follow-on formulae and special foods, and no information on the 
long-term benefits or adverse effects of such supplementation. The ESPGHAN committee 
has published recommendations on the design of trials into dietetic products for infants and 
children (410), which are applicable here (table 7). 
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Table 7: Summary of recommendations on future research on the use of infant milk formulae or 
dietary products (adapted from Aggett et al (410)) 
 
• Nutritional adequacy should be determined by outcome studies at 4-6 months. 
• Appropriate clinical studies of safety should be performed on all new components 
and combination of components in infant formulae and dietary products. 
• New modifications to formulae or dietary products should be informed by the 
systematic review of relevant existing information. 
• Formulation changes for reasons other than novel nutritional or clinical benefit 
should be at least subjected to trials of acceptability and nutritional equivalence.  
• All infant trials should be characterised with regard to factors that may affect 
outcome. Adequate blinding and good clinical practice is important. 
• Ethical approval and informed parental consent and required and should be 
declared on publication. 
• The possibility of unexpected adverse clinical outcome be addressed. 
• Study design should consider short-term and long term effects. It should include 
statistical power of the study and confidence limits of study should be reported. 
• Pilot study should be used to anticipate outcomes and enable the views of 
caregivers to be taken into account. 
• Manufacturers, scientific, academic and professional groups should collaborate to 
agree an essential portfolio of data and out-comes which will be recorded in all 
nutritional studies.  
• A central register of current trials should be established and information shared by 
manufacturers and clinical researchers 
• Confidentiality of original participants should be preserved 
• The results of abandoned studies should be made available publicly.  
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The field of systematic review continues to grow at an exponential rate. In 2007 2500 new 
systematic reviews were listed on Medline, an increase of over 100 fold from the rate in 
1991 (411;412). Over 100 groups conduct reviews and commission systematic reviews 
world wide (413). Reproduction of Muldrow’s analysis, even soon after its first publication 
in 1987, demonstrated a paradigm shift towards greater scientific method and 
reproducibility in terms of reviewing medical subject matter (414). The ESPGHAN 
committee on nutrition illustrates this evolution in review with successive improvements in 
the methodology and reporting and therefore the clinical importance of its position 
statements over time (410;415;416). 
Systematic reviews undoubtedly give ‘added value’ to the available evidence. However 
there are specific limitations to systematic review in the area of nutrition, particularly 
variables that are independent of the intervention and likely to affect outcome, such as food 
intake, conversion of food intake into nutrient values, methods and timing of intakes. Often 
the value of systematic reviews is contingent on the quality of reporting of individual 
studies, as inadequate description of ‘methods’ can exaggerate the effectiveness of an 
intervention by ≥ 30% (417). The variability in results of systematic reviews has 
demonstrated that even subtle differences in clinical question, search strategy and synthesis 
can result in marked differences in study results and recommendations (413;418-420). It is 
of note that a systematic review conducted in parallel to the one reported here generated 
similar results in terms of studies and reported outcomes. However the authors agreed that 
synthesis of these data was appropriate and generated significant outcomes for NEC 
prevention (421). This illustrates that systematic reviews are still open to cultural bias at 
the level of data interpretation. 
The need for improvements in systematic reviews has informed recommendations on the 
reporting of clinical trails. The findings of the QUORUM group and its recommendations 
have improved the reporting of individual randomised controlled trials by modelling the 
Consolidated Standards of Reporting of Trials (CONSORT) statement (422). Increasingly 
adherence to guidelines for reporting RCTs and systematic reviews are a requirement for 
publication. The outlined difficulties in performing randomised interventions in nutrition 
may make it infeasible to definitively answer clinical questions with RCTs alone. It is 
estimated that this reduces enquiry to around only 10% of original  published research 
(423).  The specific nature of individual areas of medicine, such as nutrition, may require 
individual guidelines for methods and reporting of studies. The CONSORT statement has a 
version specifically for holistic interventions. A future framework for nutritional 
systematic reviews could include the development of a specific capacity and training 
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programme in nutritional systematic review using existing reporting guidelines, and the 
development of nutrition specific guidelines and a central repository for data, which 
reviews the content and quality of current reviews and develops a list of research priorities 
(413). 
It is clear that to develop the field of probiotic therapies further for the prevention and 
treatment of both NEC and IBD greater rigour must be taken to describe the administration 
of such therapies in terms of definition and standardisation of live bacteria with gene-
typing of strains. Treating such therapies as pharmaceutical agents (rather than food 
additives) requires greater understanding of their mode of action. A greater understanding 
of probiotic functions, including the development of tools to analyse bacterial metabolic 
activity, may refine our understanding of the value of probiotic administration, through 
better definition of type, dose and timing of interventions for future studies. Thus whilst 
new nutritional therapies herald a promising era in treatment and prevention, it is the 
development of new tools to study changes in bacterial metabolic activity which are 
required to advance this. This will form the subject of the remainder of this thesis.  
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3 Development of SIP in human Faecal Microbiota:  
Experiments with Total RNA 
As discussed in the previous chapter the potential for nutritional therapies in inflammatory 
gut diseases of childhood is illustrated by the positive evidence for the prophylactic use of 
probiotics for the prevention of NEC. However, as discussed in the introduction, the role 
that the gut microbiota plays in the pathogenesis of IBD is not clear. Nutritional therapies 
have been shown to be effective in the treatment of IBD since exclusive enteral feeding, 
and to a limited extent probiotics, are effective in treating active inflammation. However 
the mechanisms of action of such therapies are poorly understood, in particular their effects 
on the metabolic activity of the gut microbiota.  
To better understand disease pathogenesis in IBD, experiments were designed to extend 
the current methodology of SIP to study human faecal microbiota. This programme of 
research was aimed to utilise SIP methodology in anticipation of the measurement of 
metabolic activity of faecal bacterial samples. This involved experiments to determine 
• Reliable extraction of bacterial total nucleic acids from human faecal samples; 
• Reliable enrichment of total RNA with 13C from labelled tracers; 
• Validation of total RNA 13C enrichment against established markers of bacterial 
metabolic activity;  
• The development of 16s rRNA capture techniques to isolate target RNA 
sequences, both at a group and a species specific level.  
The sequences of experiments were based on a number of considerations. The overall plan 
was that candidate tracers would be selected from compounds known to be involved in de 
novo synthesis of RNA and DNA as nucleic acid replication is a generic bacterial function. 
Ideally incorporation of 13C would then be dependant on the metabolic activity of the 
bacteria rather than from stimulus by tracer (as seen with 13C-glucose (371)). The purine 
and pyrimidine bases would therefore be the target for incorporation with 13C labelled 
substrates known to be involved in the synthesis pathways; urea, glycine, aspartate and 
uracil (figures 14, 15); (glutamine was discounted because it only donates nitrogen to 
RNA/DNA synthesis). Urea is an attractive substrate because its carbon enters into one-
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carbon pool (after rapid hydrolysis by bacterial urease) and it is potentially less susceptible 
to substrate bias. Moreover its existing potential for use in vivo has been demonstrated with 
the use of lactose 13C-ureides (348). Provisional data would be gathered using 13C urea. 
However, the suitability of urea as a universal tracer would be tested against the other 
candidate tracers in later experiments. The reproducibility of SIP as a marker of bacterial 
activity would also be tested against a previous validated marker of bacterial metabolic 
activity such as SCFA production.  
 
 
 
Figure 14: Purine and Pyrimidine synthesis 
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In terms of IRMS analysis, where materials could be reduced to dry weight with a 
predicted carbon content of ≥500µg the EA-IRMS would be deemed sufficiently sensitive 
for analysis. Where samples were likely to have a smaller carbon content or where the 13C 
signature would be particularly low, then samples were kept in solution and analysed via 
the LC-IRMS. 13C incorporation was expressed as ∆13C (∆13C = δ13C sample – δ13C 
baseline) above baseline. 
Unless stated otherwise, comparisons between sets of data were made by Student’s t-test (2 
tailed) in Microsoft Excel (Windows XP) and ANOVA using SPSS (SPSS Inc, Chicago, 
USA). A p value of ≤0.05 was taken as statistically significant.  
The first series of experiments focused on the extraction of total RNA from faeces, 
enriching total RNA with 13C and the comparison of 13C enrichment of total RNA with 
SCFA profiles.  
3.1 Experiment 1: Nucleic Acid and RNA Extraction 
3.1.1 Aims 
The aim of this experiment was to determine that adequate yields of RNA could be reliably 
obtained from 6g stool samples to perform 16s rRNA isolation experiments. A nominal 
yield of 10mg of RNA was calculated to be adequate to perform multiple probe 
experiments.  
3.1.2 Materials and methods 
Human stool samples were used for all experiments; these were obtained from healthy 
volunteers from within the Division of Developmental Medicine, University of Glasgow. 
All samples were voided between 0800-1100 on the day of use and were used within 2hr of 
voiding. Nucleic acids were extracted from the faecal slurry as previously reported (368). 
6g of fresh stool were homogenized in a stomacher 400 (Seward Medical, London, UK) for 
2min as 20% faecal slurries in a phosphate buffered solution (PBS) (0.1mM phosphate 
buffer, 0.0027mM potassium chloride, 0.317mMsodium chloride pH 7.4 (Sigma-Aldrich, 
London, UK) before use for nucleic acid extraction (for initial studies an aerobic buffer 
was permitted). Faecal slurries were then centrifuged at 15,000g for 30min and bacterial 
cells were obtained by pipetting out 1ml of the creamy layer of the pellet (containing high 
concentrations of bacterial cells). Bacterial cells were lysed by the addition of Prepmann 
Ultra (Applied Biosystems, Foster City, USA) and then boiled for 10min. After mixing 
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with equal volumes of phenol:chloroform:isoamyl alcohol (24:25:1) the resulting emulsion 
was centrifuged at 20 000g for 10min the aqueous phase was then removed. This was 
repeated a further two times before being repeated with chloroform alone. Nucleic acids 
were then precipitated by placing at -200C with 0.1 volume of 3mM sodium acetate and 
two volumes of ethanol for 30min, followed by centrifugation at 20 000g for 15min. The 
pellet of nucleic acids were dried at room temp for 20min and then re-suspended in 2ml 
eppendorf tubes in 266µl of tris-phosphate EDTA buffer. To isolate purified RNA, DNA 
was removed by the addition of 40µls per eppendorf of RNAase free DNAase (1U/µl) 
(Promega, Southampton, UK) after addition of 30µls of the accompanying reaction buffer 
(Promega, Southampton, UK) and incubation at 370C for one hour. Enzymes were 
removed by sodium acetate and alcohol precipitation as previously described.  
3.1.3 Results 
Following the standard protocol, extractions were on average 10-20mg of bacterial RNA 
per 6g of faecal material. Table 8 shows the yield of total nucleic acids from the first eight 
samples processed with the protocol.  
Table 8: Yield of bacterial RNA from first 8 extractions from 6g of faecal material  
 
Experiment Weight (mg) 
1 13.1 
2 17.2 
3 14.8 
4 14.8 
5 10.4 
6 12.6 
7 13.7 
8 19.5 
Mean 14.5 
SEM 2.8 
 
3.1.4 Conclusions 
This protocol provided a reliable method of extracting adequate total RNA for 16s rRNA 
isolation experiments, working on the assumption that 20% of total RNA is 16s rRNA. A 
nominal figure of 1mg 16s rRNA would be sufficient for standard elemental analysis 
IRMS (EA-IRMS). Therefore the next logical step was to develop a model for enrichment 
of total RNA with 13C tracers before proceeding to 16s rRNA experiments. A set of 
experiments was designed to test candidate 13C tracers, and then to examine the validity of 
changes in 13C incorporations in total RNA as a marker of metabolic activity.  
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3.2 RNA Labelling Experiment: Multiple 13C Tracer 
Incorporation 
3.2.1 Aims 
To test the suitability of various 13C labelled tracers in the labelling of total nulciec acids 
and total RNA in human faecal samples. 
3.2.2 Materials and methods 
Two separate freshly voided faecal samples (from the same individual on two occasions) 
were divided into 26 x3g aliquots as 10% w/v faecal slurries in two (13 in medium 1, 13 in 
medium 2) separate culture media. To these culture media supportive electrolytes, to a 
Sorenson’s phosphate buffer solution pH 6.6, were added. These had been boiled for 
20min and then purged with nitrogen for 10min to achieve anaerobic conditions. Culture 
media differed in amounts of supportive carbohydrate (see table 9). 
Table 9: Culture media used in 13C tracer incorporation experiments 
 
Culture 
Medium 
Contents 
1 250ml Sorensons buffer pH 6.6  
625mg NaCl, 60.15mg MgSO4, 2.9mg CaCl2, 1000mg NH4Cl 
300mg Pectin, 1660mg cornstarch  
2 250ml Sorensons buffer pH 6.6 
625mg NaCl, 60.15mg MgSO4, 2.9mg CaCl2, 1000mg NH4Cl 
2000mg Raftilose 
3 250ml Sorensons buffer pH 6.6  
2000mg Raftilose 
4 250ml Sorensons buffer pH 6.6  
 
All specimens were again equilibrated in a waterbath at 370C for 30min prior to the start. 
At time zero two bottles, one of each media, were snap frozen as before and labelled T0. 
The remaining 24 samples were inoculated with one of the following 13C tracers (6 
samples, 3 for each media): 37.5mg 13C urea (99 atom%), 5mg [U-13C4 15N] aspartate (99 
atom%), 35mg [4-513C2] uracil (99 atom%), 24mg [U-13C3] glycine (99 atom%). These 
tracers were all normalised for total weight of 13C, except for aspartate which was given at 
one seventh of weight due to its cost. The tracers were selected as they are precursors in 
the de novo synthesis of purines and pyrimidines, but enter the pathways at different 
points. They all therefore have potential as generic tracers of metabolic activity. Samples 
were sequentially removed at 2, 6 and 24hr and snap frozen and stored as before (one 
sample in each medium with each tracer at every time point). Samples were then defrosted 
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and total nucleic acids and total RNA were obtained as described in 3.1.2. Total RNA was 
predicted to be small so was analysed by LC-IRMS for total carbon content and 13C 
incorporation. 
3.2.3 Results 
In both media (medium 1 and medium 2) significant enrichments above natural abundance 
(T0 samples) were seen in RNA over time (figures 15, 16). ∆13C enrichments were 
consistently higher with the 13C-urea tracer and highest enrichments were seen over shorter 
time-points (2 and 6hr) but these enrichments were not statistically significant.  
 
Figure 15: 13C incorporation ∆13C (0/00) in total RNA over three time points using four tracers in 
culture Medium 1 
Asp= aspartate, Gly= glycine 
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Figure 16: 13C incorporation ∆13C (0/00) in total RNA and Eubacterial 16s rRNA over varying time 
points using multiple tracers in culture Medium 2 
Asp= aspartate, Gly= glycine 
 
When examining the mean incorporations of 13C for all four tracers there was significantly 
greater 13C enrichments from 13C urea in comparison to all other tracers (figure 17). When 
correcting for initial concentration of tracers (scaling up 13C4, 15N aspartate), the mean 
incorporations across both culture media showed most consistent 13C incorporation for 
13C4, 15N2 aspartate and 13C urea in RNA. Again only 13C urea had significantly greater 
incorporations than 13C2 uracil and 13C3 glycine (figure 18). 
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Figure 17: Mean 13C incorporation ∆13C (0/00) (SEM) of four tracers in both media 
Asp= aspartate, Gly= glycine, a= significantly greater incorporation than aspartate, uracil and glycine 
p<0.05 
 
 
Figure 18: Mean 13C incorporation ∆13C (0/00) (SEM) across all tracers in both media correcting 13C4 
15N2 aspartate for concentration  
Asp= aspartate, Gly= glycine, a= greater incorporation than uracil and glycine p<0.05 
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3.2.4 Conclusion 
 13C urea showed consistently greatest enrichments in comparison to other SI-labelled 
tracers in this culture model for faecal bacterial metabolic activity. The ability of urea to be 
incorporated most readily into RNA fitted with our understanding of where 13C, from 13C 
urea hydrolysis, enters the one-carbon pool. Although [13C4, 15N2] aspartate also showed 
promise, its metabolism may be less generic and the costs of obtaining tracer preclude 
large scale experiments. It was therefore concluded that using 13C urea tracers was the next 
logical step, until such time as these tracers could be retested using 16s rRNA. The first 
step was to determine whether such perturbations in 13C incorporation were a reliable 
proxy for bacterial metabolic activity by comparing 13C urea enrichment with a validated 
marker.  
3.3  Experiment 2: 13C Enrichment of Bacterial Total RNA 
and comparison with SCFA 
3.3.1 Aims 
The following experiments were designed to develop a method for the reliable 
incorporation of 13C tracer into the nucleic acids of faecal bacteria, and to demonstrate that 
tracer incorporation can be predictably changed by manipulation of selected substrates for 
metabolic activity. The validation of 13C incorporation into nucleic acids was to be done in 
comparison with alternative markers of metabolic activity. SCFAs were chosen as previous 
data exist on SCFA changes upon fermentation of specific substrates in these types of 
culture model experiments, knowledge of the relevance of SCFA changes to disease 
pathogenesis, and the potential use of butyric acid as therapeutic agent (115-
117;240;241;424).  
3.3.2 Subjects, materials and methods 
Early morning stool samples were obtained from four healthy adults. Subjects reported 
themselves as ‘well’ with no specific dietary regimens and had not received oral antibiotics 
within eight weeks of participating in the study. Stool specimens were used within 2hr of 
voiding. A minimum of 36g stool was required for each experiment.   
Aliquots of stool were homogenised into multiple 20% slurries for 1min using a high speed 
domestic blender. As each protocol variation was carried out in triplicate, homogenisation 
was carried out in 18g or 9g batches (3g or 6g depending on size of initial stool sample). 
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Sorenson’s phosphate buffer (SPB) pH 6.6 was used as the base for the slurries. The 
phosphate buffer had been prepared the previous 24hr, deoxygenated by boiling for 5min 
followed by purging with nitrogen for 20min and then sealed and stored at room 
temperature overnight. Three additional variations were made to the SPB with the addition 
of electrolytes and a carbohydrate source; either Raftilose®, (oligofructose, Beneo-Orafti, 
Tienen, Belgium), pectin or L-rhamnose (table 10). The fourth solution acted as a control 
with Sorenson’s phosphate solution only.  
Table 10: Culture media 1 to 4 for RNA incubation experiment 
 
Medium Contents 
1 250ml Sorensons buffer pH 6.6  
625mg NaCl, 60.15mg MgSO4, 2.9mg CaCl2, 1000mg NH4Cl   
1000mg Oligofructose 
2 250ml Sorensons buffer pH 6.6 
625mg NaCl, 60.15mg MgSO4, 2.9mg CaCl2, 1000mg NH4Cl  
1000mg Pectin 
3 250ml Sorensons buffer pH 6.6  
625mg NaCl, 60.15mg MgSO4, 2.9mg CaCl2, 1000mg NH4Cl   
1000mg L-Rhamnose 
4 250ml Sorensons buffer pH 6.6  
 
Specimens of 30ml or 15ml slurries were decanted into 50ml crimped topped glass vials 
and each flask was deoxygenated by flushing with nitrogen for 30sec. All specimens were 
placed in a 370C waterbath agitating at 40 cycles per min and allowed to equilibrate for 
20min. At time zero all vials were spiked with weight equivalents of 99% 13C urea (either 
50mg in 500µls or 25mg in 250µl) and shaken for 1min. One control vial (T0) was 
immediately snap frozen by placing in ethanol which had been chilled to <-200C with dry 
ice. The other twelve samples were replaced in the water bath and left to incubate for 4hr. 
Samples were then removed from the waterbath, 2.5ml of slurry was removed from each 
sample and mixed with 2.5ml of 1mol/L sodium hydroxide to fix SCFA profile, these 
samples were then stored at -200C for future SCFA analysis. The slurries were then all 
snap frozen with chilled ethanol and stored at -200C for future nucleic acid extraction. 
Nucleic acids were extracted from the faecal slurry by the method previously described. 
The resultant RNA pellets were weighed and resuspended in ultrapure water at a 
concentration of 2.5mg/50µls. Purity of RNA was demonstrated by spot check with 
ultraviolet spectrophotometric analysis and agarose gel elctrophoresis (figure 19). The 
concentration of total RNA was determined by measuring the ratio of the absorbance of 
total RNA to protein. Typically 2µl of RNA extract were dissolved to a final volume of 
50µl with distilled water and its absorbance was measured in UV at 260 (nucleic acids) and 
   96 
280 (proteins) nm corrected for the background absorbance at 320 nm. A ratio of 
260:280nm greater than 1.8 represented RNA fraction of high purity. 
The amount and integrity of RNA were estimated visually by electrophoresis on agarose 
gel (figure 20). Typically 2µl of RNA template were mixed with 3µl of loading buffer 
(Bromophenol 6 X (B0126, Sigma)) and loaded onto the wells of an agarose gel (0.8% 
containing ethidium bromide 5µl for 50ml of agarose). The electrophoresis was run in 1 x 
TBE (Tris Borate EDTA) for 30 minutes at 100V.   
 
Figure 19: Agarose gel elctropheresis confirming purity of RNA in bacterial specimen 
 
3.3.2.1 Analysis of 13C incorporation in total nucleic acids and RNA 
Samples were diluted to 1 in 100 concentration with ultrapure water were and analysed in 
25µl aliquots by LC-IRMS. Total C in sample and relative 13C:12C were analysed. 13C 
incorporation was expressed as δ13C parts per mille above 13C natural abundance (∆13C).  
3.3.2.2 SCFA extraction and analysis 
SCFAs were extracted using methods based on the previously described departmental 
protocol (425). 100µl of internal standard solution (86.1mmol/L 2-ethylbutyric acid) and 
100µl of orthophosphoric acid were added to 800µls of ultrapure water which had 50µl of 
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the faecal slurry/sodium hydroxide solution added to it. After homogenisation 3ml of 
diethyl ether was added to each sample which was vortexed for 1min, and the pooled ether 
phase was collected as a supernatant. This step was repeated twice. 
SCFA analysis of the pooled extract was performed using a TRACE 2000 gas 
chromatographer (ThermoQuest Ltd, Manchester, UK) using nitrogen (30ml/min) as a 
carrier. Calibration was carried out using an external standard which was run five times 
prior to analytical run and the response factor for each SCFA calculated from the average. 
A coefficient of covariance was calculated as a quality control check for the performance 
of the instrument. An external standard was also run after every twelfth sample. For 
measurement 1µl of pooled extract was automatically injected at 2300C onto the column. 
The column was a FFAP column (30m × 0.32mm; 0.22um film thinkness; Promochem, 
UK). The column temperature was held at 800C for 1min and increased by 150C per min 
until it reached a final temperature of 2100C. The total concentrations of acetic, propionic, 
and butyric acid were calculated automatically by the software by peak area ratio analysis 
against the internal standard and corrected for the response factor of each SCFA 
determined by the external standard. The relative proportions of SCFAs were measured in 
each assay sample. 
3.3.2.3 Statistical comparison of 13C RNA incorporation vs. SCFA 
profiles 
Comparisons were made between total SCFAs and culture media, relative SCFA profiles 
and culture media and SCFA profiles and 13C incorporations were analysed using ANOVA 
model in SPSS. Correlations between all measured parameters (total SCFAs, total C2, C3, 
C4, relative C2:C3:C4 proportions and 13C incorporations versus media support) were 
analysed using the Pearson Correlation Coefficient.  
3.3.3 Results 
13C enrichments were recorded in all four samples from all four individuals, indicating 
bacterial sequestration of labelled tracer (figures 20-23). Intra- and inter-individual 
variations were apparent. However mean 13C incorporations for the group across all four 
individuals showed reasonable reproducibility as expressed by standard error of mean 
(SEM). Significant differences were seen in mean 13C incorporation between groups. 
Incorporation was significantly higher in medium 2 (pectin) and medium 3 (L-rhamnose) 
(figure 24).  
   98 
 
Figure 20: Mean (SEM) 13C incorporation ∆13C (0/00) in bacterial RNA in four culture media in subject 
1  
a=ns, b=significantly greater incorporation than medium 4 p<0.05) 
 
Figure 21: Mean (SEM) 13C incorporation ∆13C (0/00) in bacterial RNA in four culture media in subject 
2 
a=ns 
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Figure 22: Mean (SEM) 13C incorporation ∆13C (0/00) in bacterial RNA using four culture media in 
subject 3 
 a= less incorporation than media 2, 3, 4 (p<0.05), b=significantly greater incorporation than medium 1 
and 4 and less than medium 3 (p<0.05), c= significantly greater incorporation than media 1, 2 and 4, 
d= significantly greater incorporation than medium 1 and less than media 2 and 3 (p<0.05) 
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Figure 23: Mean (SEM) 13C incorporation ∆13C (0/00) in bacterial RNA in four culture media in subject 
4  
a= significantly greater than medium 3 (p<0.05), b=significantly less than medium 3 and greater than 
medium 4 (p<0.05) 
 
 
Figure 24: Mean (SEM) 13C incorporation ∆13C (0/00) into bacteria RNA in all four subjects 
a= significantly less incorporation than medium 3 and greater than medium 4 (p<0.01), b= significantly 
less than medium 3 (p<0.05) and greater than medium 4 (p<0.01), c= significantly greater 
incorporation than medium 2 (p<0.05) and media 1 and 4 (p<0.01), d= significantly less incorporation 
than media 1, 2 and 3 (p<0.01) 
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SCFA analysis showed intra-individual reliability between triplicate samples. Total SCFAs 
were increased in all subjects in media 1-3 in comparison to medium 4 (figure 25). 
Addition of all three carbohydrates (oligofructose, pectin and L-rhamnose) was associated 
with significantly increased production of acetate, propionate, and butyrate, (p<0.05 vs. no 
carbohydrate) except that pectin was not associated with increased propionate nor was L-
rhamnose associated with increased butyrate production. SCFA profiles (% of total SCFA) 
showed significant changes in the relative proportion of C2-C4 depending on carbohydrate 
support. L-rhamnose was associated with significantly more propionate production and 
significantly less acetate and butyrate (figure 26). When comparing SCFA profiles with 
13C incorporation there was a significant correlation between propionate production and 
RNA enrichment and an inverse relationship between RNA incorporation and butyrate 
production (R2=0.44 p<0.017) (figure 27).  
 
Figure 25: Mean total SCFAs (µmol/ml) in all four subjects in four different media 
a= significantly less total SCFA in comparison to media 1, 2 and 3 (p<0.05) 
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Figure 26: Mean SCFA proportions (%) and 13C incorporation ∆13C (0/00) in bacterial RNA in all four 
subjects in four media 
 a= significantly greater production of propionate and less acetate and butyrate than media 1, 2 and 4 
(p<0.05) 
 
 
Figure 27: ∆13C (0/00) and butyrate concentrations across 4 media in all subjects  
a= negative association between RNA incorporation and butyrate production R2=0.44 p<0.017 
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3.4 Discussion 
This set of experiments demonstrated adequate isotopic enrichments of bacterial RNA to 
achieve sufficient 13C incorporation for detection by LC-IRMS. These enrichments showed 
reliable and predictable differentiation under stimuli for metabolic activity. There was 
marked inter-individual variation in enrichments. However the microbiome, and therefore 
metabolic signatures, of the gut microbiota show great variation from individual to 
individual. More importantly intra-individual variation in terms of 13C enrichment 
according to media was less marked. Carbohydrate substrate support is known to relate to 
SCFA production by bacteria within the gut (426;427). Fermentation of SCFAs in vivo is 
regulated by total fibre content of a complex diet and the relative resistance to digestion of 
NDCs, colonic transit time and the existing microbial pool (428). Faecal concentrations of 
SCFAs are however kept relatively stable by absorption and utilisation of SCFAs making 
faecal SCFA profiling relatively uninformative in the in vivo profile (429).  
Human in vivo studies have shown a wide variety in individuals’ ability to excrete SCFA 
in stool samples (428).  Pectin supplementation of the diet has been demonstrated to 
increase total SCFAs in human faecal samples, although ratios between them are most 
often unchanged. In vitro studies have shown clearer correlations with substrate support 
and SCFA profiles. Pectin has been correlated with increased propionate production in a 
rat colonic fermentation model (430). L-rhamnose has been correlated with marked 
increases in propionate production in in vitro models of human faecal samples (431). The 
current in vitro model experiment conforms to previous work that suggests bacterial 
fermentation has been increased by the addition of carbohydrates as indicated by increased 
total SCFAs in comparison to controls (430). In this experiment the mean proportion of 
propionate was increased by the addition of L-rhamnose, in keeping with previous 
observations (431). Changes in mean RNA 13C enrichment correlated with increased total 
SCFA production and changes in SCFA profiles between different media. This suggests 
that 13C incorporation is also a marker of bacterial activity. 13C enrichment of RNA 
represents the utilisation of substrate into cell structure in a replicating organism.  Because 
RNA turnover is more rapid than that of DNA it may be a better marker of rapid cell 
division or metabolism. This idea is strengthened by the observation that RNA enrichment 
is greater than total nucleic acid enrichment in some of the samples (data not shown).  
However significant changes in SCFAs and 13C incorporation according to culture media 
were not observed for each individual. Data relating phylogeny of bacteria present in faecal 
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microbiota and fermentative capacity are limited. It has been shown however that SCFA 
ratios can be affected in vitro by the presence of significant numbers of methane producing 
species (431). These observations, in terms of the variable fermentative capacity of 
microflora, may be a reflection of markedly different bacterial consortia between 
individuals. Such differences may limit the validity of combining inter-individual results to 
create aggregated results. The ability to link phylogenic diversity, and activity, to different 
metabolic profiles such as faecal SCFA concentration, would greatly improve our ability to 
study the metabolic capacity of such faecal samples.  
The development of the ability to probe individual species 16s rRNA for relative 13C 
incorporation should enable validation of SIP as a measure of metabolic activity. For 
example, increased 13C incorporation, relative to the total bacterial species, in identified 
propionate producing species (such as Bacteriodes and Propionobacter) could be linked to 
SCFA profiles. 13C enrichments appear to be unaffected by scaling down of the weight of 
the samples (from 6g to 3g) and, assuming 20% of total RNA is 16s rRNA, provides 
adequate material for the development of a probe capture technique to analyse species 
incorporation. The scaled down protocol may be suitable for the study of stool specimens 
from children or those from patients with IBD in relapse, where the concentration and total 
numbers of bacteria are likely to be significantly lower.  
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4 Development of 16s rRNA SIP for Assay of 
Human Gut Microbiota: Preliminary Experiments 
The experiments described in chapter 3 demonstrated that bacterial RNA could be reliably 
obtained from faecal samples and 13C enrichment of bacterial total RNA is a valid proxy of 
bacterial metabolic activity. However to understand the pathophysiology of faecal bacteria 
in IBD, metabolic changes at the species level, as well as the whole consortia, must be 
studied. Capture and recovery of 16s rRNA, as previously discussed, is the first step to be 
examined before the study of metabolic changes at a species level. In this series of 
experiments the development a protocol for the isolation of 16s rRNA from human faecal 
samples is described.  
4.1 16s rRNA Isolation Experiment 1: Initial Protocol 
4.1.1 Aims 
16s rRNA probes designed for the molecular characterisation of human faecal microbiota 
have been previously described (432).  In initial experiments the aim was to obtain 
adequate and reliable amounts of 16s rRNA by adapting previously described technique of 
magnetic bead capture of 16s rRNA (368).  
4.1.2 Materials and methods 
A starting experimental protocol was devised based on previous observations of DNA 
probe capture work within the Department (368) and using data from the manufacturers. 
Two eppendorfs with 50µls of faecal bacterial RNA (obtained as described in section 3.1) 
at a concentration of 10mg/50µl and 50µl of hybridisation buffer (5ml, SSC buffer, 20µl of 
N-lauroyl sarcosine, 20mg of NaCl, 4mg of SDS, 4ml of formamide made up to 10ml with 
ultrapure water) were mixed in a microeppendorf and then hybridised at 700C in an 
incubating oven for 10min followed by 30min at room temperature (180C). 5µl (1.78nmol) 
of a specifically designed 16s rRNA capture probe (100µmolar solution) (Sigma-Geonosis, 
Suffolk, UK) with oligonucleotide sequences corresponding to a Eubacterial 16s rRNA 
(bact 338 5’-GCTGCCTCCCGTAGGAGT-3’) and left to incubate under gentle mixing 
overnight at 250C. The RNA solution was then added to 890µl (8.9mg) of M-280 
streptavidin coated paramagnetic beads (Dynal Biotech, Wirral, UK) which had been 
washed three times (with magnetic capture of beads on each occasion) and re-suspended in 
the same volume of hybridisation buffer (here the formamide was substituted for ultrapure 
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water). The solution was incubated for 2hr under gentle mixing for 2hr at 250C. The 
streptavidin coated beads were then recaptured with a magnet and washed three times in 
ultrapure water and re-suspended in 100µl of ultrapure water.  The streptavidin coated 
beads with bound 16s rRNA were then harvested with the PTC-200 Peltier thermocycler 
(MJ research, GMI, Minnesota, USA) in a 300µl microeppendorf tube by heating to 900C 
for 3min. The resultant supernatant was removed and pipetted into a preweighted 200µl tin 
capsule (Elemental Microanalysis, Southampton, UK) and left to dry at 500C until only the 
precipitate is left. 
4.1.3 Results  
There was no appreciable increase in weight after complete drying of both eppendorfs.  
4.1.4 Conclusions 
This experiment demonstrated inadequate yield of material. A rate limiting step for the 16s 
rRNA isolation could occur at several steps of the protocol. Theoretically the concentration 
of total RNA was adequate, but hybridisation conditions, in terms of time, temperature 
concentrations of solvents and formamide appeared to affect RNA hybridisation for 
binding to capture probes.  
Capture probe volume (1.78nmols) had been calculated, on the assumption of  90% 
binding efficiency (on the basis of product information) and 16s rRNA length of 1542 base 
pairs in length, to be saturated for the total amount of RNA and binding capacity of 
streptavidin coated particles. However binding efficiency of these and the binding capacity 
of streptavidin coated beads may have limited capture of 16s rRNA. A series of 
experiments was required to identify which factors could be optimised. 
4.2 16s rRNA Isolation Experiment 2: Hybridisation 
Conditions 
4.2.1 Aims 
The aim of this set of experiments was to identify if variations in the hybridisation 
conditions which would lead to an increase in measurable nucleic acid yield. 
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4.2.2 Materials and methods 
Six microeppendorfs containing 50µl of faecal bacterial RNA (10mg/50µls) were prepared 
as described in section 4.1. The following variations in the protocol were performed; 
microeppendorfs 1 and 2 had 50µl of buffer solution added and the samples were 
hybridised at 700C for 10min and at room temperature for 30min (per-protocol). Micro 
eppendorfs 3 and 4 had no additional buffer added and were then incubated at 700C for 
10min followed by 30min at room temperature. Microeppendorfs 5 and 6 had 50µl of 
buffer solution added to them but were not incubated at 700C for 10min.  
Following hybridisation the following variations in probe capture were performed: 
micoreppendorfs 1, 3 and 5 had 1µl (0.36nmol) of bact-338 probe added whilst 2, 4 and 6 
had 5µl (1.78nmol) of bact-338 added to each. All microeppendorfs had added 890µls 
(8.9mg) of M-280 paramagnetic streptavidin coated beads which had been prewashed as 
previously described. They were all left for overnight mixing and harvested per protocol. 
The supernatants (or bands of 16s rRNA) were pipetted into preweighted tin boats and 
dried at 500C. All boats were reweighed at the end of drying (figure 28). 
 
Figure 28: Schematic conditions of methods 4.2.2 
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4.2.3 Results  
The initial experiment resulted in tin boats yielded between 0µg and 300µg of residue post 
drying (table 11). This yield was unsatisfactory with two blank cycles. It was also on a 
scale too small for accurate analysis by EA-IRMS.  
Table 11: Dry-weight of precipitates under varying hybridisation conditions 
 
Eppendorf Experimental Conditions Precipitate µg 
1 50µl RNA, standard buffer, hybridised at 700C, 
1µl capture probe 
300 
2 50µl RNA, standard buffer, hybridised at 700C, 
5µl capture probe 
100 
3 50µl RNA, no buffer, hybridised at 700C, 1µl 
capture probe 
0 
4 50µl RNA, no buffer, hybridised at 700C, 5µl 
capture probe 
100 
5 50µl RNA, standard buffer, not heated, 1µl 
capture probe 
300 
6 50µl RNA, standard buffer, not heated, 5µl 
capture probe 
100 
 
4.2.4 Conclusions 
Variations in the hybridisation conditions resulted in an appreciable precipitate in tin boats. 
However this was inadequate for analysis by EA-IRMS and no condition produced an 
order of magnitude increase in amount. A further variation on capture probe concentrations 
(1µ, 5µl and 50µl, (0.36nmol, 1.78nmol, 17.8nmol)) resulted in no improvements in yield 
(data not shown). Therefore exploration of other steps in the protocol was required to see if 
yield could be increased. Binding capacity of streptavidin coated beads and concentrations 
of buffer solution were other potential rate limiting steps in the protocol and these were 
examined next.   
4.3 16s rRNA isolation Experiment 3: Binding Capacity 
4.3.1 Aims 
The aim of this experiment was to examine the role of magnetic capture bead binding 
capacity and formamide concentrations in relation to dry weight of RNA obtained at the 
end of the protocol.  
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4.3.2 Materials and methods 
Four microeppendorfs of 100µl of RNA solution (10mg/50µl) were prepared as before. To 
microeppendorfs 1 and 2, 50µl of standard buffer solution were added and hybridised at 
700C for 10min followed by 30min at room temperature. To microeppendorfs 3 and 4, 
50µls of a modified hybridisation solution with lower concentration of solutes and 
formamide (3ml, SSC buffer, 10µl of N-Lauroyl sarcosine, 10 mg of NaCl, 2mg of SDS, 
3mls of formamide made up to 10ml with ultrapure water) was added and hybridised as 
above. Following hybridisation all microeppendorfs had 5µl (1.78nmol) of bact-338 
capture probe added and were incubated overnight at 370C as before. The following 
morning to eppendorfs 1 and 4 were added to 9.0mg of prewashed streptavidin coated 
beads in 900µls of buffer. To microeppendorfs 2 and 3 were added 9.0mg of MagnaCell-
streptavidin cellulose/iron oxide particles (Bio-Nobile, Turku, Finland), which have a 
greater surface area to weight ratio and therefore potentially a greater binding capacity, in 
1800µl of buffer solution. Mixtures were hybridised at 250C for 2hr and then harvested as 
before in the thermocycler at 900C for 3min with the washed supernatant being placed in 
preweighted tin boats and then dried at 500C (figure 29).  
 
Figure 29: Schematic of methods for 4.3.2 
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4.3.3 Results 
Weighted precipitates were greater in boats 2 and 3 (iron oxide particles) than in boats 1 
and 4. Table 12 and figure 30 demonstrate the effectiveness of the iron oxide particles. 
Table 12: Dry-weight precipitates via streptavidin beads and streptavidin iron oxide coated particles 
 
Microeppendorf Experimental conditions Dry-weight µg 
1 Standard buffer, 
Streptavidin beads 
150 
2 Standard buffer, 
Streptavidin particles 
400 
3 Modified buffer, 
Streptavidin particles 
500 
4 Modified buffer, 
Streptavidin beads 
10 
 
 
Figure 30: Comparison of mean dry-weight (SEM) between iron oxide particles and streptavidin beads 
 a= significantly less dry weight than with iron oxide particles (p<0.05) 
 
4.3.4 Conclusions 
The binding capacity of streptavidin coated beads appears to play a role in limiting 
isolation of 16s rRNA with the possibility of streptavidin capture particles increasing yield. 
However optimisation of other elements of the protocol remained to be demonstrated. 
Hybridisation conditions can only be optimised when a reliable baseline yield of material 
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can be obtained. In addition measurements of samples by EA-IRMS should confirm carbon 
signature and purity of precipitants. The concentration of total RNA may be important for 
binding potential as it may affect both hybridisation of 16s rRNA making it available for 
binding and stearic inhibition of binding by competing fragments of RNA. The 
investigation of RNA concentrations appeared to be the next logical step to examine. 
4.4 16s rRNA isolation Experiment 4: RNA Concentration 
4.4.1 Aims 
The aim of this experiment was to determine the effect of concentration of RNA and iron 
oxide particles on the yield of dry weight precipitate of 16s rRNA at the end point of the 
protocol.  
4.4.2 Materials and methods 
Six microeppendorfs of faecal bacterial RNA were prepared in the following manner: 1 
and 2 had 50µl (10mg) of RNA added, 3 and 4 for had 25µl (5mg) added and 25µl of 
ultrapure water, 5 and 6 had 12.5µl (2.5mg) of RNA added and 37.5µl ultrapure water. To 
all microppendorfs 50µl of standard hybridisation buffer was then added and they were 
hybridised at 700C for 10min followed by room temperature for 30min. Microeppendorfs 
1,3 and 5 then had 5µl (1.78nmol) of bact-338 probe added whilst 2, 4 and 6 had 10µl 
(3.56nmol) of bact-338 added. All mixtures were then incubated at room temperature 
under gentle mixing overnight. The following day to all were added 8.9mg of streptavidin 
iron oxide particles and incubated at 250C for 2hr and then harvested in the thermocycler 
using a longer harvesting cycle of 900C for 6min (as suggested by manufacturer). 
Supernatants from each mixture were dried in preweighted tin boats as before and then 
reweighed when dried out (figure 31). 
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Figure 31: Schematic of methods for 4.4.2 
  
4.4.3 Results 
Total yields of precipitate demonstrated a clear trend towards increasing yield with 
increasing concentrations of RNA in the hybridisation mixture. The binding capacity also 
appeared related to total ammount of iron oxide particles for the reaction (figure 32). 
However there was no consistent trend in variation in capture probe concentration 
suggesting that this was not a saturated step in the protocol. 
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Figure 32: Mean dry-weight of precipitate (SEM) under differing concentrations of total RNA and 
capture particles  
a= significantly greater weight than 10mg/8.9mg methods p<0.05 
 
4.4.4 Conclusions 
These experiments suggested that the protocol would now generate measurable and 
reproducible yields of precipitate. Although detectable by EA-IRMS, these yields were still 
relatively small to enable precise relative abundance 13C to be determined. The protocol 
was repeated with open drying of tin boats substituted with freeze drying tin boats after 
snap freezing them in liquid nitrogen to reduce loss of 16s rRNA by capillary action over 
the sides of the tin capsule during the evaporation process. However this resulted in no 
greater yield of precipitate (data not shown).  
The quantity of RNA proved limiting when trying to make multiple observations of 
bacterial enrichment on single specimens because high quantities of RNA are required for 
single experiments, which could not be yielded from dilute or small faecal specimens. In 
addition the quantity of capture particles required to yield sufficient material for EA-IRMS 
analysis would be prohibitively expensive for multiple observations. As stearic inhibition 
of competing strands of RNA was likely to affect binding, due to 16s rRNA being a long 
RNA strand (~1500 base pairs) it is proposed that a method that could reduce stearic 
inhibition for binding would improve the protocol. In addition the potential for scaling 
   114 
down experiments with the use of highly sensitive LC-IRMS needed to be explored to 
maintain the feasibility of multiple SIP observations from single specimens.   
A double probe method previously described by Pearson et al (370) appeared to be a 
promising approach that increased yield and reliability when probing for 16s rRNA. Here 
the oligonucleotide probe is adapted with the addition of a complementary sequence for 
another probe (CA- clamp 5’ 
CCCACCCACCCACCCACCCCCCCCAAAAAAAAAAAAAAAAAAAAA-3’), which 
has a poly-A tail, which can be hybridised to Poly-T sequences attached to a capture 
particle (figure 33). 
 
Figure 33: Modified “double probe” capture method for 16s rRNA 
 
It was therefore decided to compare the optimum streptavidin capture protocol with a 
protocol based on modification of this double probe capture technique. An initial 
comparison was devised before proceeding to a definitive experiment using measurements 
of 13C enriched material by LC-IRMS.  
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4.5 Streptavidin Double Probe Capture Comparison 1: 
Initial Comparison 
4.5.1 Aims 
The aim of the first experiment was to determine whether a double probe capture technique 
could be applied to faecal microbiota samples for the isolation of 16s rRNA. For this first 
experiment a larger volume and higher concentration of RNA were used to test the 
potential of this method. 
4.5.2 Materials and methods 
100µls (20mg) of RNA solution and 100µl of hybridisation buffer were hybridised as 
before. To the RNA solution 20µl (8.9nmol) of modified oligonucleotide probe; modified 
Bact 338- (5’-GCTGCCTCCCGTAGGAGTCCCCCGGGTGGGTGGGTGGGTGGG-3’) 
(which has an additional sequence complementary to the CA-Clamp sequence) was added 
and again incubated overnight. In parallel 400µl (4mg) of Magnetite oligo dT capture 
particles (Novagen, Munich, Germany) were washed three times in ultrapure water and 
recaptured in the eppendorf each time with a magnet. After the final wash, the particles 
were suspended in 800uls of the hybridization buffer (formamide substituted with water) to 
keep the final volumes and concentrations the same as the streptavidin particle 
experiments. 5µl (1.78nmol) of CA-clamp probe were then added to the particle mixture 
and all eppendorfs were left to incubate overnight at 250C under gentle mixing. After 
overnight incubation each microeppendorf of RNA solution was added to a 
microeppendorf of particles and CA-clamp mixture and incubated for 2hr as before. 
Particles were then washed as before three times in ultrapure water before being re-
suspended in 100µl water. Based on product information and previous data on using these 
particles (370), a lower temperature setting of 750C for 6min was used for 16s rRNA 
harvest, again in the PTC 200 Pelteir thermocycler. In parallel, a second 100µl of RNA 
(20mg) with 100µl of buffer solution was prepared and hybridised as before, before having 
20µl of Bact-338 probe added and incubated overnight as before. This solution was then 
added to 1600µl (16mg) of streptavidin iron oxide particle and incubated for 2hr. After 
triple washing the solution was harvested at 750C for 6min. Both samples’ supernatant was 
then dried in preweighted tin capsules and weighed after drying. Both tin capsules were 
analysed by EA-IRMS (figure 34). 
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Figure 34: Schematic for methods 4.5.2 
 
4.5.3 Results 
Dry weight of tin capsules revealed around 200µg of precipitate from the oligo-dT 
experiment with no appreciable weight in the streptavidin boat. However analysis of the 
precipitate by EA-IRMS confirmed the presence of carbon with a signature in keeping with 
organic matter, but still of insufficient weight to accurately assess 13C abundance of the 
material.  
4.5.4 Conclusions 
The double probe capture technique showed promise in reliably yielding greater amounts 
of 16s rRNA in that it generated a greater amount of precipitate despite using one quarter 
of the volume of capture particles, suggesting that binding efficiency was improved by the 
use of the CA-clamp.  However the scale was still insufficient for determination of 13C 
abundance by EA-IRMS. The ability of the protocol to yield 13C enriched material was 
also required to validate the capture of 16s rRNA. This would most likely to best achieved 
by final analysis using LC-IRMS which can increase the sensitivity of the protocol by 
several orders of magnitude. An experiment to examine these factors was designed. 
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4.6 Streptavidin versus Double Probe Comparison 2: 
Definitive Experiment 
4.6.1 Aims 
To compare to the optimal streptavidin 16s rRNA capture technique with the double probe 
technique in terms of reliability of yield of carbon material and yield of 13C enriched 
material via LC-IRMS. 
4.6.2 Material and methods 
A fresh 6g faecal sample was homogenized to 20% w/v slurry in Sorenson’s phosphate 
buffer solution pH 6.6, which had been boiled for 20min and then purged with nitrogen for 
10min to achieve anaerobic conditions. The sample was placed in a sterile crimped topped 
flask and allowed to equilibrate in a 370C waterbath for 30min under gentle mixing. At 
time 0 the bottle was spiked with 37.5mg of 99% 13C urea in 75µls of water. The sample 
was then incubated for 6hr to allow bacterial activity to sequestrate 13C urea before being 
removed and snap frozen by being placed in ethanol chilled to -300C by dry ice, to arrest 
bacterial activity. Sample were then stored in a -200C freezer. Total nucleic acids and total 
RNA were then extracted using the standard protocol.  Six eppendorfs of the resultant 
RNA solution were prepared in parallel, (2 with 10mg/50µls, 2 with 5mg/50µls and 2 with 
2.5mg/50µls). One microeppendorf of each concentration was prepared by the standard 
streptavidin protocol with 5µls (1.78nmols) of Bact 338 probe and 8.9mg/890µls 
streptavidin particles. The second set of three eppendorfs were prepared with the oligo-dT 
methods with 5µls (1.78nmols) of a modified Bact 338 probe (5’-
GCTGCCTCCCGTAGGAGTCCCCCGGGTGGGTGGGTGGGTGGG-3’) and 
4mg/800µls oligo-dt particles. Samples were washed three times, resuspended in 100µls of 
ultrapure water and then harvested in the thermocycler at 750C for 6min. After harvest all 
samples supernatants were kept in a solution for analysis by LC-IRMS.  The particles were 
washed once more with 100µl of ultrapure water and this was added to the solution to give 
a final volume of 200µl for analysis. The solutions were then analysed for total C and 13C 
content in 25µl aliquots by LC-IRMS (Dionex ICS 3000, Sunnyvale CA, USA, coupled to 
Liquiface interface and Isoprime isotope ratio mass spectrometer (Isoprime, Cheedle, 
UK)).  
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4.6.3 Results 
Consistently higher yields of carbon were obtained from the double probe samples (figure 
35). The weight obtained appeared to be independent of RNA concentration via the double 
probe method. These yields were on a sufficient scale for analysis by the LC-IRMS to 
detect total carbon and relative changes in 13C incorporation. 
 
Figure 35: Comparison mean weight of carbon (SEM) in oligo-dT and streptavidin capture methods  
a= p=0.06 
 
The presence of a ∆13C above natural abundance in analysed samples confirmed the 
sequestration of labelled substrate by target bacteria. Yields of 13C were reliable with the 
oligo-dT method with a reasonable standard error, whereas the streptavidin yielded only 
natural abundance in the 5mg and 2.5mg RNA eppendorfs with a wide standard error 
(figure 36). 
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Figure 36: Comparison of mean 13C enrichments ∆13C (0/00) (SEM) of 16s rRNA via the oligo-dt double 
probe capture technique and streptavidin coated particles 
 
4.6.4 Conclusions 
The double probe capture technique showed greater potential for SIP experimentation in 
terms of yield of organic carbon after harvest and reliability of material yielded, 
demonstrated by consistency in 13C enrichments in multiple specimens. Consistently, 
capture particles have shown a greater yield of total 13C in comparison to capture beads. 
This makes sense in terms of our understanding of the protocol binding kinetics and the 
greater surface area afforded by capture technique. The presence of increased quantities of 
non-RNA C in the double-probe capture technique may potentially invalidate observations 
of greater carbon yield being related to improved binding efficiency. However this 
observation, in parallel with an apparent reliability in 13C enrichment of capture material, 
suggests that the double-probe technique is more proficient. As 16s rRNA is a large 
molecule (~1500bp) it follows logic that a technique which can overcome the effects of 
competitive inhibition between RNA strands could lead to improved binding efficiency.  
Optimisation of this protocol was required, and it was felt that this could be performed in 
conjunction with examination of the SIP protocols ability to reflect varying bacterial 
metabolic activity using 16s rRNA as a proxy for total nucleic acid and generic RNA 
incorporation, at both eubacterial and group specific levels (phylogenetic level). For these 
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studies it was proposed to identify 13C incorporations into 16s rRNA using all four of the 
original candidate tracers, to test the relative reliability of these tracers in 16s rRNA in 
comparison to total RNA. The use of group specific oligonucleotide probes would enable 
the study of relative incorporation of tracers across different phylogentic groups to assess 
whether tracers exhibit substrate bias.  
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5  16s rRNA SIP Experiments on Faecal Microbiota 
To improve the SIP protocol and optimise the yield of target 16s rRNA the following 
studies on 13C enriched faecal microbiota were undertaken. The aims of this section of 
work were to validate SIP for the study of 13C enrichments of bacterial 16s rRNA as a 
proxy for total RNA incorporation and to assess whether these 13C incorporations could be 
related to bacterial metabolic activity. This was to be achieved by validating a 13C tracer at 
the 16s rRNA level, demonstrating that 16s rRNA yield would be consistently on a scale 
appropriate for LC-IRMS analysis and that appreciable 13C incorporation can be detected 
with predictable differentials across different tracers, stimuli and bacterial species.  
5.1 Faecal SIP Experiment 1: Multiple 13C Tracer 
Incorporation at 16s rRNA level 
5.1.1 Aims 
To test the suitability of various 13C labelled tracers in the SIP protocol applied to human 
faecal samples when probing at the 16s rRNA level.  
5.1.2 Materials and Methods 
Samples of frozen total RNA from the experiment described in chapter 3.2, from all four 
tracers ( [U-13C4, 15N] aspartate, 13C urea, [4,5-13C2] uracil, [U-13C3] glycine), from both 
media (1 and 2) and all three time points (2, 6, 24hr) were defrosted and prepared as 
previously described in 2.5mg/50µl aliquots. 16s rRNA was obtained from all samples 
using 5µls (1.78nmol) of modified eubacterial probe (modified Bact 338) using the oligo-
dT protocol described in section 4.6. Total RNA and 16s rRNA were analysed by LC-
IRMS for total carbon content and 13C incorporation. 
5.1.3 Results 
In both media (medium 1 and medium 2) significant enrichments above natural abundance 
(T0 samples) were seen in RNA and 16s rRNA over time (figures 37, 38). 13C enrichments 
were an order of magnitude greater in the total RNA in comparison to 16s rRNA. However 
relative changes in 13C enrichment were in proportion over time-points. 13C enrichments 
were consistently highest with the 13C-urea tracer and best enrichments were seen over 
shorter time-points (2 and 6hr). 
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Figure 37: 13C incorporation ∆13C (0/00) in total RNA and Eubacterial 16s rRNA at three time points 
using multiple tracers in culture Medium 1 
 
 
Figure 38: 13C incorporation ∆13C (0/00) in total RNA and Eubacterial 16s rRNA at three time points 
using multiple tracers in culture Medium 2 
 
   123 
At the 16s rRNA level 13C urea there was significantly greater 13C incorporation than from 
all other tracers (figure 39). When correcting for initial concentration of tracers (scaling up 
13C4 N2 aspartate), the mean incorporations across both culture media showed most 
consistent 13C incorporation for [U-13C4, 15N] aspartate and 13C urea in both RNA and 
eubacterial 16s rRNA (figure 40). However only 13C urea demonstrated significantly 
greater 13C incorporation than 13C2 uracil and 13C3 glycine at the 16s rRNA level (figure 
41).  
 
Figure 39: Mean 13C incorporation ∆13C (0/00) across all tracers in both media  
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Figure 40: Mean 13C incorporations ∆13C (0/00) across all tracers in both media correcting [U-13C4 15N] 
aspartate for concentration  
 
Figure 41: Mean 13C incorporations for all time points in both media for all for tracers, correcting for 
[U-13C4 15N] aspartate concentrations 
a+b= significantly greater incorporation to uracil and glycine p<0.05  
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5.1.4 Conclusion 
13C urea generated consistently greatest enrichments of nucleic acids in comparison to 
other SI-labelled tracers. However the relationship between total RNA and 16s rRNA was 
not linear, but appeared in proportion for the majority of samples. The ability of urea to be 
incorporated most readily into RNA fitted with our understanding of where 13C urea enters 
into the one-carbon pool (after hydrolysis to HCO3¯/CO2) making it a potential ‘universal 
tracer’ i.e. by entering via the most basic substrates would be less prone to sequestration 
bias. The experiments showed that the solubility of [4,5-13C2] uracil was poor in solutions 
which reduced its availability for incorporation into bacterial nucleic acids. Aspartate 
showed reasonable levels of incorporation, but it was less reliable with inconsistent 
incorporation and, as a result, failed to reach statistically significant better incorporation 
than uracil or glcyine. Glycine demonstrated good solubility, yet resulted in low levels of 
tracer incorporation. The reasons for this are unclear as glycine enters purine synthesis at 
an early stage and is essential for nucleic acid synthesis. One explanation may be that the 
demands on glycine for bacterial protein synthesis reduce its availability for nucleic acid 
synthesis. 
The 13C signal was again diluted between observations of total RNA and 16s rRNA, the 
dilutional factors were consistent across all the tracers, suggesting that these were not a 
factor in this process. Dilution of the 13C enriched 16s rRNA therefore must be an artefact 
of the 16s rRNA isolation and harvesting process. Contamination of the 13C signal by 
unenriched C could be due to several steps of the protocol where carbon is added, such as 
from the oligonucleotide probe, residual CA-clamp or from capture particles. More 
detailed examination of the protocol was required to fully understand this.  
It was therefore concluded that using 13C urea tracers would be the next logical step to 
examine a working model of SIP as a potential tool to explore the stimuli for bacterial 
metabolic activity and species specific incorporations. However the limited number of 
samples and variation of isotope incorporation was beyond the ability of the chosen 
method to demonstrate differences in 13C incorporation according to stimuli. Nor did it 
examine group specific activity. A set of experiments was then designed to examine these 
questions. 
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5.2 Faecal SIP Experiment 2: 13C Urea Incorporation 
Under Varying Stimuli and Time Frames 
5.2.1 Aims 
To assess the potential for the current SIP protocol to detect changes in 13C incorporation 
in bacterial 16s rRNA under varying stimuli for metabolic activity. 
5.2.2 Materials and methods 
Two freshly voided stool samples were each prepared in 13 separate crimp topped serum 
vials. Four separate culture media were prepared by the addition of supportive electrolytes 
to a volume of Sorenson’s phosphate buffer solution pH 6.6, which had been boiled for 
20min and then purged with nitrogen for 10min. Culture media differed in level of 
supportive electrolytes and supportive carbohydrate (table 13). 6g of stool was diluted to 
make 20% slurry with culture media and crimped topped tube was sealed before being 
flushed again with oxygen free nitrogen for 30sec. All specimens were then placed in a 
gentle agitating waterbath at 370C and left to equilibrate for 30min. At time zero each 
crimped topped vial was inoculated with 37.5mg of 99% 13C urea in 75µls of water. 
Samples from each culture medium were sequentially removed at 2hr, 6hr and 24hr and 
snap frozen. Frozen samples were immediately stored at -200C until being defrosted for 
analysis. Total nucleic acids and total RNA were isolated according to the standard 
protocol. Samples of  total RNA with highest enrichments (medium 1 to 3, time-points 2hr 
and 6hr) were then probed for 16s rRNA with a modified eubacterial probe (modified Bact 
338) using the oligo-dT method from section 1.2.8.2 using aliquots of 50µls/2.5mg of 
RNA. 
Table 13 Culture media used in 5.2.2 
 
Medium Contents 
1 250ml Sorensons buffer pH 6.6  
625mg NaCl, 60.15mg MgSO4, 2.9mg CaCl2, 1000mg NH4Cl   
1000mg Oligofructose 
2 250ml Sorensons buffer pH 6.6 
625mg NaCl, 60.15mg MgSO4, 2.9mg CaCl2, 1000mg NH4Cl  
1000mg Pectin 
3 250ml Sorensons buffer pH 6.6  
625mg NaCl, 60.15mg MgSO4, 2.9mg CaCl2, 1000mg NH4Cl   
1000mg L-rhamnose 
4 250ml Sorensons buffer pH 6.6  
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5.2.3 Results  
Total nucleic acids from all four media over all three time-points were analysed by LC-
IRMS and shifts in 13C enrichment above a nominal baseline from a T0 sample were 
expressed as ∆13C above natural abundance. Total nucleic acids enrichments were 
significantly higher in media 1 and 2 over the timeframe (figure 42, 43). Medium 3 had 
moderate enrichments with medium 4 having the lowest enrichment over all time-points. 
These findings correspond with the analysis of total RNA from all media and time points. 
Media 1 and 2 had all the significantly higher enrichments (figure 44, 45). Tracer 
incorporations were not as high in total RNA as in the total nucleic acids. 
 
Figure 42: 13C enrichments ∆13C (0/00) in bacterial total nucleic acids from 4 culture media at three time 
points 
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Figure 43: Mean 13C incorporations ∆13C (0/00) in bacterial total nucleic acids from 4 culture media at 
the three time points 
 a=significantly greater incorporation than media 4 p<0.05 
 
Figure 44: 13C enrichments ∆13C (0/00) in bacterial total RNA from 4 culture media at the three time 
points 
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Figure 45: Mean 13C incorporations ∆13C (0/00) in bacterial total nucleic acids from 4 culture media at 
the three time points 
 a= significantly greater incorporation than 4 p<0.05 
 
Isolated 16s rRNA again demonstrated lower enrichments of 13C in comparison with total 
RNA; however yields were again in proportion with total RNA across the three media and 
both time points (figure 46).  
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Figure 46: 13C incorporations δ13C (0/00) in bacterial total RNA and eubacterial 16s rRNA in culture 
media 1-3 at 2hr and 6hr 
 
5.2.4 Conclusions 
The 16s rRNA enrichments were in proportion to those in the paired total RNA samples. 
These enrichments also were significantly greater in the culture media that would have 
provided most support for bacterial activity. The protocol therefore offered opportunity to 
examine activity-related changes in the bacterial pool. The next logical step was to 
investigate the potential for detecting individual species specific changes in 13C 
incorporation in comparison to the whole bacterial consortia. 
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5.3 Varying 13C incorporations across Different Bacterial 
Species 
5.3.1 Aims 
To assess the potential for the current SIP protocol to detect species specific changes in 13C 
incorporation into 16s rRNA according to metabolic stimulus. 
5.3.2 Materials and methods 
Residual total RNA yielded from the multiple culture media (section 5.2.2) was prepared 
in 2.5mg/50ul aliquots as before with a paired eppendorf of oligo-dT particles modified 
with 5µls (1.78nmol) of CA-clamp. The RNA/buffer mixture was then probed using 5µl 
(1.78nmol) of a species specific Bifidobacterial probe (modified Bif 164 5’CATCCGGC 
ATTACCACCCCCCCCGGGTGGGTGGGTGGGTGGG-3’) to isolate Bifidobacterial 16s 
rRNA. This was done for limited highly enriched samples (medium 1 and at 2 time-points 
2hr and 6 hr). Isolated material was analysed by LC-IRMS and compared with eubacterial 
13C incorporation for the same samples from the previously displayed data.  
5.3.3 Results 
Similar total weight of carbon was extracted using the species specific Bifidobacterial 
probe as from the eubacterial probe. Figure 47 displays the 13C enrichments of 
Bifidobacteria relative to total bacteria. The Bifidobacterial enrichment continued to rise at 
the 6hr time-point, converse to total RNA and eubacterial 16s rRNA, this trend in rising 
enrichment was more pronounced in the oligofructose medium (medium 2).  
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Figure 47: 13C encorporations ∆13C (0/00) in eubacterial 16s rRNA and Bifidobacterial 16s rRNA in 
media 1 and 2 at 2hr and 6hr 
 
5.4 Conclusions of Faecal Microbiota SIP Experiments 
The faecal bacterial experiments yielded encouraging results. The SIP protocol 
consistently detected a measurable and reproducible weight of carbon from each probe 
capture experiment and consistently detected 13C enrichments above natural abundance. 
13C urea appeared to be the most reliable tracer at RNA and 16s rRNA levels with 
significantly greater incorporation than other candidate tracers. The enrichments of total 
RNA were related to support for bacterial activity, supported by changes relating to SCFA 
profile changes. These changes were also mirrored in the 16s rRNA from a eubacterial 
probe. The basic media chosen were designed to be as universally supportive of bacterial 
replication, at a pH that suited most gut microbiota (pH 6.6) and the electrolytes chosen 
were important co-enzymes for cellular function. The addition of a carbon source 
consistently increased bacterial metabolic activity as evidenced by a greater enrichment in 
total nucleic acids, total RNA and 16s rRNA in the samples to which a carbohydrate source 
was added. Cornstarch, as a complex carbohydrate, is a relatively generic carbon source for 
bacterial metabolic activity across species, whereas oligofructose is a preferential substrate 
for Bifidobacteria. Differences in the activity profile of Bifidobacterial probed 16s rRNA 
were detected and these appeared to be most marked in the oligofructose media although 
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these were only single observations. Urea still appeared to be a good potential tracer as 
incorporations were seen in all experiments and levels were related to metabolic activity. 
RNA and 16s rRNA enrichments were different with a marked dilution of 13C signal 
between the former and the latter in all experiments. The initial experiments with the single 
probe capture technique had inexplicable ‘blank cycles’ where no appreciable carbon was 
detected. This problem appeared to have been overcome by the use of the double-probe 
capture technique but there remained variation in the dilution from total RNA to 16s rRNA 
in apparently identically conditioned experiments. Although differential incorporations 
were observed from the eubacterial group and the Bifidobacteria, these differences were 
minimal and did not demonstrate clearly better incorporation by the Bifidobacteria when 
stimulated by the oligofructose medium.  
The observations from these experiments appeared to lack specificity, the 16s rRNA signal 
was again diluted and possibly contaminated by ‘background’ carbon. This dilution could 
possibly involve non RNA material within the supernatant or non specific binding of other 
cell material less likely to be 13C enriched over shorter time periods (DNA, cell proteins). 
The most likely explanation was that the blank carbon term results from recovery of probe 
nucleic acid sequences that were released into the supernatant in the high temperature 
melting of the probe-16s rRNA complex. The capacity of the protocols to isolate RNA 
without contamination with processing materials from protocol such as oligonucleotide 
probe, CA-clamp and capture particles is also important as these again will be sources of 
unenriched carbon. Although not necessarily a major problem if the amount of background 
carbon is consistent and reproducible, it does require greater 13C incorporation into 16s 
rRNA to be able to detect differences against a background of natural abundance carbon.  
The specificity of probes for binding when examining differences in species activity is the 
limiting factor in observing significant differences between species. Although encouraging, 
the data from section 5 suggested that optimisation of binding specificity was still required. 
Validation of the purity of specimens and a greater degree of reproducibility of the 16s 
rRNA results was sought in order to optimise the potential of SIP for the study of human 
faecal bacterial physiology and pathophysiology. It was decided that investigation of this 
would be best achieved by testing the experimental protocol further using a highly 
enriched model to amplify any potential differences in enrichment of target materials and 
thus to test the specificity of individual steps of the capture protocol. 
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6 16s rRNA SIP Experiments Using a 13C Enriched 
Pure Culture Model 
In chapter 5, experiments designed to determine that the SIP protocol could yield reliable 
quantities of 13C enriched 16s rRNA were outlined. In addition, changes in 13C 
incorporation predictable by stimuli for bacterial metabolic activity were demonstrated. 
However 13C incorporation in 16s rRNA is greatly diluted in comparison to that in total 
RNA. This dilution is also likely to affect the accuracy of any observation made on 
incorporation into 16s rRNA, both at a consortia and a species level. The aims of the 
following experiments were to investigate the faecal microbiota protocol further, focusing 
on effects on yield, purity and specificity of the probe hybridisation for enriched 16s 
rRNA. This was to be done by utilising a 13C enriched pure culture model to produce a 
sample of 13C enriched RNA of a known nucleic acid sequence that a specific 
complementary oligo-nucleotide probe could be designed to target.  
6.1 Preparation of 13C Enriched E. coli RNA for Pure 
Culture SIP Experiments 
An inactivated lyophilised specimen of a genetically characterised non-pathogenic E. coli 
(ATCC 25922; sourced from the Department of Microbiology, Royal Hospital for Sick 
Children Glasgow) was taken from a single transport swab and plated onto multiple agar 
gel plates with Maconkeys standard No. 3 gel under aseptic conditions. Culture plates were 
then incubated at 370C for 24hr to allow growth of pure colonies to form. Colonies were 
then removed by sterile ring and placed in a 2ml sterile flask containing 2ml of liquid 
culture medium. Bacteria were added until a standardised optical density of solution (80-
88%) was achieved which correlated with106 cfu/ml. 1ml aliquots of this sub-culture 
medium were used to inoculate a 50ml sterile flask of culture medium. The flasks were 
then placed in a 370C waterbath under vigorous agitation (40 cycles/min) for 48hr.  
As with previous experience within the laboratory, a relatively complex medium and a 
second sub-culturing of culture broth for a further 48hr were both required to yield 
optimum shifts in optical density of the culturing media. Sub-cultures were diluted to 10-2, 
10-4 and 10-6 density and plated on Mackonkeys number 3 and Columbian blood agar 
plates at each phase to ascertain the identity and purity of culture growths. Even with 
meticulous aseptic techniques E. coli were likely to be contaminated with at least one other 
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bacterial species after more than two sub-culture steps. Experiments were therefore limited 
to two sub-cultures.  
After a second sub-culture phase the sterile flasks were decanted into two 30ml centrifuge 
tubes and centrifuged at 15,000g for 20min. A bacterial pellet was then identified at the 
bottom of the centrifuge tube. This was removed with 1ml of culture solution and pipetted 
into a 2ml eppendorf. Bacteria were then processed to total nucleic acids and total RNA by 
the standard protocol and frozen at a concentration of 2.5mg/50µls.  
For 13C enrichment of E. coli the only carbon source present in the medium was glucose 
(10atom% 13C). This enriched glucose was added to both subculture media so that the 
bacteria were exposed to 10 atom% 13C as the sole carbon source for at least 96hr. After 
extraction analysis of total RNA confirmed 13C enrichment of around 3atom%. These were 
deemed suitably enriched to study the SIP protocol.  
6.2  Pure Culture Experiment 1: Faecal Microbiota 
Comparator Experiment 
6.2.1 Aims 
To determine the ability of the current experimental protocol to demonstrate species 
specificity by utilising highly 13C enriched pure cultures of E. coli as a positive control 
with unenriched faecal microbiota. 
6.2.2 Materials and Methods 
Six eppendorfs were prepared with 2.5mg/50µls of 13C enriched E. coli total RNA and 
50µls of hybridisation buffer, these were hybridised at 700C for 10min followed by 250C 
for 30min. To the first three samples (1, 2, 3) 5µl (1.78nmol) of modified eubacterial probe 
was added (Bact 338) and to the second three (4, 5, 6) 5µl (1.78nmol) of modified 
Bifidobacterial probe was added (Bif 164). In parallel 6 eppendorfs were prepared with 
400µls (4mg) of oligo-dT paramagnetic particles, which were washed three times in 
ultrapure water before resuspension in 800µls of hybridisation buffer. Each of these then 
had 5µls (1.78nmol) of CA-clamp probe added. All the eppendorfs were incubated 
overnight at 250C under gentle mixing. The RNA/probe solution were then each added to a 
particle eppendorf and then incubated for a further 2hr. The particles were removed by 
magnetic capture, washed three times with ultrapure water before resuspension in 100µl of 
ultrapure water. Particles were harvested in the peltier thermocycler at 750C for 6min. The 
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supernatant was removed and the particles were washed with a further 100µl of water to 
leave a 200µl sample. All samples were analysed in 25µl aliquots by the LC-IRMS.  
This experiment was repeated again with the alteration that each 2.5mg/50uls of RNA as a 
composite of 20% highly enriched E. coli and 80% RNA from non enriched faecal 
bacteria.  
6.2.3 Results  
In the pure E. coli experiment, supernatant material demonstrated consistent enrichment 
with 13C well above baseline in all six samples. Although 16s RNA enrichments were on a 
smaller scale than E. coli total RNA they were in proportion (roughly 4:1) and the pure E. 
coli arm, specimens 1, 2 and 3, were on a higher scale than in the previous faecal culture 
experiments. The 20%/80% mixed specimens, 4, 5 and 6, showed a proportional reduction 
in enrichments (figure 48). Neither of the experiments showed any specificity towards the 
Bact-338 probe and in the 20%/80% diluted sample enrichment appeared greater in the 
Bif-164 samples.    
 
Figure 48: 13C enrichments ∆13C (0/00) of 16s rRNA from pure E. coli culture and an 80% faecal 
microbiota 20% E. coli solution, probed with eubacterial (bact 338) and Bifidobacterial (Bif 164) 
probes 
a= significantly greater incorporation than the 80% faecal microbiota 20% E.coli in both bact 338 and 
Bif 164 probes, b= significantly greater incorporation than the 80% faecal microbiota 20% E.coli with 
the bact 338 probe, both p<0.05 
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6.2.4 Conclusions 
This experiment demonstrated reproducibility in the capacity to obtain enriched material in 
proportion to the total RNA from which it was obtained. A higher enrichment might also 
help demonstrate significant differences in bacterial activity. However the protocol failed 
to achieve species or group selective binding suggested by the previous faecal 
Bifidobacterial experiments. In fact enrichments trended towards greater enrichment in the 
Bif-164 samples. A possible explanation for this may be non-specific binding of RNA to 
available sites on the poly-T tail of the particles. In particular, messenger RNA (mRNA) in 
some bacterial groups is terminated by poly-A sequences (433). If mRNA enrichment was 
greater than 16s rRNA and non specific binding of mRNA was greater in the Bif-164 
probe arm this could generate the results seen previously. The logical next step was to 
investigate non-specific binding of the protocol.  
6.3 Pure Culture Experiment 2: No Probe vs. Open Clamp 
Experiment 
6.3.1 Aims  
To evaluate the role that 13C enriched non 16s rRNA material and non specific binding of 
mRNA might play in contaminating the 13C signal in harvested material from the final step 
in SIP protocol. To test the hypothesis that contamination involves non-specific binding to 
the oligo-dT particles (i.e. open Poly-T sites) or to the bacterial complementary sequence 
on the oligo-nucleotide probe the following experiments were performed.  
6.3.2 Materials and methods 
Stored highly 13C enriched E. coli RNA was defrosted and prepared in 12 x10µl aliquots 
(500µg) with 10µl of standard hybridisation buffer (40% formamide). RNA was hybridised 
at 700C for 10 min then allowed to rest at room temperature.  
In parallel, six eppendorfs were also prepared with 1.2mg of oligo-dT particles in 200µls of 
buffer having been washed three times in ultrapure water (‘no probe’).  A further 6 
eppendorfs were prepared with 1.2mg of oligo-dT particles in 200µls of buffer which then 
had 1µl of CA-clamp added to each eppendorf (‘open clamp’). Oligonucleotide probes 
were not added to any of the eppendorfs. All RNA mixtures and particles were then 
incubated in parallel overnight at 250C.  
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The following day the contents of the 12 RNA eppendorfs were added sequentially to the 
particle solutions. This gave six pots with a ‘no probe’ set up for binding (figure 49) and 
six pots with an ‘open clamp’ set up (see figure 50). RNA particle mixtures were incubated 
together at 250C for 2hr before being removed. The particles were then captured by magnet 
and washed three in ultrapure water before being resuspended in 50µls ultrapure water. 
Three eppendorfs from each arm of the experiment were placed in tin boats and particles 
dried in an oven at 400C for 2hr. A further three sets of particles were placed in the peltier 
theromocycler and harvested at 750C for 6min. The resultant particles captured with a 
magnet and the 50µl supernatant kept for analysis. The particles were washed once more 
with 50µls ultrapure water to give a total of 100µls liquid sample for analysis. The post 
harvested particles were resuspended in 50µls of ultrapure water and dried in tin boats as 
before (figure 51). All particle samples were then analysed by EA-IRMS and the liquid 
samples were analysed by LC-IRMS. 
 
Figure 49: Schematic representation of the ‘no probe’ experiment 
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Figure 50: Schematic representation of the ‘open clamp’ experiment 
 
 
Figure 51:  Schematic of ‘no probe’ versus ‘open clamp’ experiment  
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6.3.3 Results  
Both the ‘no probe’ and ‘open clamp’ arms of the experiment yielded similar amounts of 
total carbon. Enrichment above a nominal baseline was detected, but these yields were 
very low in comparison to the high enrichment of total nucleic acids and in comparison to 
the per protocol yields from the previous experiment (figure 52). No significant difference 
was detected in enrichments between the two arms of the experiment. Analysis of the 
particles did not detect any significant differences in enrichment between particles that had 
been dried immediately and those that had been harvested via the thermocycler (not 
shown). 
 
Figure 52: 13C enrichments ∆13C (0/00)   for 16s rRNA yielded from the ‘no probe’ vs. ‘open clamp’ 
experiment (NS) 
 
6.3.4 Conclusions  
Enrichments of nucleic acids in this experiment were consistently lower than total RNA 
enrichments in comparison to the previous experiments. This suggested that if non specific 
binding occurred then in it might in part require the bacterial probe to facilitate binding. In 
order to determine that ‘per protocol’ methods yielded greatest enriched material further 
experiments were performed.  
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6.4 Pure Culture Experiment 3: No Clamp vs. per 
Protocol Comparator 
6.4.1 Aims  
To analyse the potential for non specific binding of probe and other RNA to Poly-T sites 
and to test the ‘per protocol’ approach as the optimal method to yield the highest 
enrichment of 13C from total RNA. 
6.4.2 Materials and Methods  
Stored highly 13C enriched E. coli total RNA was defrosted, prepared into six 50µl (2.5mg) 
aliquots and then hybridised at 700C for 10min with 50µl of hybridisation buffer (40% 
formamide). After equilibrating at 250C for 30min 5µls of modified E. coli probe was 
added to each eppendorf and then incubated at 250C under gentle mixing.  
In parallel six eppendorfs were prepared with 400µl (4mg) of oligo-dT paramagnetic 
particles. Three eppendorfs were simply washed three times in ultrapure water, 
resuspended in 800µls of hybridisation buffer and then incubated over night at 250C (‘no 
clamp’) (figure 53). The second set were modified per protocol; after washing three times 
in ultrapure water they were resuspened in 800µls of hybridisation buffer and 5µl of CA-
Clamp probe were added to each eppendorf and incubated overnight at 250C. The particles 
were washed three times with ultrapure water to remove any unbound CA-Clamp and then 
resuspended again in 800µl of fresh hybridisation buffer.  RNA solutions were then 
sequentially added to the particles eppendorfs and incubated together for 2hr. All particles 
were then captured by a magnet removed from solution and washed three times in 
ultrapure water before being resuspended in 200µls of ultrapure water. The particles were 
then all divided into two 100µl aliquots, the first half being dried in tin boats at 400C for 
2hr, the second half for harvest in the thermocycler.  The particles for thermocycling were 
harvested at 750C for 6min and the 100µl supernatant was removed and the particles were 
washed with a further 100µl of ultrapure water which was also kept (giving a total of 
200µls for analysis by LC-IRMS. The particles post thermocycling were also resuspended 
in 100µls ultrapure water and then dried in tin boats as before (figure 54). All stored 
particles were then analysed by EA-IRMS.  
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Figure 53: Schematic representation of the ‘no clamp’ experiment 
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Figure 54: Schematic for ‘no clamp’ versus ‘per protocol’ experiment 
 
6.4.3 Results 
Both arms of the experiment yielded similar amounts of carbon. Significant enrichments of 
13C were seen above baseline in both experiment arms and these were significantly higher 
in the ‘per protocol’ arm (figure 55). Analysis of the oligo-dt particles revealed very 
modest enrichments of 13C (in comparison to total C of the particles). These were greater in 
the pre harvest samples and the highest enrichments were in the ‘per protocol’ samples 
(figure 56).  
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Figure 55: Mean (SEM) 13C enrichments (parts/mille) of 16s rRNA samples from ‘no clamp’ and ‘per 
protocol’ experiments 
 
 
Figure 56: 13C enrichments ∆13C (0/00) of oligo-dt particles from the ‘no clamp’ and ‘per protocol’ 
experiments, before and after harvesting in the Peltier thermocycler  
a= significantly greater incorporation than post harvest p<0.05 
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There was a significant difference in the pre harvest 13C incorporation between the ‘no 
clamp’ and the ‘per protocol’ experiment with it being highest in the per protocol arm 
(figure 57). There was also a significant reduction in the particle enrichments between pre 
and post harvest in the ‘per protocol’ arm. Comparisons of all four recently used variations 
of the protocol revealed that the ‘per protocol’ arm yielded significantly 13C incorporations 
than all other methods (figure 58). 
 
Figure 57: Mean (SEM) 13C incorporations ∆13C (0/00) in pre harvest particles in ‘no clamp’ and ‘per 
protocol’ arms 
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Figure 58: 13C incorporations ∆13C (0/00) across ‘no probe’, ‘open clamp’, ‘no clamp’ and ‘per protocol’ 
experiments 
a= significantly greater incorporation than ‘no probe’ and ‘open clamp’p<0.05, b= significantly 
greater incorporation than ‘no probe’ and ‘open clamp’ p<0.01 
6.4.4 Conclusions 
The combination of results from this and the preceding experiment demonstrated that 
enrichment was greatest in the ‘per protocol’ methods (figure 59).The experiments have 
shown that the ‘per protocol’ methods are the most reliable for obtaining consistently 
enriched RNA which is in proportion to total RNA. However it was not possible to 
consistently demonstrate species specificity in binding. However all binding appeared to be 
affected by the presence of all components of the ‘double probe’ technique. It is possible 
that mRNA may interfere with binding by interference with available poly-T sites (i.e. 
those not taken up with a CA-Clamp after hybridisation).  
 
6.5 Pure Culture Experiment 4: Poly-A Wash 
6.5.1 Aims 
To examine the effects of non-specific binding of mRNA, or other material to Poly-T sites 
on paramagnetic particles, as a potential for hindering probe specificity of SIP protocol.  
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6.5.2 Materials and Methods  
18 aliquots of highly 13C enriched E.coli total RNA were prepared in eppendorfs with 
50µls (2.5mg) of RNA and 50µl of hybridisation buffer (40% formamide). These were 
hybridised at 700C for 10min and then at 250C for 30min. Nine of these eppendorfs were 
prepared ‘per protocol’ (each with a parallel eppendorf of 4mg paramagnetic particles 
washed three times, hybridised with 5µl (1.78nmol) of CA-clamp, washed again three 
times and then suspended in 800uls of hybridisation buffer) three with 5µl (1.78nmol) of 
modified E. coli probe 
(CCCCCCTTTGGTCTTGCCCCCCGGGTGGGTGGGTGGGTGGG), three with 
modified eubacterial probe (Bact-338) and three with modified Bifidobacterial probe (Bif-
164).  
For the Poly wash arm x9 eppendorfs of RNA/buffer were prepared as the per protocol arm 
(3 modified E.coli, 3 Bact 338, 3 Bif 164). After washing, hybridisation with CA-Clamp 
and re-washing, the paramagnetic particles were then hybridised again to a second oligo-
nucleotide probe 5µl (1.78nmol) ‘poly-A’ (AAAAAAAAAAAAAAAAAAAAAAAAA). 
This was done at 250C with gentle mixing overnight. After this second step the particles 
were then washed three times before being resuspended in 800µls of hybridisation buffer. 
All 18 RNA mixtures were added to their paired particles and incubated together at 250C 
for 2hr. The particles were then removed, washed three times and then resuspended in 
100µls ultrapure water for harvesting in the peltier thermocycler. This was done at 750C for 
6min (figure 59). Particles were washed once more with 100µls of ultrapure water to give a 
total of 200µls supernatant. Analysis of samples for relative 13C encorporation was by LC-
IRMS.  
   148 
 
Figure 59: Schematic for ‘poly-A’ experiment 
 
6.5.3 Results 
All samples demonstrated modest 13C enrichments above baseline (figure 60) which was 
on scale with total RNA (8:1). There was no significant difference between the poly-A 
experiment and the ‘per protocol’ arms in terms of 13C incorporation. In the poly-A arm 
there was, again, the suggestion that enrichments were highest in the Bif-164 samples.  
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Figure 60: Comparison of ∆13C (0/00) enrichments using the ‘poly-A wash’ technique versus ‘per 
protocol’ (parts/mille) of 16s rRNA using modified E.coli, eubacterial and Bifidobacterial probes 
6.5.4 Conclusion 
Species, or probe specific, specificity was not demonstrated. Again there was a suggestion 
that enrichments were greater in the Bifidobacteria probed specimens. This was counter to 
our understanding of the probe capture technique. The lack of effect of adding the poly-A 
wash step the protocol demonstrates that these limitations in the protocol are not related to 
non specific binding of mRNA alone.  
6.6 Conclusions of Pure Culture Experiments 
The current research on pure cultures demonstrated that 13C isolation and analysis of 
bacterial RNA was possible, and enriched material could be reliably isolated. Highly 
enriched supernatants were isolated, only from highly enriched components of bacterial 
RNA using this E. coli model. Although not optimised the ‘per protocol’ method yielded 
significantly better results than other variations carried out suggesting a degree of 
specificity in the binding of material to the double probe. In addition demonstration of a 
reduction of enrichment of particles after thermocycler harvesting suggested some 
efficiency of the disassociation methods.  
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Repeated analysis failed to resolve dilution of signal and specificity of binding, particularly 
at a group level. As the purity of the startingRNA product was confirmed by gel 
electrophoresis and UV spectrometry, it was presumed that starting material was relatively 
pure bacterial RNA; therefore contaminants could have come only from reagents used in 
the protocol.  
Buffer constituents or other components of the RNA preparation are unlikely to bind to 
poly-T sites significantly and contamination with these is unlikely as particles were triple 
washed on two occasions prior to analysis. The melting temperature of probes, as opposed 
to the bacterial RNA, may vary according to base pair length and GC content of 16s rRNA 
and probes. However, even if harvest temperatures exceed probe melting points resulting 
in significant dilution with un-enriched probe material, it would be expected that the 
dilution factor would have been relatively constant when using the same type of probes. 
This was not the case as marked variations in enrichments between identical experimental 
conditions occurred. Non-specific binding of material remains an unanswered issue and is 
a likely source of loss of specificity. However it can be assumed that enrichment of other 
sources of RNA (mRNA) might achieve relatively uniform enrichment at a consortia level; 
again this would not fit with variations between identical experimental conditions.  
Specificity of binding remained a key issue as, even with 16s rRNA oligonucleotide 
probes, target RNAs will come from a ‘range’ of sequences rather than one sequence. 
Recently work combining SIP with FISH analysis has shown that as more about 
unculturable bacteria subspecies is learnt, what were initially thought of as sub-group 
specific probes will isolate a consortia of related sequences (434). To learn more about the 
phylogeny of such bacteria the authors suggested that a panel of related probes be used to 
characterise relative binding specificity. Miyatake et al (435) have improved SIP 
methodology for specific functional SIP in marine sediments by applying oligonucleotide 
probes with additional probes that are complementary to the sequences directly upstream 
and downstream of target sequences. Such data suggest that designer oligonucleotides will 
never achieve absolute specificity, but rather an ‘optimal profile’ for considered work. 
Such relative specificity may hamper experiments where differential incorporation of 
tracer into related species are being studied.  
Clearly this methodology of SIP has generated significant results, but further work to 
predictably enrich 16s RNA, improve 13C signal above background and between groups 
and confirm groups/species specificity is required before SIP can be used to perform 
clinical observations in inflammatory diseases.  
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7 Conclusions and Future Research 
The hypotheses formulated and tested by the research outlined in this thesis (section 1.15) 
were 
1. Probiotics prevent NEC in at risk infants of very low birth weight (VLBW). 
2. The human gut microbiota can be labelled by stable isotope probing (SIP) to 
measure metabolic activity. 
3. Quantitative measurement of the metabolic activity of the unculturable gut 
microbiota is a useful way of studying changes in the microbiota, compared 
with measures of bacterial diversity, and may enlighten our understanding 
of bacterially mediated inflammatory stimuli in inflammatory gut diseases of 
childhood. 
7.1 Summary of Principle Findings of the Systematic 
Review 
The research described in chapter 2 has demonstrated that: 
• The administration of prophylactic enteral probiotics to VLBW and <33wk infants 
appear to significantly reduce the risk of proven (Bell’s stage ≥ 2) NEC. 
• The administration of prophylactic enteral probiotics to VLBW and <33wk infants 
appears to significantly reduce all cause mortality.  
• Insufficient data exist to determine whether probiotics reduce NEC related 
mortality in VLBW and <33wk infants. 
• Greater numbers of subjects are required to determine the safety of enteral 
probiotics administration to VLBW and <33wk infants. 
• Optimisation of specific type, dosage and timing of oral probiotics for the 
prevention of NEC is required.  
   152 
The current evidence broadly supports the use of prophylactic enteral probiotics for the 
prevention of NEC in VLBW and <33wk infants. Yet this clinical application lacks the 
foundations of adequate knowledge of the principle mechanisms by which orally 
administered bacteria establish themselves as ‘residents’ in the gastrointestinal tract, their 
primary interactions with the host environment or their therapeutic mechanisms of action. 
Nevertheless, in conjunction with evidence from studies of infectious diarrhoea, atopic 
dermatitis (section 1.4) and pouchitis in IBD (section 1.8.3), this research supports the 
clinical applications for nutritional therapy. The gold standard of double blinded placebo 
trials, in testing food products in humans, are limited (as illustrated in sections 1.4 and 
1.8.3), not only because of lack of volition by manufacturers to test them properly, but also 
because of difficulties in generating appropriate placebos for trials (436), or defining the 
active ingredient which may involve components or metabolites of bacteria. At present 
faecal markers, such as biochemical changes in stool parameters (SCFAs or Ig levels) are 
the only commonly used methods, yet the site of desired action of probiotics may be 
remote from site of administration within the gastrointestinal tract, or indeed in another 
organ systems of the body. 
Probiotic studies to date lack scientific rigour; there is no standardisation of preparations 
and probiotics acceptance and scientific use is threatened by pressure from the commercial 
purveyors of these products as ‘health foods’. The marketing of ‘functional foods’ or 
‘nutraceuticals’ remains a contentious and difficult area to legislate. The ‘General Food 
Law Regulation’ of the European Parliament 2002 is complex and is ambiguous in 
determining whether certain products should be regulated under this act or by medicinal 
Law (437). In the USA the Food and Drug Administration defines live bacteria as ‘live 
biotherapies’ but this definition falls short of the standards required for the scientific 
definition of probiotic agents (438). Identification and enumeration of live bacteria in a 
complex matrix is difficult, time consuming and costly (439). The Fermented Milks and 
Lactic Acid Bacteria Beverages Association of Japan has set a minimum of 107 bacteria to 
be considered a ‘dose’ of  a probiotic (440), although others have suggested dosages as low 
as 105  (441). At present there is little incentive for manufacturers of commercial products 
to adhere to pharmaceutical standards for commercially available produce (442). Where 
the possibility of untruthful or misleading marketing of products is possible the integrity of 
the science of probiotics as a whole suffers. 
Man has been consuming bacterially augmented food since at least 3500BC (443), yet it is 
only now in the 21st century that the science of probiotics may have come of age. The 
establishment of the routine use of enteral probiotics for the prevention of NEC, as the 
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leading contender for clinical application, may serve as the crucible for the legitimisation 
of live microbial therapy within the medical community. However the establishment of 
probiotic therapy within the armoury of clinical therapies requires recognition of the 
threats posed by the commercialisation of this science and the adherence to the required 
principles outlined namely; identification, enumeration; mechanisms of action (both in 
vitro and in vivo), efficacy and safety in well designed double blind placebo trials in human 
subjects. 
7.2 Novel Techniques to Sample the Gut Microbiota and 
SIP 
The research described in chapters 3-6 of this thesis represented a logical series of 
experiments that have demonstrated that:  
• Faecal bacterial RNA can be reliably obtained from human faecal samples (section 
3.1). 
• Faecal bacterial RNA can be enriched with sufficient 13C for detection by IRMS 
(section 3.2). 
• 13C enrichment of bacterial total RNA in human faecal samples can be modified 
predictably with stimuli for metabolic activity (section 3.2), and that these changes 
in incorporation have been validated against another marker of bacterial metabolic 
activity (3.3).  
• Capture of bacterial 16s rRNA from human faecal samples is possible using oligo-
dT particles and a double probe capture technique (sections 4.5-4.6). 
• 13C incorporations can be detected in 16s rRNA and correlated with total RNA 
incorporation (section 5.1). 
• 13C urea was the most reliable candidate tracer for SIP experiments at the RNA and 
16s rRNA levels (section 5.1).  
• 16s rRNA SIP of human faecal samples currently lacks species specificity to 
identify group specific changes in 13C incorporation (Section 6.2). 
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• Optimal 13C incorporation using the techniques described achieved some specificity 
in overall binding capacity (section 6.4). 
Methods to study the gut microbiota have expanded rapidly in the last five years (as 
detailed in sections 1.9-1.12). Novel culture techniques, such as microbead culture, allow 
simultaneous single cell culture of multiple individual microbes (444), expanding our 
knowledge of the contents of this complex ecosystem. Yet the majority of these bacteria 
remain uncultured.16s rRNA has been key to the characterisation of unculturable bacteria 
and has enlightened us to the wealth of information that remains undisclosed about the gut 
microbiota. The development of ‘high throughput’ methods of community profiling such 
as FISH-MAR and microarray has demonstrated correlations between host factors and 
microbial populations (445). However, defining the metabolic consequences of these 
bacteria remains beyond the scope of such methods. The birth of meta ‘omic’ sciences has 
led to insights into the activity of unculturable bacterial communities. Here screening for 
biomarkers of activity in DNA, mRNA or protein metabolites can define the metabolic 
‘potential’ of a bacterial community (446).  However analysis of these markers still 
requires the analysis of functionality outwith the ecosystem, such as by transference of 
genes to vectors such as E. coli (447). SIP, in concert with other meta ‘omic’ approaches 
shows the potential to link the metabolic activity of the gut microbiota to diversity both in 
vitro and in vivo.  
The hypothesis that changes in bacterial metabolic activity can be used as a disease marker 
in faecal samples (section 1.15) has been advanced by the research described in this thesis 
by the application of SIP-IRMS to human faecal microbiota. The principle of achieving 13C 
incorporation into faecal bacterial RNA by virtue of their metabolic functioning was 
reliably demonstrated. The use of probe specific hybridisations and LC-IRMS analysis has 
overcome the requirement for high levels of 13C enrichment of bacterial RNA for 
separation of isotope labelled RNA or DNA by centrifugal SIP methods (362;367). This 
order of magnitude of improvement in sensitivity allows the study of changes of bacterial 
metabolic activity according to stimuli in concert with other markers of bacterial metabolic 
activity in human faecal samples. The scale of such incorporation is such that experiments 
could be envisaged in ecosystems where there is a large flux of substrate and subsequent 
dilution of tracer, such as the human large bowel. SIP is uniquely placed to link function to 
phylogeny without the confounders of colonocyte metabolism and in vitro effects of 
metabolite analysis. The use of 13C urea as a tracer for delivery of labelled carbon to 
bacterial RNA shows promise as a reliable marker of activity which is cheap, safe and 
deliverable to the human gut microbiota in vivo. The use of a novel ‘double probe’ 
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oligonucleotide probe capture technique for isolation and extraction of 16s rRNA with a 
priori knowledge of bacterial groups opens up the potential study of the changes of 
metabolic activity of individual species or higher level of taxa within complex consortia. 
Differences between the whole consortia incorporations and Bifidobacteria were 
demonstrated and appeared to relate to stimuli for metabolic activity. Such individual 
changes may be important in terms of substrate availability for the whole ecosystem or 
metabolite effects on the responses of the gut immune system. 
The complexity of these interactions will undoubtedly require observations of bacterial 
numbers and activity to study effects on the host. As new candidate anti-inflammatory 
bacteria are identified by molecular techniques (448), their phylotype can only be inferred 
by genetic sequencing. Likewise the metabolic profile that infers such properties will need 
to be linked to culture independent technology. It is the combination of these techniques 
that will allow us to determine how bacteria respond to their environment and how these 
metabolic reponses confer protection or risk in diseases such as IBD. 
7.3 Current Limitations in SIP and Immediate Research 
Agenda 
The methods developed in chapters 3-6 have shown that it is possible to reliably obtain 13C 
enriched bacterial RNA on a scale appropriate for analysis by LC-IRMS. These 
enrichments have been demonstrated to be related to biochemical stimuli for metabolic 
activity and have been validated against other markers of metabolism in in vitro models. 
The current methods, as yet, are unable to clearly demonstrate specificity at bacterial group 
level whilst utilising 16s rRNA probe capture technology. The complexity of the SIP lies 
in the difficulty in hybridising, isolating and harvesting specific sequences of lengthy RNA 
(~1500 base pairs). However the varying yields of 13C in 16s rRNA experiments suggests 
that there are factors other than the limitations of binding capacity in the current SIP 
methodology. While there are several potential rate-limiting steps which remain 
unidentified, optimisation of the 13C signal at the16s rRNA level needs to be achieved, as 
dilution by unenriched carbon to the degree seen these experiments will hinder analysis of 
genuine changes in metabolic activity.  Greater specificity of oligonucleotide binding is 
also required to enable valid observations at the species specific level. 
The immediate future work into the optimisation of SIP should focus on hybridisation of 
RNA and hybridisation conditions, particularly melting points of probe binding and 
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capture particles. Probe efficiency may also be improved by establishing methods to 
reduce non specific binding of non 16s rRNA to oligonucleotide probes. With optimisation 
of the current SIP protocol from as little as 6g of faecal material would yield adequate 
RNA to perform multiple probe capture experiments. Using probes for the ten dominant 
bacterial phylotypes in human faeces, >95% gene coverage of samples enabling analysis of 
major group changes in activity in comparison to the whole consortia. Such a scale would 
make the possibility of studying diseases using small stool samples from children. 
Analyses of both species-specific changes and the consortia in patients with IBD in relapse 
and remission versus controls would be the immediate goal of a programme of research 
using methods. Success with such an approach would provide the platform for the study of 
gastrointestinal diseases where the gut microbiota are important in the aetiology such as 
NEC and allergic diseases.  
7.4 Towards SIP in vivo 
The opportunity to apply SIP in vivo will emerge as the methodology and applications 
mature and the obstacles encountered in in vitro studies are overcome. The technical 
challenges involved in enriching and isolating 16s rRNA are all resolvable. Progress will 
be driven by the recognition that the complex environmental and immunological factors 
which influence bacterial activity in vivo are difficult to replicate in vitro or in animal 
models. The potential to deliver a SIP tracer to an appropriate site within the gut will lead 
to the opportunity to biopsy or collect luminal and/or faecal contents and link 
metabolically active phylogenic groups through their degree of nucleic acid enrichment.  
This key goal requires validation, but in due course may reveal the functional significance 
of different groups of bacteria in inflammatory and other gastrointestinal diseases.   
 
Fuller understanding of the metabolic activity of the gut microbiota in IBD could 
ultimately lead to new, targeted therapies.  For instance the delivery of ‘designer’ non-
digestible carbohydrates that select for and induce the proliferation of particular bacterial 
species in the colon could modulate the microbiota in favourable ways through the 
production of anti-inflammatory products with cyto-protective and mucosal-healing 
properties. The identification of unculturable bacteria as anti-inflammatory or probiotic 
may in turn be delineated by culture independent assays of function. Such an approach 
requires integration of our growing understanding of the metabolic activity and diversity of 
the gut flora within the trinity of aetiological factors that include the host genotype and 
immune response (see section 1.6).  Current research is transforming the simple 
interrelations of genetics, immunology and gut microbiota into a hierarchical network of 
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metabolic pathways, immune interactions and genetic regulations (figure 61) which 
represents a real working hypothesis upon which we can continue to develop focussed 
studies and targeted therapies exploiting the role of the microbial flora in IBD. 
 
Figure 61: Hypothesised interrelationship between bacterial diversity and activity in relapsing IBD
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Appendices 1: Initial 16s rRNA probe capture protocol 
 
 
 
Step 1 Faecal enrichment 
a. 6g fresh stool + 30mls sterile PBS 
b. Homogenise for 2 min (max speed) in stomacher 
c. Centrifuge at 20,000g for 30 minutes. 
d. Remove as much liquid as possible but do not 
disturb the creamy layer 
e. Vortex the pellet vigorously for at least 1 minute 
 
 
 
Step 3 Removal of DNA 
 
a. Add 30µls of 10x Reaction buffer 
b. Add 40 µls of DNAse ONE (1 U/ µl) 
c. Mix and incubate for 1 hour at 37°C 
d.   Remove enzyme by ethanol precipitation. (See step 2L to 
20) and resuspend in 300 µls of ultrapure water  
 
 
SStep 4 Hybridisation 
50uls of total RNA solution is mixed with 50uls of 2 
times hybridisation buffer. This is made up as follows:
 
 
Step 2 Total RNA recovery 
a. Remove all remaining liquid from 1e and 
transfer to a micro-centrifuge tube. 
b. Add 1 volume (or as much as possible) of Prep- 
man ultra reagent. 
c. Heat in boiling waterbath for 10 minutes and 
cool at room temperature for 2 minutes. 
d. Centrifuge at 20,000g for 10 minutes. 
e. Transfer supernatant to a fresh 2ml micro- 
centrifuge tube. 
 
f. Add an equal volume of phenol: chloroform: 
isoamylalcohol (25:24:1) 
g. Mix (by inversion) until emulsion forms. 
h. Centrifuge at 20,000g for 5 mins until the 
phases are well separated. 
i. With a pipette, remove the aqueous phase (not 
yellow coloured layer) 
j. Repeat stage f-i two times removing as much 
protein as possible. 
 
k. Add an equal volume of chloroform and repeat 
steps g-i. 
l. To the resultant sample add 0.1 volumes of 3M- 
sodium acetate and 2 volumes of ethanol. 
 
m. Incubate on ice for 30 minutes. 
n. Recover nucleic acid by centrifugation at 
>10,000g (max speed) for 15 mins at 4°C 
 
o. Remove liquid and dry the pellet by leaving 
open on petri dish with cover over. 
p. Re-suspend the pellet in 266 of TE buffer 
5mls of 20 x SSC buffer   10x 
20 µls of N-Lauroyl sarcosine solution  0.2% 
20 mgs of NaCl    0.2% 
4 mgs of SDS    0.04% 
4 mls of formamide   40%  
Made up to lOmIs with ultrapure water. 
This is hybridised at 70°C for 10 minutes then incubated at 
room temperature for 30 minutes. 
 
Biotinylated capture probe is added (1.78nmols) 5 µls and 
the hybridisation mixture is incubated overnight at room 
temperature under gentle mixing. 
 
 
 
 
Step 5 Harvesting of 16S rRNA by Magnetic Separation. 
a.  Harvesting is performed using 8.9mg of M-280 paramagnetic 
streptavidin coated beads (Dynal Biotech, Wirral, UK). Take 
the amount of beads that you need. I.e. At 10mg beads/ml 
that is 890uls per reaction and wash them in water using the 
magnets for separation. Discard the supernatant each time. 
Do this three times  
b.  Re-suspend after washing in 900 µls of hybridization buffer 
without formamide., I.e. substituting water for the formamide 
part of the buffer. 
 
c. Add 900 µls of beads to the 105 uls of RNA solution from 
Step 4 and incubate on rotation for 2 hours at room 
temperature. 
d.  Wash the beads 3 times in equal volumes of ultrapure water, 
discarding the supernatant each time and then add 100 µls 
of water after the final wash. 
e.  The 16S rRNA is harvested by incubation at 90°C for three 
minutes followed by the magnetic removal of the beads. The 
supernatant contains the purified RNA. 
f.   Add 100 µls of product to a pre-weighed tin capsule and 
dry at 50°C. Weigh capsule afterwards.
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Appendix 2: Final 16s rRNA probe capture protocol 
 
 
Step 1 Faecal enrichment 
f. 6g fresh stool + 30mls sterile PBS 
g. Homogenise for 2 min (max speed) in stomacher 
h. Centrifuge at 20,000g for 30 minutes. 
i. Remove as much liquid as possible but do not 
disturb the creamy layer 
j. Vortex the pellet vigorously for at least 1 minute 
 
Step 3 Removal of DNA 
d. Add 30µls of 10x Reaction buffer 
e. Add 40 µls of DNAse ONE (1 U/ µl) 
f. Mix and incubate for 1 hour at 37°C 
d.   Remove enzyme by ethanol precipitation. (See step 2L to 
20) and resuspend in 300 µls of ultrapure water  
 
 
S    Step 4 Hybridisation 
50uls (2.5mg) of total RNA solution is mixed with 50uls of 
2times hybridisation buffer. This is made up as follows:
 
 
Step 2 Total nucleic acid recovery 
q. Remove all remaining liquid from 1e and 
transfer to a micro-centrifuge tube. 
r. Add 1 volume (or as much as possible) of Prep- 
man ultra reagent. 
s. Heat in boiling waterbath for 10 minutes and 
cool at room temperature for 2 minutes. 
t. Centrifuge at 20,000g for 10 minutes. 
u. Transfer supernatant to a fresh 2ml micro- 
centrifuge tube. 
 
v. Add an equal volume of phenol: chloroform: 
isoamylalcohol (25:24:1) 
w. Mix (by inversion) until emulsion forms. 
x. Centrifuge at 20,000g for 5 mins until the 
phases are well separated. 
y. With a pipette, remove the aqueous phase (not 
yellow coloured layer) 
z. Repeat stage f-i two times removing as much 
protein as possible. 
 
aa. Add an equal volume of chloroform and repeat 
steps g-i. 
bb. To the resultant sample add 0.1 volumes of 3M- 
sodium acetate and 2 volumes of ethanol. 
 
cc. Incubate on ice for 30 minutes. 
dd. Recover nucleic acid by centrifugation at 
>10,000g (max speed) for 15 mins at 4°C 
 
ee. Remove liquid and dry the pellet by leaving 
open on petri dish with cover over. 
ff. Re-suspend the pellet in 266 of TE buffer 
5mls of 20 x SSC buffer   10x 
20 µls of N-Lauroyl sarcosine solution  0.2% 
20 mgs of NaCl    0.2% 
4mgs of SDS    0.04% 
4 mls of formamide   40%  
Made up to lOmIs with ultrapure water. 
This is hybridised at 70°C for 10 minutes then incubated at 
room temperature for 30 minutes. 
 
Biotinylated capture probe is added (1.78nmols) 5 µls and 
the hybridisation mixture is incubated overnight at room 
temperature under gentle mixing. 
 
 
Step 5 Harvesting of 16S rRNA by Magnetic Separation. 
a.  Harvesting is performed using 4mg of novagen Oligo-dt 
particles . Take the amount of beads that you need. I.e. At 
10mg particles/ml that is 400uls per reaction and wash them 
in water using the magnets for separation. Discard the 
supernatant each time. Do this three times.  
b.  Re-suspend after washing in 800µls of hybridization buffer 
without formamide., I.e. substituting water for the formamide 
part of the buffer. 
c.  Particles are hybridised with 1.78nmols 5µls of CA-Clamp 
modified probe by inucabation overnight at room temperature 
under gentle mixing. 
 
d.  Add 805µls of particles to the 105 uls of RNA solution 
from Step 4 and incubate on rotation for 2 hours at room 
temperature. 
e.  Wash the partilces 3 times in equal volumes of ultrapure 
water, discarding the supernatant each time and then add 
100 µls of water after the final wash. 
e.  The 16S rRNA is harvested by incubation at 75°C for 6 
minutes followed by the magnetic removal of the particles. 
The supernatant contains the purified RNA. 
f.   100ul supernatant is removed and particles are washed 
with a further 100uls of water, which is removed to give a 
final 200ul sample for analysis.
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